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ABSTRACT OF DISSERTATION

EFFECTS OF ADIPOGENIC COMPOUNDS ON GROWTH PERFORMANCE,
HORMONAL STATUS AND FAT DEPOSITION OF FINISHING BEEF STEERS
Processes that regulate site of fat deposition in beef cattle are poorly understood.
For the producer to procure the greatest profit, it is ideal to maximize intramuscular fat.
Furthermore, to understand the physiological mechanisms affecting fat depots, it is
necessary to evaluate hormones involved in growth regulation. Using a 2 x 2 factorial
design of treatments, four experiments were conducted to examine two adipogenic
compounds, chlortetracycline and dexamethasone. Synovex-S® and Revalor-S® were
used to investigate potential interactions between growth implants and adipogenic
compound. Growth performance, carcass quality, organ and fat mass and plasma
hormone concentrations were measured in these studies.
In Exp. 1, 24 steers received either 0 or 350mg chlortetracycline/d, with or
without Synovex-S®. On d 30, 56 and 106, steers received a bolus injection of 1 ug/kg
BW thyrotropin-releasing hormone and 0.1 ug/kg BW GH-releasing hormone and serial
blood samples were collected. Synovex-S® increased (P ≤ 0.009) rate and efficiency of
gain and decreased (P = 0.05) time to peak for GH concentrations. Chlortetracycline
attenuated (P ≤ 0.05) the effects of implant on triiodothyronine release, slaughter weight
and carcass quality.
In Exp. 2, 96 steers received either 0 or 39.6 ppm
chlortetracycline/d, with or without Revalor-S®. Implant increased (P < 0.0001) ADG;
however, efficiency of gain was greater for implanted steers in the absence of
chlortetracycline (interaction, P ≤ 0.03).
In Exp. 3, 144 steers received either 0 or 0.09 mg dexamethasone/kg BW on d 0,
28 or 56, with or without Revalor-S®. Average daily gain was lower (P = 0.0003) for
implanted steers receiving dexamethasone compared to those receiving no

dexamethasone (interaction, P = 0.05). Omental fat mass was greater (P = 0.01) for
non-implanted steers receiving dexamethasone compared to no dexamethasone
(interaction, P = 0.006). In Exp. 4, 96 steers received either 0 or 0.09 mg
dexamethasone/kg BW on d 0, 28, 56 or 84, with or without Revalor-S®. Average
daily gain and efficiency of gain were both 13% greater (P ≤ 0.05) with implant.
Conversely, DEX lowered ADG by 10% (P = 0.007). There were no effects of
treatment on fat mass weights.
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Chapter 1
Introduction
Although fat deposition has been studied extensively in ruminants, the
mechanisms controlling this process remain poorly understood. The effect of breeds of
cattle (Charles and Johnson, 1976; Cianzio et al., 1982) and nutrition (Gill et al., 1993) on
the amount of subcutaneous fat (backfat) and intramuscular fat (marbling) has been well
documented. In the 1950’s, livestock production in the United States shifted from
animals raised on small, family farms and fed grass to large, intensive production systems
in which animals were managed according to physiological stage and fed diets intended
to maximize growth performance. For cattle, this shift meant a change from pasture to
feedlot finishing, where cattle were kept in large groups and grain was the primary feed
source. This diet change maximized weight gain in a short period; however, it also
increased the percentage of gain associated with fat (Smith et al., 1984; Jones et al.,
1985). It is generally accepted that 10-12 mm of backfat indicates that the animal is
ready for slaughter, as marbling will likely be sufficient for the animal to grade Choice
(Block et al., 2001). However, an excess amount of backfat or visceral fat represents an
economic loss, as these fat depots are not part of the usable carcass, while greater
amounts of intramuscular fat, or marbling, increase the value of the carcass.

Yet, it is

not clear why this increase in intramuscular fat occurs.
Type II diabetes research has helped to elucidate some of the cellular mechanisms
involved in visceral and intramuscular fat deposition in humans and rats (Bonora 2000;
Hegarty et al., 2002). While sites of lipogenesis and fatty acid precursors differ between
humans and ruminants, it is possible that some similarities exist regarding changes in fat
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deposition when diets high in carbohydrates are consumed. When humans consume
carbohydrates and fat in excess of daily energy requirements, they usually become obese,
and as a result could become Type II diabetic and insulin resistant (Kahn et al., 2006).
Insulin resistance is a physiological state in which tissues such as subcutaneous fat and
muscle become resistant to insulin. Cells in these depots have stored the maximum
amount of triglyceride and it is hypothesized that they are capable of storing no more
lipid droplets (Frayn 2001). Therefore, lipid deposition shifts from subcutaneous and
visceral sites to intramuscular sites. This shift has been well-documented in humans;
however, it has not been documented in beef cattle.
While a shift in fat deposition due to obesity in beef cattle has not been
documented, research regarding the addition of particular compounds to beef cattle diets
for the enhancement of intramuscular fat has been conducted. In particular, feeding
chlortetracycline (CTC) at subtherapeutic levels (350 mg/steer/d) has been shown to
increase marbling in growing steers fed for 91 d (Rumsey et al., 2000). While the
mechanism by which CTC accomplishes this increase in marbling is unclear, there are
some indications that it is achieved through changes in hormones released from the
anterior pituitary, namely growth hormone (GH) and thyroid-stimulating hormone (TSH;
Rumsey et al., 1999).
Another compound which has been widely used in human and rat models to study
insulin resistance and changes in fat deposition is the synthetic glucocorticoid,
dexamethasone. It has been found that one-time or frequent doses of dexamethasone
induce temporary insulin resistance, as indicated by a glucose challenge and changes in
plasma insulin concentrations (Matsumoto et al., 1996; Severino et al., 2002; Nicod et al.,
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2003; Binnert et al., 2004). Furthermore, frequent, long-term doses of dexamethasone
have caused a semi-permanent state of insulin resistance; administration of
dexamethasone over long periods of time also generates other adverse side-effects
commonly associated with glucocorticoids, such as compromised immunity, increased
blood pressure and lowered threshold for seizure (Veterinary Drug Handbook, 1999).
While it is possible for these negative side effects to occur, the use of dexamethasone in
research offers an opportunity to study the physiological changes associated with insulin
resistance and fat deposition as they relate to Type II diabetes. Particularly, it may be
possible to use dexamethasone to study changes in fat deposition in beef cattle.
Although, dexamethasone has been used to a limited degree in ruminants, its
effect on intramuscular fat deposition has been significant. For example, in one study
dexamethasone has been used in sheep for the improvement of feed intake and body
weight gain (Adams and Sanders, 1992). In another, the use of intramuscular injections
of dexamethasone in beef cattle at several intervals prior to slaughter and found
improvements in the number of cattle grading Choice (Brethour 1972). This research
provided an additional model for studying ways to manipulate intramuscular fat in beef
cattle.
Therefore, the two main goals of the research discussed in this dissertation were
to 1) investigate the effects of CTC and dexamethasone on the amount of intramuscular
fat in beef cattle and 2) determine if CTC and dexamethasone interacted with hormonal
growth implants to affect overall weight gain and the amount of intramuscular fat.

Copyright © Susanna E. Kitts 2011
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Chapter 2
Literature Review
Physiological control and mechanisms of fat deposition in ruminants
In today’s society, body fat generally has negative connotations and viewed as
unhealthy. If present in excess, harmful conditions such as diabetes are inclined to
develop. However, adipose tissue has great physiological significance and provides
benefits in mammals which are often overlooked. Fat imparts insulation for humans or
other mammals living in cold environments, provides energy and vitamin storage, and
produces cytokines, which have a role in inflammation.
Dietary lipid supply
Fat is a very efficient form in which energy is stored, and is vital for the
production of prostaglandins, thromboxanes and leukotrienes, as well as for cell
membrane structure. Triglyceride synthesis requires either a dietary source of a specific
fatty acid or synthesis of fatty acids within the body. Furthermore, dietary substrates
such as carbohydrate or fat can greatly affect triglyceride synthesis. In humans, both
carbohydrate and fat are consumed in roughly equal proportions; however, in general,
ruminants ingest more carbohydrate and less fat. Also, fat is digested differently in
ruminants because of the rumen; therefore, it is necessary to understand this process in
order to appreciate how the proportion of precursors for triglyceride synthesis is different
in ruminants.
Cattle on pasture consume mostly structural lipids such as phospholipids or
galactolipids (≤ 50%; Church, 1988). In a feedlot situation, cattle may consume more
grain and oil seeds, which contain most of the lipid as storage lipid or triglycerides (65-
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80%; Church, 1988). In both settings, ruminal metabolism allows no oxidation of lipid in
the rumen, as it is an anaerobic environment (Church, 1988). Many of the lipids entering
the rumen are polyunsaturated and bacteria use polyunsaturated fat to dispose of excess
hydrogen atoms in a process called biohydrogenation (Church, 1988; Bauchart et al.,
1996).
There are three types of lipid which can pass from the rumen to the small
intestine: unaltered, dietary lipid after hydrogenation by ruminal microbes, and microbial
lipid (Church, 1988). Because of these differences, fat entering the small intestine bears
little resemblance to the fat ingested in the diet. Most of the fat tends to be highly
saturated, which ruminants are able to digest to a higher degree than non-ruminants
(Church, 1988).
Digestion and absorption of fat in ruminants
In ruminants, the digesta entering the small intestine is very acidic, which
negatively affects the solubility of fat and bile acids (Church, 1988). Bile and pancreatic
juice emulsify fat entering the small intestine (Church, 1988; Bauchart et al., 1996), and
pancreatic secretions contain high amounts of bicarbonate, promote an increase in pH.
Because of the acidity of the duodenum, most hydrolysis of triglycerides begins to occur
in the mid-jejunum at a slightly higher pH, also the site at which fatty acids are
solubilized and converted to micelles by bile acids. (Church, 1988). Only about 20% of
fatty acids are absorbed in the proximal jejunum, with the remainder absorbed in the midand distal jejunum.
Once fatty acids are formed into micelles, they diffuse into the villous cell where
re-esterification occurs in the membrane of the smooth endoplasmic reticulum (Church,
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1988). The re-esterified fatty acids are packaged with either tri-, di-, or mono-glycerides,
phosphlipid, cholesterol and apoproteins to form chylomicrons that exit into the
intercellular space (Church, 1988). Chylomicrons diffuse through gaps in the basement
membrane to the lamina propria and enter the lymph system (Church, 1988). In
ruminants, chylomicrons are generallyprevalent when unsaturated fatty acids are
presented to the small intestine, while very low density lipoproteins (VLDL) are
predominantwhen high amounst of saturated fat are fed (Church, 1988; Bauchart et al.,
1996).
Transport of fat
While fatty acids with a chain length less than C14 can enter the blood directly,
most lipids are transported by the lymph system as chylomicrons and VLDL (Church,
1988). A small amount of lipid can also be present in the blood as low (LDL) or high
(HDL) density lipoproteins or non-esterified fatty acids (NEFA) associated with albumin
(Church, 1988). Once chylomicrons and VLDL enter the plasma, a component
associated with apoprotein C activates lipoprotein lipase, which is present on the surface
of endothelial cells lining the capillary walls of capillaries in skeletal muscle, adipose and
mammary tissue (Church, 1988). This hydrolysis allows fatty acids to be taken up by
tissue for oxidation or synthesis of triglycerides.
Triglyceride synthesis
Unlike non-ruminants, synthesis of fatty acids is minimal in the liver of
ruminants. Almost 100% of de novo lipogenesis occurs in the adipose tissue of
ruminants (Ingle et al., 1972). In general, the precursors for fatty acid synthesis in
ruminants differ from that of non-ruminants (Ingle et al., 1972). While the main
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precursor for acetyl-CoA in non-ruminants is glucose, in ruminants, acetate is the main
substrate due to fermentation in the rumen (Ingle et al., 1972), although a considerable
amount of glucose is available to the small intestine when ruminants are fed high
concentrate diets (Harmon and McLeod, 2001). A study by Hanson and Ballard (1967)
sought to determine the contribution of glucose and acetate to lipogenesis in the adipose
tissue of sheep and cattle. Mesenteric adipose tissue was incubated with either glucose or
acetate and the conversion of each substrate to fatty acid measured. It was determined
that the incorporation of acetate into the mesenteric adipose tissue of sheep and cattle was
212% and 266% greater, respectively, than the incorporation of glucose. While this data
shows a preference for acetate as a substrate for lipogenesis in mesenteric adipose tissue,
other research has demonstrated that the precursors used for lipogenesis in ruminants also
appear to be site-dependent. Research by Smith and Crouse (1984) evaluated the relative
contributions of acetate and glucose as carbon precursors for fatty acid synthesis in
intramuscular and subcutaneous adipose tissue obtained from 16-month old Angus steers.
It was found that acetate supplied 70-80% of the acetyl units for lipogenesis in
subcutaneous adipose tissue and only 10-25% in intramuscular adipose tissue. However,
glucose provided 50-75% of the acetyl units in intramuscular fat and only 1-10% in the
subcutaneous depot. While acetate is the main lipogenetic substrate for ruminants, this
study shows that lipogenic substrates can differ based on the location of adipose depots.
Ruminant diets normally have a moderate effect on the composition of adipose
tissue because of ruminal hydrogenation. However, feeding poly-unsaturated fatty acids
in excess of the capacity of the rumen for hydrogenation can allow some fat to escape to
the small intestine for absorption (Church 1988). In this case, triglyceride synthesis in
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adipose tissue will reflect the composition of the unsaturated fatty acids absorbed. If a
high-concentrate diet is fed, a shift towards greater propionate production will occur in
the rumen (Church 1988, Bergman, 1990). However, despite the greater production of
propionate, acetate still constitute at least 50% of the VFA produced (Bergman, 1990).
Additionally, up to 20% of starch intake in high-concentrate diets can bypass ruminal
fermentation and enter the small intestine for digestion to glucose (Huntington 1997).
Therefore, a high-concentrate diet ultimately provides acetate, propionate and glucose as
lipogenic precursors. Acetate can be taken up by adipose tissue and used to form acetylCoA for fatty acid synthesis. Propionate is removed from the portal blood by the liver, as
it is the major substrate for gluconeogenesis in ruminants (Coleman et al., 1995). Finally,
glucose absorbed by the small intestine from both bypass starch and glucose produced
from propionate can also be used to form acetyl-CoA. However, in ruminants glucose is
essential for glycerol formation, as they cannot convert glycerol 3-phosphate to glycerol
(Vernon and Flint, 1988).
Fat deposition and maturity
Cattle producers and feedlots constantly manipulate the growth of cattle to change
nutrient partitioning and feed-conversion efficiency. The strategies employed attempt to
increase muscle tissue deposition at the expense of adipose tissue growth. This approach
contradicts the natural physiology of the animal. Both muscle and adipose tissue rank
relatively low in priority in the body’s allocation of nutrients compared with bone,
lymphoid and neural tissue, as well as gut maintenance (Wray-Cahen et al., 1998).
However, to manipulate growth processes successfully, it is helpful to understand the
growth and development of cattle.
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All muscle tissue develops from the proliferation and differentiation of satellite
cells. Some of the growth factors that play major roles in the regulation of muscle
growth include the insulin-like growth factors (IGFs), fibroblast growth factors (FGFs),
and transforming growth factor-β (TGF-β; Wray-Cahen et al., 1998). Regardless of diet
composition, lean tissue accretion has a higher priority than adipose tissue in the young,
growing animal (Hammond 1952). Furthermore, with increasing maturity, the rate of
protein growth decreases (Byers, 1982; Owens et al., 1995). To maximize lean tissue
gain for cattle in the latter stages of the finishing period, it is a common practice to
implant these cattle with a growth promotant containing combinations of estrogen or
trenbolone acetate plus progesterone to repartition nutrients.
As cattle grow and once they reach mature weight, excess available energy is
retained as fat. Thus, total fat composes a higher percentage of body weight gain with
increasing maturity and days on feed. There are at least 5 primary fat depots and 1
secondary fat depot in the ruminant animal. The primary fat depots consist of omental,
mesenteric, subcutaneous, intermuscular and kidney, pelvic and heart fat (KPH; Charles
and Johnson, 1976). The secondary fat depot of major interest is intramuscular fat, i.e.,
marbling. While it is preferable that the amount of fat in the omental, mesenteric and
KPH fat depots is low to reduce non-carcass weight, the amount of intramuscular fat
should be high to improve quality grade and thus, increase profit.
Although there may be differences in fat distribution between the frame sizes of
steers as they mature, there is a similar pattern of fat deposition. Cianzio et al. (1982)
compared the adiposity of steers of small and large frame size from 11 to 19 mo of age.
The smaller framed steers showed an earlier increase in the rate of fat deposition from 11
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to 13 mo of age. Interestingly, as fattening proceeded the growth rate of pelvic and
mesenteric fat decreased in the large frame steers; however, with the exception of pelvic
fat, all fat depots (subcutaneous, intermuscular, kidney, omental, mesenteric) increased at
the same rate in the small frame steers. However, intramuscular fat increased at a rate
similar to that of total fat in both frame sizes, demonstrating that this depot is not the last
type of lipid to be deposited. These findings contradict other work which suggests that
intramuscular fat is the last fat depot to develop (Hammond, 1955; Hood and Allen,
1973; Vernon et al., 2001).
In another study which evaluated fat distribution in the carcass, Johnson et al.
(1972) also showed that intramuscular fat did not increase with fattening. Rather, the
authors hypothesized that the expression of intramuscular fat is late maturing. These
studies demonstrate that overall, fat deposition increases at a steady rate throughout the
growing and finishing periods. However, as protein accretion decreases later in the
finishing period, fat assumes a greater proportion of weight gain. At this point, the
amount of intramuscular fat present becomes of great importance because of its proximity
to slaughter time. While some research suggests that intramuscular fat increases
throughout growth, the rate at which it is deposited may be affected by a myriad of other
factors such as genetics, growth history and type of diet (Cianzio et al., 1982). It is
possible that the high concentrate diets fed to finishing cattle may cause insulin
resistance, which in turn may increase the amount of intramuscular fat. These
possibilities will be explored in depth in a later section of this review.
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Effects of chlortetracycline and dexamethasone on fat deposition in ruminants and
non-ruminants

General effects of antibiotics in livestock
It has been demonstrated for some time that the addition of antibiotics to livestock
feed improves growth performance. Some of the common additives include
chlortetracycline, oxytetracycline, penicillin, bacitracin, streptomycin, tylosin and
oleandomycin (Wallace, 1970). While some of these additives may be used more in
some species than others, they all share a common characteristic of suppressing or
inhibiting the growth of microorganisms. Controlling the outbreak of disease caused by
microorganisms became especially important in the 1950’s with the development of
confinement rearing of food animals in large flocks and herds (Gustafson and Bowen,
1997). Although it is not entirely clear how these antibiotics improve growth
performance, there are theories which propose metabolic, nutrient-sparing and disease
control effects (Wallace, 1970). While it seems that activity against Gram-positive
bacteria is important for swine and poultry, any further mechanisms of action by
antibiotics in non-ruminants is unclear (Gustafson and Bowen, 1997).
In ruminants, ionophore antibiotics have been shown to be very effective in
altering energy utilization by shifting acetate and butyrate production to propionate, as
well as improving feed efficiency (Richardson et al., 1976; Bergen and Bates, 1984).
Additionally, antiobiotics have routinely been used as prophylactics to protect entire
herds or flocks of animals at risk for disease. This is especially true of young cattle that
have traveled long distances, as they are at risk for respiratory disease caused by
Pasteurella haemolytica or P. multocida (Gustafson and Bowen, 1997). These animals
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are under extreme stress and many feedlot workers dose with a broad spectrum antibiotic
feed additive to prevent reduced growth performance and death. Antiobiotics are
effective in improving growth and feed efficiency; however, specific antiobiotics such as
chlortetracycline (CTC) have been shown not only to increase growth and efficiency of
feed utilization, but to improve carcass quality as well (Bohman et al., 1957; Landagora
et al., 1957; Perry et al., 1958; Heinemann and Fanelli, 1963; Rumsey et al., 2000).
Chlortetracycline, growth performance and carcass quality in ruminants
Historically, CTC has been fed to beef steers, dairy calves and sheep with
differing effects on average daily gain, efficiency of weight gain and carcass
characteristics. Most experiments have shown an increase in average daily gain for beef
steers and dairy calves (Bohman et al., 1957; Landagora et al., 1957; Perry et al., 1958;
Heinemann and Fanelli 1963). In an experiment by Landagora et al. (1957), 54 dairy
calves received either the basal ration, 50-75 mg CTC/d in milk or 400 mg CTC HCl/d
intramuscularly. While there was no difference in weight gain between the calves
administered CTC orally or intramuscularly, calves treated with CTC gained 0.1 kg
BW/d more than calves given only a basal ration. A study by Perry et al. (1958)
demonstrated that steers fed 80 mg CTC/d gained 5.4% more than steers receiving no
CTC. In another experiment, steers fed for an average of 77 d received either 0 or 75 mg
CTC/d (Heinemann and Fanelli, 1963). The steers fed CTC gained 0.28 kg more than the
steers fed no CTC. Burroughs et al. (1959) summarized the results of 112 experiments
involving the feeding of subtherapeutic levels of antibiotics to cattle and found that CTC
increased ADG by 4% over animals receiving no CTC. However, a study by Harvey et
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al. (1968) showed no improvements in ADG for steers fed 75 mg CTC/d for an average
of 175 d.
Similar to ADG, the effects of CTC on efficiency of BW gain has been variable in
cattle, especially during the finishing phase. In a growing and finishing experiment by
Heinemann and Fanelli (1963), steers receiving 75 mg/d chlortetracycline had more
efficient weight gain compared to steers fed no chlortetracycline. Likewise, Perry et al.
(1954) observed an increase of 18% in feed efficiency when chlortetracycline was fed at
a rate of 75 mg/d. However, many studies have shown chlortetracycline to have no effect
on efficiency of weight gain (Neumann et al., 1951; Bohman et al., 1957; Rumsey et al.,
2000; Kitts et al., 2006). While the cause of varying responses to CTC in these
experiments is unclear, it has been suggested that the effects of CTC on growth
performance are more apparent under stressful conditions that are more immunologically
challenging to the animal (Visek 1978). Thus, it is possible that the benefits of CTC
observed in younger animals are due to the suppression of non-beneficial bacteria which
sometimes proliferate under conditions of stress, such as weaning or transport.
Most of the data regarding the effects of CTC on carcass quality has shown
limited or no improvement (Bohman et al., 1957; Landagora et al., 1957; Bohman and
Wade, 1958; Heinemann and Fanelli, 1963; Rumsey et al., 2000; Kitts et al., 2006). In an
experiment by Bohman et al. (1957), 48 steers (351 kg) were fed 0 or 70 mg/d CTC for
either 119 or 126 d. Evaluation of carcass grade and dressing percentage revealed no
effect of CTC. In another study by Bohman and Wade (1958), 48 steers (~2 yr old) were
fed 0 or 70 mg/d CTC for 120 d and the percentage of separable fat in the 9-10-11 rib cut
was determined. Chlortetracycline did not change the percentage of separable fat.
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Heinemann and Fanelli (1963) used 72 steers (299 kg) receiving a supplement of 75 mg/d
of CTC for either 84 or 97 d. At slaughter, steers were evaluated for grade, thickness of
the round and chuck, loin area, and fat cover at the 12th rib. These carcass characteristics
were not affected by CTC. A later study by Kitts et al. (2006) used 96 steers (401 kg) fed
either 0 or 39.6 ppm/d CTC for either 126 or 140 d. There was no effect of CTC on
longissimus area, longissimus fat cover, KPH fat, marbling or yield grade.
Conversely, two experiments have shown oral CTC to have limited improvements in
carcass quality and increased carcass fat deposition. Landagora et al. (1957) used 54
newborn Jersey and Holstein calves that were slaughtered at 12 or 16 weeks of age. The
control group received the basal ration, the second group was fed 50-75 mg/d CTC, and
the third group received an intramuscular injection of 400 mg/d CTC HCl. There were
no differences in measurements between calves fed or injected with CTC; however,
calves fed or receiving injections had heavier carcass weights, higher dressing
percentages, increased size and weight of round and rib cuts, and higher meat yields. In
another experiment by Rumsey et al. (2000), thirty-two steers (286 kg) were fed CTC
(350 mg/d) for 91 d and then slaughtered. Chlortetracycline increased longissimus fat
cover and tended to increase slaughter weight and marbling. It is notable that the
experiments in which carcass quality and fat deposition were improved used younger
animals and higher dosage levels of CTC per unit BW. It is possible that CTC is not
effective in older animals, such as those used in the previous experiments.
Chlortetracycline, growth performance and carcass quality in non-ruminants
In general, CTC has been shown to improve growth performance and carcass
quality in non-ruminants, such as swine and poultry. In an experiment by Hill and
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Larson (1955), 81 baby pigs obtained by hysterectomy were fed a milk diet and half of
the pigs were supplemented with 10 ppm/d CTC for 24 d. Pigs were then fed solid feed
for 56 d and received 200 ppm/d CTC. During the initial period, pigs receiving CTC
gained 11% more BW than the control animals. Likewise, pigs receiving CTC during the
second period gained 16% more BW relative to the control animals. Chlortetracycline
clearly improved growth performance of suckling and weanling pigs in this experiment.
In another study by Braham et al. (1958), chicks and rats were used to determine
the effects of several antibiotics, including CTC, on weight gain. One hundred twenty
chicks were fed two levels of 5 different antibiotics, including CTC, for 4 weeks. Chicks
received 0, 10, or 1000 mg/kg diet penicillin, CTC, novobiocin, zinc bacitracin or
streptomycin. Chicks receiving 1000 mg/kg CTC weighed 31% more after 4 weeks
relative to chicks receiving no antibiotic. There was no effect on weight gain for chicks
fed 10 mg/kg CTC after 4 weeks. In this same experiment, 60 male albino rats were fed
0 or 1000 mg/kg diet penicillin, CTC, novobiocin, zinc bacitracin or streptomycin for 4
weeks. Rats receiving CTC gained 38% more BW compared to rats fed no CTC.
Clearly, CTC enhanced weight gain in both growing chicks and rats when fed at high
levels.
Few studies have shown substantial improvements in carcass quality of nonruminants fed CTC; furthermore, most research regarding the effects of CTC on carcass
quality has been limited to swine. An experiment by Kelly et al. (1957) evaluated 48
weanling pigs (13 kg) divided into two groups of 24 pigs each. From each group, six
pigs were removed at 39, 57, 75, and 93 kg BW for slaughter. The first group received a
basal ration and the second group received the basal ration plus 22 ppt/d CTC. There
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were no effects of CTC on the carcass composition or quality of pigs slaughtered at 57,
75, or 93 kg BW; however, barrows receiving CTC and slaughtered at 39 kg BW had
14% more fat in the carcass relative to barrows receiving no CTC. Furthermore, these
barrows had greater backfat thickness compared to barrows fed no CTC. Another study
by Wallace et al. (1955) evaluated the influence of CTC on growth and carcass quality of
pigs fed restricted rations. A total of 110 weanlings pigs (19.9 kg) were used in 3
experiments, one in drylot and two in pasture. In each experiment, rations were fed as
unrestricted, allowed 80% of feed consumed by the unrestricted group, or allowed 60%
of feed consumed by the unrestricted group. These treatments were repeated and
supplemented with CTC (20g/ton). Pigs were slaughtered when they reached a finished
weight of 86 kg. In Exp.1, the unrestricted group that received CTC had the highest
dressing percentage, but no effect when feed intake was controlled. There were no
effects of CTC on carcass characteristics in Exp. 2 or 3. These studies indicate few
effects of CTC on carcass quality.
Effects of chlortetracycline on pituitary and thyroid hormones
Little research has been done related to the effects of CTC on hormones released
from the pituitary and thyroid glands. Early research had suggested the positive growth
effects of CTC to be attributed to its antimicrobial actions (Gustafson and Bowen, 1997).
However, it is has been hypothesized that CTC affects growth via an endocrine axis
(Landagora et al. 1957). This idea is supported by a study performed by Hsu et al.
(1970). Chicks were fed a basal ration containing no CTC, basal ration plus 25 ppm
untreated CTC or basal ration plus 1 ppm decomposed CTC. After 4 weeks, the chicks
were evaluated for growth and thyroid histology and function. It was observed that
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chicks receiving the untreated CTC gained more body weight than chicks fed the basal
ration or basal ration plus decomposed CTC. Examination of the thyroid glands of the
chicks fed untreated CTC showed stimulation of growth due to hypertrophy and
hyperplasia. These data supported the theory that the positive effects of CTC on growth
may be due to effects on an endocrine axis involving the thyroid gland and not due solely
to antimicrobial effects.
Growth hormone (GH) and thyroid-stimulating hormone (TSH) released from the
pituitary gland, and triiodothyronine (T 3 ) and thyroxine (T 4 ) released from the thyroid
gland, have significant roles in the growth and metabolism of animals (Larsen 2003). A
primary function of GH is to mediate growth through an increase in protein synthesis
(Owens et al., 1993). This increase in protein synthesis takes place at the expense of fat
synthesis. Therefore, it has been suggested that the increase in fat deposition observed
with the administration of CTC may be a result of decreased synthesis or release of GH
(Rumsey et al., 1999).
Thyroid hormones (T 3 and T 4 ) play major roles in energy metabolism, acting to
increase basal metabolic rate, promote protein synthesis, and stimulate fat mobilization
via lipolysis (Sokoloff et al., 1968; Thenen and Carr, 1980). The stimulation of fat
mobilization leads to increased plasma fatty acid concentrations in plasma and oxidation
of fatty acids by tissues. Because it has been observed that CTC increases fat deposition,
it would be expected that circulating concentrations of thyroid hormones would decrease.
Rumsey et al. (1999) used 32 steers (285 kg) fed either a 10 or 13% CP diet and either a
corn meal carrier or carrier + 350 mg CTC daily. After 56 d, steers were injected with
1.0 ug/kg BW TRH + 0.1 ug/kg BW GHRH and blood samples collected for 360 min
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after releasing hormone injection. Chlortetracycline decreased the amount of GH
released from the pituitary and over time, decreased circulating TSH and T 4 . This study
also evaluated the effects of CTC on insulin-like growth factor-1 (IGF-1; McLeod et al.,
2003). IGF-1 is a hormone with growth promoting effects and most tissues in the body
possess receptors for IGF-1. IGF-1 is produced primarily by the liver in response to GH
(Davey et al., 2001). It is also synthesized and released in target tissues in a
paracrine/autocrine fashion (Adams 2002). In the study by McLeod et al. (2003), blood
was collected on d 0, 7, 14, 28, 56 and 84 prior to feeding and analyzed for IGF-1. Over
the entire experiment, circulating IGF-1 concentrations were unaffected by CTC.
However, there was a tendency for steers receiving 10% protein + CTC to have lower
IGF-1 concentrations on d 7 and 14 compared to steers receiving 13% protein.
General physiological effects of glucocorticoids
A variety of steroids are synthesized from cholesterol in the adrenal cortex,
including glucocorticoids, aldosterone and androgens. These steroids are released into
the circulation and have numerous effects on intermediary metabolism.
Theglucocorticoidsare produced mainly in the zonae fasciulata and zonae reticularis
layers of the adrenal gland (Veterinary Pharmacology and Therapeutics, 1995). In most
mammals, the major glucocorticoid is cortisol; however, in rats, the major glucocorticoid
is corticosterone. Cortisol is synthesized from cholesterol and released into circulation
under the influence of adrenocorticotropic hormone (ACTH; Larsen 2003). In humans,
cortisol is secreted in response to pulsatile ACTH release with diurnal variation;
however, studies have not confirmed diurnal variation in species such as the ruminant
(Alila-Johansson et al., 2003; Hudson et al., 1975).
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Glucocorticoids have effects on virtually all cell types and almost every
physiological system in mammals. In the cardiovascular system, glucocorticoids reduce
capillary permeability and enhance vasoconstriction, thereby increasing blood pressure
(Veterinary Drug Handbook, 1999). In the nervous system, glucocorticoids can stimulate
appetite, lower seizure threshold and alter behavior. While glucocorticoids normally
suppress release of endogenous corticosteroids, some conditions such as liver disease or
diabetes may abolish suppression by glucocorticoids (Veterinary Drug Handbook, 1999).
Additionally, release of TSH, follicle-stimulating hormone, prolactin and luteinizing
hormone may be reduced when glucocorticoids are administered. The conversion of T 4
to T 3 may be reduced and insulin binding to insulin receptors may be inhibited by
glucocorticoids (Veterinary Drug Handbook, 1999). Glucocorticoids can suppress the
immune system by decreasing production of lymphocytes, monocytes and eosinophils.
Glucocorticoids have an antagonistic effect to that of insulin, leading to increased
glucose production from amino acids and reduced incorporation of amino acids into
protein (Veterinary Pharmacology and Therapeutics, 1995). While glucocorticoids
enhance lipolysis in the abdominal/visceral areas, pharmacological amounts can result in
insulin resistance and Type II diabetes, ultimately causing redistribution of fat to muscle
(Amatruda et al., 1985; Lewis et al., 2002). It is likely that this redistribution occurs
because glucocorticoids stimulate appetite, causing hyperinsulinemia, which results in
lipogenesis and ultimately obesity. (Veterinary Pharmacology and Therapeutics, 1995).
As a result, diabetes mellitus may develop from prolonged glucocorticoid use at high
dosage levels.
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Dexamethasone
Specifically, dexamethasone (DEX) is a synthetic glucocorticoid which acts as an
anti-inflammatory agent and immunosuppressant. While many of the effects of DEX are
similar to those of the naturally occurring hormone, cortisol, its effects are 20-30 times
more potent than those of hydrocortisone. It is also considered to be a “long-acting”
glucocorticoid (duration of action › 48 h; Veterinary Pharmacology and Therapeutics,
1995).
While glucocorticoids have been used to treat specific conditions, they obviously
have a myriad of effects on all systems of the body. Therefore, many adverse effects can
occur with long-term use of these drugs, especially with high dosage levels. A few of
these effects include growth retardation in young animals, dull, dry haircoats, weight
gain, diarrhea, pancreatitis, lipidemias, diabetes mellitus, muscle wasting and behavioral
changes (Veterinary Drug Handbook, 1999). Despite these negative side effects,
glucocorticoids such as DEX have been used extensively in research experiments,
particularly to study glucose metabolism in both animals and humans (Plested et al.,
1987; Vernon and Taylor, 1988; Matsumoto et al., 1996; Schneiter and Tappy, 1998).
Effects of dexamethasone on glucose metabolism
A study by Schneiter and Tappy (1998) evaluated the effects of administration of
DEX on the metabolism of an oral glucose load. Six human volunteers (71.6 ± 2.8 kg)
received 2 mg/d DEX in 4 doses (0.5 mg/dose) over a 2-d period. On the morning of the
glucose tolerance test, the volunteers received 1 mg DEX and ingested 75 g of [U-13C]
glucose. The 2-d treatment with DEX elevated circulating blood glucose over the control
subjects who received no DEX. Also, plasma insulin was approximately 400 pmol/L
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higher in individuals receiving DEX compared to those receiving no DEX. These results
suggest that glucose tolerance is impaired with chronic administration of DEX.
In another experiment by Matsumoto et al. (1996), twenty human volunteers were
used to examine the dose-dependent effects of DEX on glucose tolerance. Ten subjects
received a low dose of DEX (2 mg/d) for 3 d, and the other ten received a high dose of
DEX (6 mg/d) for 3 d. Each subject underwent anintravenous glucose tolerance test
before and after DEX administration. In that study, glucose tolerance was impaired to a
greater extent in the individuals who received the high-dose of DEX relative to those
receiving the low-dose. Additionally, individuals receiving both the high and low doses
of DEX had higher plasma insulin levels compared to those receiving no DEX. These
results suggest that glucose tolerance is impaired in a dose-dependent manner when DEX
is administered. Vernon and Taylor (1988) conducted a study in lactating and nonlactating sheep to determine the effects of DEX on control of glucose metabolism in
adipose tissue. Adipose tissues samples were obtained from lactating and non-lactating
sheep and DEX added to a final concentration of 0, 0.1, 1, 10 or 100 nM. It was observed
that increasing concentrations of DEX decreased glucose uptake by adipocytes in both
the lactating and non-lactating sheep.

In another study by Buren et al. (2002), rat

adipocytes were isolated from epididymal fat pads and incubated for 24 h in the absence
or presence of DEX at 0.3 µmol/L and insulin (104 µU/mL). The cells were then washed
and incubated with various insulin concentrations (0-1000 µU/mL) and D-[U-14C]
glucose. Glucose uptake was terminated after 1 h and cell-associated radioactivity
determined. It was found that the addition of DEX during the 24 h prior to the glucose
uptake assay decreased both basal and insulin-stimulated glucose uptake by 40-50%
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compared with the control cells. The results of these studies show that DEX inhibits
glucose uptake and utilization in the adipocytes of both sheep and rats.
Effects of dexamethasone on adipogenesis and adipocyte differentiation
While DEX has been shown to inhibit glucose uptake and utilization in
adipocytes, the effects of DEX on fatty acid synthesis are less clear. Some research in
humans has suggested that insulin-stimulated fatty acid synthesis in adipose tissue is
inhibited when DEX is administered (Cigolini and Smith, 1979). However, most recent
research suggests that DEX stimulates fatty acid synthesis in both mice and humans
(Dolinsky et al., 2004; Gounarides et al., 2008; Wang et al., 2004). In an experiment by
Dolinsky et al. (2004), mice were injected for 4 d with 40 mg/kg BW DEX and killed 24
h after the final injection. The mice receiving DEX had 2-fold higher plasma
triacylglycerol (TAG) concentrations compared to mice receiving no DEX.
Diacylglycerol acyltransferase (DGAT) is an enzyme that catalyzes the final stage of
TAG synthesis; the expression of this enzyme was evaluated in the livers of mice injected
with DEX and found to be increased at least 1.5-fold compared to mice given no DEX.
In the study by Wang et al. (2004), subcutaneous fat was obtained from the abdominal
region of non-obese, non-diabetic women and cultured with either no hormone (control),
with insulin alone or with insulin plus DEX. After 5 days of culture, fatty acid synthase
(FAS) gene expression was evaluated. Insulin enhanced mRNA abundance of the FAS
gene 14-fold and insulin plus DEX enhanced FAS mRNA abundance 100-fold. In
another study by Goundarides et al. (2008), male mice were maintained on a high-fat diet
for 2 months prior to receiving 3 intraperitoneal injections of 11 mg/kg DEX over a 5-d
period. At least 3 d before DEX injections and on d 8 following the last DEX dose, fat
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distribution was determined by magnetic resonance imaging. Relative to body weight,
the results showed visceral fat to be 50% greater in the mice injected with DEX. These
studies clearly indicate that DEX stimulates fatty acid synthesis in the liver, subcutaneous
and visceral fat depots. In the liver and subcutaneous adipose depot, the increase in fatty
acid synthesis is accomplished by increasing expression of various enzymes involved the
fatty acid synthetic pathways.
The effects of DEX on adipocyte differentiation are also vague; some research
suggests that DEX inhibits a specific stage of adipocyte differentiation (Pairault and
Lasnier, 1987), while most indicates that DEX promotes adipogenesis through adipocyte
differentiation (Lepar and Jump, 1992; Smas et al., 1999; Zilberfarb et al., 2001). The
three stages of differentiation for preadipocytes include determination, commitment and
terminal differentiation (Pairault and Lasnier, 1987; Gregoire et al., 1998). Preadipose
cell lines such as 3T3-F442A are already committed to the adipocyte lineage and are
commonly used to study the progression of preadipocytes into terminal differentiation;
however, entrance into the differentiation stage as well as the rate of differentiation can
be manipulated based on the use of inhibitory or inducing agents (Gregoire et al., 1998).
The most common inducing agents used for adipocyte differentiation include insulin and
DEX, while retinoic acid has been shown to prevent differentiation (Pairault and Lasnier,
1987).
In a study by Pairault and Lasnier (1987), the effects of retinoic acid, DEX and
insulin on terminal differentiation were evaluated in 3T3-F442A preadipocytes. The
programming of 3T3-F442A preadipocytes for differentiation takes place at confluence
when cells stop their growth. At this point, culture medium is supplemented with
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effectors to be tested for the differentiation process. The 3T3-F442A cells were grown to
confluence and allowed to differentiate in the presence of insulin for 10 d. At d 0, 2, 4, 6
and 8, either retinoic acid, DEX or retinoic acid plus DEX were added to the cell culture.
On d 11, the cells were prepared for enzyme extraction of glycerophosphate
dehydrogenase (G3PDH), an enzyme with specific activity induced during adipocyte
differentiation. The inhibitory effect of DEX on differentiation was overcome by the
presence of insulin. When retinoic acid was added to the cells on d 0, G3PDH activity
was essentially zero, increasing slowly until d 10. However, the addition of retinoic acid
and DEX strongly inhibited the expression of G3PDH, thus preventing differentiation.
These results suggest that retinoic acid plus DEX prevent preadipocyte differentiation
that cannot be reversed in the presence of insulin. However, the presence of insulin
reverses the inhibition of differentiation by DEX, but it is unable to reverse inhibition by
retinoic acid.
A study by Zilberfarb et al. (2001) evaluated the effects of DEX on TNF-α
expression and adipocyte differentiation. TNF-α expression has been shown to increase
in obesity and insulin resistance and is an inhibitor of adipocyte differentiation (Stephens
and Pekala, 1992; Hotamisligil and Spiegelman, 1994). Human preadipocytes (PAZ6
cells) from infant perirenal adipose tissue were cultured to confluence and supplemented
with DEX and insulin or insulin alone. In the absence of DEX, the expression of
adipocyte markers such as insulin sensitive glucose transporter (GLUT-4), hormone
sensitive lipase (HSL) and lipoprotein lipase (LPL) was barely detectable, suggesting that
DEX is necessary for adipocyte differentiation. The expression of TNF-α was reduced in
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the presence of DEX, suggesting that the positive effect of DEX on adipocyte
differentiation is mediated by the inhibition of TNF-α.
Use of dexamethasone in ruminants
The main uses of DEX in cattle are for the treatment of arthritis, nerve damage
and ketosis (Veterinary Drug Handbook, 1999). However, some studies have
investigated the effects of DEX on feed intake and body weight changes in sheep and
effects on the amount of intramuscular fat in cattle (Brethour 1972; Adams and Sanders,
1992). Research by Adams and Sanders (1992) investigated the use of DEX to improve
feed intake and reduce body weight loss in sheep moved inside animal houses or into
feedlots. Wethers injected with DEX at the time of introduction into the animal house ate
more and lost less weight than untreated sheep within the first 24 h and over a 10-d
period. In the feedlot situation, sheep treated with DEX gained more weight than
untreated sheep after 5 d. These results suggest that a single injection of DEX helps to
improve feed intake and reduce weight loss associated with movement of animals to a
new environment.
Another study by Brethour (1972) was conducted in response to the observation
that foundered cattle treated with DEX tended to have higher carcass grades. Cattle with
an average weight of 364 kg were injected IM with 10 mg of DEX 132, 90, 76 or 33 d
prior to slaughter. When cattle were injected with DEX 90, 76 or 33 d prior to slaughter,
marbling score, a measure of intramuscular fat, was improved. These results certainly
suggest that single injections of DEX have the potential to increase intramuscular fat,
thus increasing carcass value and producer profit.
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Effects of anabolic steroids on tissue deposition in ruminants
Anabolic steroids
Anabolic steroids have been administered to beef cattle for several decades to
enhance growth rate and lean tissue deposition. The use of steroids has provided an
economic advantage for beef cattle producers, as enhancing growth rate can reduce the
cost of producing meat. Additionally, lean tissue deposition is preferred by producers
over fat deposition, as more muscle increases the value of the carcass (McKenna et al.,
2002). An increase in lean tissue deposition is generally accomplished at the expense of
fat and requires altering the animal’s endocrine system (Buttery and Dawson, 1990).
Several anabolic steroids have been developed to improve the growth of ruminants and
these steroids are based on natural sex steroids. Some of these include estradiol, estradiol
benzoate plus progesterone, estradiol benzoate plus testosterone, zeranol and trenbolone
acetate (Buttery and Dawson, 1990). Most anabolic steroids are administered to steers or
heifers as an ear implant sometime after weaning to increase growth rate and lean tissue
deposition.
Nutrient partitioning
Nutrient partitioning refers to the processes by which available nutrients are
channeled in varying proportions to different metabolic functions (Friggens and
Newbold, 2007). Nutrients such as glucose or amino acids may be shuttled to tissues
such as vital organs, muscle, adipose tissue or in the case of the dairy cow, milk. The
priority for conducting nutrients to different tissues is determined by the energy status of
the animal; specifically, maintenance needs of the vital organs first must be met, then
nutrients will be used for growth in young animals. Regarding beef cattle, nutrient
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partitioning becomes an important consideration for producers during the growth period
after weaning, as it is crucial to increase growth rate, maximize lean tissue deposition and
minimize adipose tissue as the animals approach “market weight,” the point at which they
are utilized for meat (Mitchell 2007). Excess adipose tissue in the form of backfat
(subcutaneous fat) or visceral fat is unable to be utilized and considered an economic
loss; therefore, the ability to manipulate nutrient partitioning via nutritional approaches or
anabolic steroids has provided an economic benefit for producers (Trenkle and Marple,
1983: Mitchell 2007).
Many factors control nutrient partitioning, particularly energy status, genetics,
physiological state, and environment. All of these elements can interact in a complex
manner to determine the destination of nutrients at any given time. It is now a common
practice to use anabolic steroids to manipulate nutrient partitioning and especially in the
case of cattle with less than optimal genetics, maximize lean tissue deposition. The most
common mechanisms by which anabolic agents repartition nutrients towards lean tissue
include alterations in endogenous hormone levels, alterations in enzyme activity
associated with protein turnover, and reductions in protein turnover (Lemieux et al.,
1985; Sinnett-Smith et al., 1983).
As an animal approaches maturity, body composition changes due to variation in
growth rate of different organs and tissues. In terms of growth of a young animal, the
brain grows first, followed by bone, skeletal muscle and adipose tissue (Beitz 1985). As
the animal grows, protein and fat accretion occur simultaneously; however, as the animal
approaches maturity, the rate of protein accretion decreases and fat accretion continues
(Beitz 1985). In order to change this scenario in favor of continued protein accretion
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during different periods of growth, Lemieux et al. (1990) used 45 steers either not
implanted or implanted at 90-d intervals with Ralgro® or Synovex-S®. The animals
were evaluated for body composition using deuterium oxide dilution during a 100-d
growing phase and a 136-d finishing phase.

During the growing phase, protein gain

increased an average of 26.5 g/d for the implanted steers compared to the non-implanted
steers. Fat gain decreased by 78% for the implanted vs. non-implanted steers. During the
finishing phase, protein gain for implanted and non-implanted steers was similar to that
of the growing phase; however, fat gain was decreased for the implanted steers by only
9%, as compared to the non-implanted steers. When the relationship between daily
protein gain and daily empty body gain was evaluated, it was determined that between
the growth and finishing phases, daily protein gain at any rate of gain decreased for all
implant groups. This decrease reflects a lower priority for protein growth during the
finishing phase. However, during the finishing phase, cattle implanted with either
Ralgro® or Synovex® still deposited protein at greater rates than non-implanted cattle.
These results indicate that both Ralgro® (zeranol) and Synovex® (estrogen) repartition
nutrients from fat to protein deposition during both the growing and finishing phases in
cattle.
Mechanism of action of growth implants – Synovex
Synovex® growth implants are anabolic steroids manufactured by Fort Dodge
Animal Health in Overland, KS. Synovex® includes a series of implants for calves,
heifers and steers which are based on natural sex steroids. This series includes estradiol
benzoate plus progesterone (Synovex®C and Synovex®S) and testosterone propionate
plus estradiol benzoate (Synovex®H). These growth implants have been shown to
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increase growth rate by 8-15% and feed conversion efficiency by 5-10% (Buttery and
Dawson, 1990).
Research has shown that estrogen affects growth through the somatotropic axis;
specifically it can increase the release of growth hormone (GH), which helps to regulate
growth and development (Leung et al., 2004). The regulatory mechanism of estrogen on
GH occurs via secretion, clearance and action (Leung et al., 2004). In humans, oral
estrogen administration to postmenopausal women has been shown to increase circulating
GH levels, thereby restoring normal GH secretion (Dawson-Hughes et al., 1986). Some
of the functions of GH include growth of skeletal muscle through increased protein
synthesis, as well as stimulation of lipid oxidation and resting energy expenditure (Leung
et al., 2004; Moller et al., 1990). Another study performed in vitro with pituitary glands
isolated from cycling female rats sought to determine the effects of estrogen on growth
hormone synthesis and storage (Childs et al., 2005). When pituitary cells were incubated
with estrogen concentrations ranging from 0.01-10 nM, the percentage of GH antigenbearing cells increased. Pituitary cells were also stimulated with analogs of GHRH and it
was found that estrogen increased the number of cells with GHRH receptors. These
results support the positive effect of estrogen on GH production.
In cattle, an increase in GH secretion by the administration of an estrogen growth
implant is beneficial in stimulating protein synthesis and subsequent lean tissue
deposition. Loy et al. (1988) used Charolais-crossbred steers receiving either no implant,
implanted initially and on d 84 with Ralgro® (zeranol), or implanted initially and on d 84
with Synovex-S® (progesterone plus estradiol benzoate). On d 94, steers received a
pituitary challenge, which consisted of a thyrotropin releasing hormone (TRH) injection.
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Blood samples collected at 15 and 20 min post-challenge showed greater integrated areas
above the GH level at time of TRH injection for both implanted groups of steers
compared to non-implanted steers. Additionally, the pituitary glands of the steers were
removed at slaughter, weighed and analyzed for GH content. The weights of the pituitary
glands for both groups of implanted steers were 49% heavier compared to the nonimplanted steers. Likewise, the pituitary glands of the implanted steers contained 20%
more GH than the glands of the non-implanted steers. These data demonstrated not only
a greater GH content in the pituitary glands of steers receiving Synovex-S®, but a greater
release of GH immediately following a TRH challenge.
Other research by Gopinath and Kitts (1984a) evaluated the effects of SynovexS® implants on GH secretion and clearance rates in growing beef steers. To determine
GH secretion and clearance rates, twelve growing Hereford beef steers were used. Six
steers were non-implanted controls and six received Synovex-S® implants at the base of
the ear (200 mg progesterone and 20 mg estradiol benzoate). Two steers from each
treatment were chosen randomly to study GH kinetics. Blood samples were collected at
30 min intervals for 3.5 h to establish basal GH concentrations. The steers were then
injected with 6 mg bovine GH and serial blood samples collected at 5 min intervals for 50
min and then at 60, 90 and 120 min following GH challenge. Plasma basal GH
concentrations were increased in the implanted compared to non-implanted steers. Also,
the disappearance of GH after the challenge was determined to occur in a biexponential
fashion over a period of 120 min. There was an initial rapid phase lasting 5 min and a
slow disappearance phase lasting 42 min. During the initial rapid phase, the implanted
steers demonstrated an increased half-life of GH of 3.2 min relative to the control steers.
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The secretion rate of GH was also found to be increased in the implanted steers when
compared to the control steers. These results demonstrate that circulating basal
concentrations, secretion rate and half-life of GH are increased with estrogenic growth
implants in growing beef steers.
The thyroid hormones triiodothyronine and thyroxine (T3 and T4, respectively)
are important regulators of basal metabolic rate and protein synthesis (Welle and Nair,
1990). Thyroid hormone synthesis and release from the thyroid gland is stimulated by
thyroid-stimulating hormone (TSH), which is produced and released by the anterior
pituitary gland. In turn, the release of TSH is controlled by thyrotropin-releasing
hormone, which is released from the hypothalamus. Research has shown estrogen to
have pronounced effects on thyroid hormone metabolism. Estrogen has been shown to
increase the capacity of T 4 binding to thyroxine-binding globulin (TBG) in plasma,
decrease basal metabolic rate, increase release of TSH from the pituitary and increase
thyroid activity (Engbring and Engstrom, 1959). A study by Engbring and Engstrom
(1959) in which human athyrotic patients received estrogen and adequate T 4 replacement
therapy showed an increase in the half-life of T 4 from 6.9 to 10.6 d. Another experiment
by Dowling et. al (1960) supports a decrease in the fractional rate of turnover of T 4 from
plasma. The results from these studies suggest that with estrogen administration,
circulating T 4 levels remain high for a longer period of time, thus increasing the
availability of T 4 for conversion to T 3 in the peripheral tissues.
Another study by Lima et. al (2006) investigated the effects of estrogen on thyroid
hormone levels in normal and ovariectomized rats. Low and high doses of estradiol were
administered to control and ovariectomized adult female rats, as well as pre-pubertal
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females. The researchers found that estradiol increased the thyroid weights of the control
and pre-pubertal females. Also, when estrogen replacement was administered to
ovariectomized rats, the decreased serum T 3 levels were normalized. It was determined
that neither the low or high dose of estrogen affected circulating TSH concentrations,
suggesting that the increased thyroid weight and improved T 3 levels were direct effects
of estrogen on the thyroid gland.
Studies in cattle have investigated the effects of Synovex-S® implants on
circulating plasma concentrations of T 3 and T 4 , as well as on growth performance. An
experiment by Kahl et al. (1992) used 24 Angus-Hereford crossbred steers in a 56-d
feeding experiment. Steers received 4 treatments of control, Synovex-S® ear implant, T 3
injection every other day, or Synovex-S® plus T 3 injection every other day. Jugular
blood was sampled on d 0 and at 2-week intervals. The steers receiving T 3 injections had
increased T 3 concentrations, decreased TSH concentrations and essentially suppressed T 4
production. However, Synovex-S® implant decreased T 3 plasma concentrations, but had
no effect on TSH or T 4 concentrations. When steers received T 3 plus Synovex-S®, this
treatment had no effect on T 3 concentrations; however, this treatment decreased TSH and
T 4 concentrations. The authors state that this data indicates that the only thyroid
hormone required to maintain normal or Synovex-S® stimulated body weight gain and
protein deposition was T 3 . Synovex-S® stimulated body weight gain by 22 and 20% and
protein gain by 35 and 36% in non-T 3 and T 3 -injected steers, respectively.
These experiments show that Synovex® growth implants improve growth and
feed efficiency via changes in GH and thyroid hormones, which ultimately increases lean
tissue gain.
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Insulin resistance syndrome and the relationship with adipose tissue and fat
deposition in non-ruminants
Insulin resistance
Insulin resistance is a physiological condition in which normal levels of insulin
are not adequate to elicit an insulin response from tissues such as adipose, skeletal or
liver (Cosford 1999). The lack of response to insulin may be caused by disturbances to
the binding of insulin to receptors on the membrane or disruptions of the insulin signaling
cascade (Cosford 1999). In an individual with normal metabolism, insulin is released
from the pancreatic β-cells in response to a meal and signals glucose uptake by insulinsensitive tissues, thus decreasing blood glucose and insulin released by the pancreas
(Kahn and Flier, 2000; Matthaei et al., 2000). When an individual is insulin resistant,
body tissues are no longer sensitive to insulin and glucose is not removed from the blood.
Because glucose is not removed from the bloodstream, the pancreas responds by
releasing more insulin, resulting in hyperinsulinemia (Matthaei et al., 2000). Normal
blood glucose levels in humans range between 4.5 and 5.0 mmol/L and as an individual
becomes insulin resistant, these levels increase to between 5.0 and 6.5 mmol/L (Weir and
Bonner-Weir, 2004). As blood glucose levels rise and an increasing amount of insulin is
released, β cells in the pancreas begin to fail and release less insulin (Weir and BonnerWeir, 2004). This abnormal relationship of insulin-resistant tissues and dysfunctional βcells in the pancreas usually represents the final stage in the development of Type II
diabetes (Matthaei et al., 2000). However, while it appears that the development of
insulin resistance precedes Type II diabetes, the etiology of insulin resistance is not clear.
Frequently, insulin resistance is observed in conjunction with hyperinsulinemia, obesity
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and arterial hypertension (Matthaei et al., 2000). This collection of disorders may be
present for many years before Type II diabetes develops.
Insulin resistance, obesity and Type II diabetes
The relationship between insulin resistance, Type II diabetes and obesity may be
considered causative, as it has been suggested that insulin resistance leads to obesity,
which eventually leads to the development of Type II diabetes (Cosford 1999). Although
obesity is strongly correlated with insulin resistance, not all obese individuals have
insulin resistance, nor does insulin resistance always result in obesity (Cosford 1999).
Insulin resistance can result in obesity primarily through the anabolic effects of insulin on
fat metabolism. Insulin promotes glucose entry into adipocytes, increases production of
acetyl-CoA, enhances fatty acid entry into adipocytes for adipogenesis and aids in the
differentiation of preadipocytes to adipocytes (Cosford 1999; Kahn and Flier, 2000).
Insulin also inhibits lipoprotein lipase, thus decreasing the catabolism of fat (Cosford
1999). While an individual may be resistant to insulin and glucose transport is impaired,
it is possible that adipose tissue remains somewhat sensitive to insulin’s antilipolytic
effect as lower concentrations of insulin are sufficient to inhibit lipolysis (Kahn and Flier,
2000). These promoting factors, along with a lack of exercise, can increase the efficiency
of weight gain and ultimately lead to obesity.
Although a characteristic of both obesity and Type II diabetes is insulin
resistance, it has not been shown that all of insulin’s actions are impaired in individuals
with both conditions. Typically, assessing insulin resistance involves measures of
peripheral glucose disposal and the suppression of hepatic glucose production, both of
which are impaired. While glucose homeostasis may be compromised, hepatic
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lipogenesis and adipose tissue storage in certain depots are usually driven to excess
(Kahn and Flier, 2000; Frayn 2001). It is unclear why such discord exists in the action of
insulin; however, it is likely that changes in insulin signaling pathways and transcription
factors contribute.
However, in ruminants some research suggests that insulin resistance may also be
due to a low capacity of glucose transport (Sasaki 1990). Lipogenesis from [U-14C]
glucose was measured in ovine and rat adipocytes with a similar sensitivity to insulin. A
glucose concentration of 0.1 mM was used and glucose transport was reduced in the
ovine adipocytes to 15% of the transport in rat adipocytes in the basal state and all insulin
concentrations. If a lower glucose transport capacity is combined with possible changes
in insulin signaling, the possibility of severe insulin resistance may exist in ruminants fed
high-carbohydrate diets.
Insulin resistance and glucocorticoids
Glucocorticoids play an important role in the regulation of metabolic homeostasis.
Specifically, they are released in response to a stressor and assist in allocating energy
stores both after the stress has ended and during periods of prolonged stress. Indeed,
their natural role is to enhance gluconeogenesis in the liver and inhibit insulin-dependent
glucose uptake in the periphery. Overall, glucocorticoids oppose the actions of insulin
and excess glucocorticoids, especially long-term presence, creates a state of hypertension,
central obesity and glucose intolerance (Andrews and Walker, 1999). In the long-term,
glucocorticoids are capable of inducing insulin resistance, and many researchers use
compounds such as DEX to induce insulin resistance and study this syndrome.
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Mechanisms of glucocorticoid-induced insulin resistance
One way in which glucocorticoids can induce insulin resistance is through the
decreased translocation of glucose transporters (GLUT 4) to the surface of muscle and
adipose cells. Dimitriadis et al. (1997) used male Wistar rats injected with 0.5 mg/d DEX
for 5 d to induce insulin resistance. Soleus muscle was removed and examined for rates
of glucose transport using 3-O-methylglucose and GLUT4 abundance. 3-Omethylglucose is a glucose analogue which is transported like glucose but not further
metabolized, and therefore provides a direct estimate of the rate of glucose transport
(Narahara and Ozand, 1963). Dexamethasone decreased the rate of 3-O-methylglucose
transport into the soleus muscle at physiological concentrations of insulin. These results
suggest that glucose transport was decreased through an effect of DEX on the sensitivity
of the muscle to insulin. Furthermore, the abundance of GLUT transporters in the
membrane of the muscle cells was assessed when stimulated by insulin. Dexamethasone
reduced insulin-stimulated increases in GLUT4 translocation in the soleus muscle by
approximately 60%. This suggests that the effect of DEX on insulin-stimulated glucose
transport is via a decrease in the translocation of the GLUT4 glucose transporters from
cytosol to the plasma membrane (Dimitriadis et al., 1997).
Glucocorticoids also promote insulin resistance through the inhibition of glucosestimulated insulin secretion from pancreatic β-cells. As insulin sensitivity in muscle and
adipose tissue decreases and blood glucose concentrations remain elevated, the pancreas
compensates by releasing more insulin from the β cells. However, the presence of
glucocorticoids inhibits the release of insulin from the pancreatic β cells, thus
precipitating insulin resistance. Glucocorticoids mediate their effects on decreased
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insulin secretion from the pancreas through a glucocorticoid receptor located in
pancreatic β-cells (Fisher et al., 1990). This receptor is a nuclear hormone receptor that is
a ligand activatable transcription factor (Beato et al., 1995). Delaunay et al. (1997)
evaluated the role of glucocorticoids in β-cell function by increasing the glucocorticoid
sensitivity of β-cells in transgenic mice. This increase in sensitivity was accomplished by
overexpressing the glucocorticoid receptor under the control of the insulin promoter.
Glucose homeostasis and β-cell function were evaluated in mice that were 3-4 months
old. These mice were fasted overnight and then dosed with 0.5 or 2 g glucose/kg BW.
Transgenic and non-transgenic mice had identical fasting blood glucose concentrations
and similar blood glucose levels 5 or 10 minutes after intravenous injection. However, at
60 minutes following intravenous injection of either 0.5 or 2 g glucose/kg BW, transgenic
mice exhibited higher blood glucose concentrations compared to control mice.
Furthermore, the transgenic mice had lower fasting plasma insulin concentrations, and
reduced plasma insulin at 5 and 60 minutes following glucose injections compared to the
control mice. These data indicate defective insulin release from the β-cells of the
pancreas in mice with increased sensitivity to glucocorticoids and shows that
glucocorticoids directly inhibit insulin release (Delaunay et al., 1997).
Another way in which glucocorticoids promote insulin resistance is through an
increase in lipolysis. Elevated free fatty acids (FFA) are common in Type 2 diabetes,
insulin resistance and obesity, and are most likely due to increased FFA release
associated with an expansion of fat mass (Jensen et al., 1989). Free fatty acids have been
proposed as providing one of the links between obesity and insulin resistance (Boden and
Shulman, 2002). Furthermore, FFA assist in the development of insulin resistance by
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inhibiting glucose transport through both direct and indirect effects on the GLUT-4
glucose transporter. A direct effect may occur through GLUT-4 synthesis or vesicle
trafficking, budding or fusion (Kahn 1995). Indirect effects likely occur through the
modification of upstream insulin signaling events (Dresner et al., 1999).
Glucocorticoids have been proposed to play a role in increasing lipolysis from
adipose tissue, thus leading to increased plasma FFA concentrations (Divertie et al.,
1991; Samra et al., 1998). Furthermore, Samra et al. (1998) observed that while there
was an increase in the systemic appearance for glycerol during hypercortisolemia, there
was a decrease in FFA efflux from abdominal tissue. Based on these findings, a study by
Djurhuus et al. (2002) examined the effect of an acute physiological elevation of
circulating cortisol concentrations on systemic and regional adipose tissue. These
researchers sought to determine whether cortisol preferentially stimulates lower body
adipose tissue lipolysis as opposed to abdominal lipolysis. Seven healthy young adult
males (age 27 ± 2.5) were used in a single-blind, placebo-controlled, randomized trial.
After an overnight fast, the subjects were injected with either hydrocortisone sodium
succinate or 0.09% saline and blood samples collected for approximately five hours for
the analysis of serum cortisol and FFA. The release of glycerol from both the abdominal
and femoral interstitial areas was also determined. The researchers found that cortisol
increased serum FFA and glycerol, while there was no difference in the release of
glycerol from the upper (abdominal) or lower (femoral) body regions. These results
suggest that cortisol increases systemic lipolysis, which may promote insulin resistance.
However, this study proposes no difference in the lipolysis between the abdominal region
and other regions of the body (Djurhuus et al., 2002).
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Insulin resistance and adipose depots
It has been suggested that a relationship exists between specific fat depots and
insulin resistance. Specifically, there appears to be a correlation between fat in the
visceral and subcutaneous abdominal regions and insulin resistance (Bonora 2000).
Research has shown that visceral fat cells are more sensitive to the lipolytic effect of
catecholamines and less sensitive to the antilipolytic effect of insulin; therefore, more
FFA are released from this fat depot and contribute to insulin resistance by decreasing
glucose transport (Kahn and Flier, 2000). The net result of this increase in lipolysis from
the visceral fat depot is diversion of FFA towards nonadipose tissues such as the liver and
muscle. The blood supply of the visceral fat depot drains directly into the portal vein,
which travels directly to the liver. The liver must then repackage the FFA into
triglycerides and very low density lipoproteins (Lewis et al., 2002). Similarly, a release
of FFA from other adipose tissues delivers these FFA to the periphery. As adipose tissue
becomes insulin resistant through down-regulation of GLUT4, FFA and other fuels may
be diverted from adipose to nonadipose tissues, such as muscle (Lewis et al., 2002). As
FFA and possibly glucose are taken up by muscle tissue, they are converted to
intramuscular fat. However, it is not known whether triglycerides accumulate in the
muscle of insulin-resistant individuals because of a defect in fatty acid oxidation,
increased FFA flux to muscle or because of an imbalance between FFA uptake,
esterification or triglyceride lipolysis (Lewis et al., 2002).
As insulin resistance progresses, muscle usually becomes insulin-resistant; this is
significant, as skeletal muscle accounts for 70-80% of whole-body insulin-stimulated
glucose uptake (DeFronzo et al., 1981). It is likely that skeletal muscle becomes insulin
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resistant as a result of increased availability of circulating FFA. Randle et al. (1963)
suggested that an increase in FFA supply to the muscle leads to preferential fat oxidation,
therefore leading to a reduction in uptake and oxidation of glucose. However, while the
reduction in glucose oxidation has been confirmed (Boden et al., 1991), the contribution
of this cycle to the reduction in insulin-stimulated glucose uptake remains unclear
(Hegarty et al., 2003). While lipid infusion causes inhibition of glucose oxidation,
insulin stimulation of glucose uptake is unaffected for several hours and its impairment is
more closely associated with a reduction in glycogen synthesis rather than glucose
oxidation (Hegarty et al., 2003).

Insulin resistance and tumor necrosis factor-α
While the mechanisms involved in the causation of insulin resistance are complex
and remain to be fully elucidated, the involvement of tumor necrosis factor-α (TNF-α) in
adiposity and the development of insulin resistance has been determined (Hotamisligil et
al., 1995). TNF-α is a cytokine produced by macrophages and involved in systemic
inflammation (Beutler and Cerami, 1989). It has also been shown to be highly expressed
in the adipose tissue of obese subjects (Hotamisligil et al., 1995) and a lack of TNF-α
seems to protect obese mice against insulin resistance (Uysal et al., 1997). The
mechanistic effects of TNF-α seem to be through paracrine and autocrine action of
adipocytes in white adipose tissue (Arner, 2003). A study by Hotamisligil et al. (1996)
demonstrated that exposure of human adipocytes to TNF-α inhibits insulin signaling and
induces insulin resistance by affecting certain insulin receptor substrate proteins.
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In addition to the effects of TNF-α on adipocytes, a direct effect on skeletal
muscle has been difficult to establish. As skeletal muscle is responsible for
approximately 80% of glucose disposal, insulin resistance is first detectable in this organ
(Lorenzo et al., 2008). In subjects with Type II diabetes, the number of GLUT4 proteins
available to transport glucose inside the cell can remain normal; however, the capacity of
insulin to stimulate the translocation of GLUT4 to the plasma membrane may be
impaired (Lorenzo et al., 2008). This impairment of insulin may be due to the effects of
TNF-α, but studies have shown conflicting results. A study by Nolte et al. (1998)
showed no inhibitory effect of TNF-α on insulin-induced glucose uptake, while another
study by Rosenzweig et al. (2002) showed an inhibitory effect of TNF-α on insulin
action. However, further research seems to support the idea of an impairment of insulin
by TNF-α. A study by de Alvaro et al. (2004) used differentiated cultures of neonatal rat
skeletal muscle maintained in a low-glucose medium. These cells responded to acute
insulin stimulation by increasing glucose uptake and GLUT4 translocation to the plasma
membrane. However, when TNF-α was added to the medium, insulin-stimulated glucose
uptake and GLUT4 translocation were impaired. The results of these studies show the
important role of the cytokine TNF-α in the development of insulin resistance in both
adipose and skeletal muscle tissue of non-ruminants.
In ruminants, the relationship between TNF-α and insulin has been studied in
dairy cows and steers (Kushibiki et al., 2001; Ohtsuka et al., 2001). Kushibiki et al.
(2001) used Holstein steers between 16 and 18 months of age and treated them with
either a subcutaneous injection of saline or rbTNF once daily for 9 d. Plasma glucose,
NEFA and insulin concentrations were measured and increased in the steers treated with
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rbTNF compared to the control group. Another study by Ohtsuka et al. (2001) evaluated
Holstein dairy cows diagnosed with fatty liver. Cows were classified into 3 groups based
on the severity of fatty liver and assessed for serum TNF activity and glucose disposal
rate. The two groups of cows most severely affected with fatty liver were determined to
have higher serum TNF concentrations compared to the group with mild fatty liver.
Also, the severely affected groups had lower glucose disposal rates compared to the
mildly affected group. The results of this study showed that in dairy cows diagnosed
with fatty liver, there is a correlation between increased serum TNF concentrations and
insulin resistance, as shown by decreased glucose disposal rates. Overall, these studies
demonstrate that as in non-ruminants, there is a relationship between increased TNF-α
and insulin resistance.
The relationship between insulin resistance, obesity and Type II diabetes is very
complex and much remains to be determined regarding how the disorders develop and
are associated. Furthermore, most of the research related to these areas has been
performed in non-ruminants, mainly humans and rats. Further research needs to be
conducted in ruminants in order to understand the extent and mechanisms controlling
how high-carbohydrate diets might induce insulin resistance through obesity.
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Chapter 3
Experiment 1
Effects of chlortetracycline (CTC) and Synovex-S® on growth rate and on plasma
growth hormone (GH) and thyroid hormone concentrations following
administration of thyrotropin-releasing hormone (TRH) and GH-releasing hormone
(GHRH) in beef steers

Introduction
Subtherapeutic feeding of chlortetracycline (CTC) has been reported to have
growth-promoting effects for ruminants, swine, and poultry, but the mechanisms
responsible for these effects are unknown. It is generally hypothesized that growth
promotion by antibiotics in ruminants is a result of effects on digestive tract
microorganisms or gut wall thinning. However, CTC-induced changes in carcass
composition in calves suggest that this antibiotic may also influence growth via an
endocrine mechanism (Landagora et al., 1957). Recently we have shown oral
administration of CTC to temporally elevate circulating IGF-1 (McLeod et al., 2003)
concentrations; however, chronic administration of CTC reduced plasma concentrations
of growth hormone (GH), thyroid-stimulating hormone (TSH), and thyroxine (T 4 )
following injection of thyrotropin-releasing hormone (TRH) and growth hormonereleasing hormone (GHRH) in beef steers (Rumsey et al., 1999d). Corresponding with
this shift in circulating hormone concentrations were both an increase in subcutaneous fat
and a marbling score (Rumsey et al., 2000). Taken in concert, these data support the
notion that CTC affects tissue deposition by suppressing pituitary responsiveness to
GHRH and TRH.
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Implants containing estradiol and progesterone are used in finishing beef cattle to
improve feed efficiency and enhance lean tissue growth. Contrary to the reduced plasma
concentrations of GH, TSH, and T 4 observed with CTC administration, implantstimulated increases in cattle protein accretion are considered to be mediated by increases
in GH, IGF-1, TSH, and thyroid hormones (Gopinath and Kitts, 1984b; Johnson et al.,
1996; Rumsey et al., 1997). Although it is clear that estrogenic implants repartition
nutrients from fat to muscle tissue, the manner in which hormone profiles are altered
during repartitioning is still unclear (Lemieux et al., 1990). Moreover, with the exception
of circulating IGF-1 concentrations (Johnson et al., 1996), little research has investigated
the time-course effects of hormonal implants on GH, TSH, and thyroid hormones.
Considering the opposing actions of CTC and growth implants on pituitary and
thyroid hormone profiles and the lack of information regarding the time-course effects of
both CTC and growth implant, the primary objective of the current study was to test the
effects of oral CTC and Synovex-S® on circulating concentrations of GH and thyroid
hormones induced by an injection of TRH + GHRH in finishing beef steers on d 30, 56,
and 106 of a 112-d finishing study. Additionally, we measured the effects of CTC and
Synovex-S® on growth performance and carcass traits of these steers to evaluate the
relationship between hormone release and tissue deposition.

Materials and Methods
Animals and Treatments
The protocol for the research discussed in this report was approved by the
University of Kentucky Institutional Animal Care and Use Committee. Twenty-four
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Simmental-Angus crossbred steers were purchased from a single farm in Central
Kentucky. Steers were initially housed on pasture for 30 d upon arrival at the University
of Kentucky Animal Research Center, during which time they were dewormed using
ivermectin (Merial, Duluth, GA) and vaccinated using Bovi-Shield™4 and Ultrabac®7
(Pfizer Animal Health, Exton, PA). After 30 d, steers were moved to group pens (4
steers/pen) for a 30-d backgrounding period during which they were adapted to corn
silage until a body weight (BW) of approximately 340 kg was achieved. The group pens
measured 14.6 x 2.4 m and were located on a concrete pad partially covered with a roof.
The steers had continuous access to automatic waterers.
After the 30-d backgrounding period, steers were limit-fed two transition diets for
an additional 30 d at 2.25% BW for adaptation to ad libitum intake of the experimental
diet (Table 3.1). During this time, adaptation to handling and haltering was accomplished
by tying groups of four steers in a group-pen twice weekly. Steers were separated into
three groups of eight steers to facilitate intensive blood sampling on hormone challenge
days. The experiment start day for group 2 was one week after group 1, while group 3
started three weeks after group 1.
Ten days before each group started on the experiment, steers were moved into
individual pens measuring 2.4 x 1.8 m and covered by a roof. Each pen had an individual
feed bunk and waterer. During this period, steers were initially limit-fed the
experimental diet at 2.0% BW, followed by a gradual step-up to ad libitum intake over a
9-d period. For the duration of the experiment, steers were exercised by turning them out
into larger pens in groups of four from 0730-0900 each day. Before feeding, individual
body weights were determined once every two weeks for each group of steers; however,
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initial and final body weights were determined by weighing steers on two consecutive
days.
Across groups, steers were assigned randomly to a 2 x 2 factorial arrangement of
treatments. Treatments included a corn meal + molasses carrier containing either 0 or
350 mg CTC (Aureomycin, Alpharma Animal Health, Fort Lee, NJ) and Synovex-S® ear
implant (200 mg progesterone + 20 mg 17-β estradiol benzoate) or no Synovex-S®. The
level of CTC used in this study was the same as that used by Rumsey et al. (1999d,
2000), which had been shown to induce changes in carcass traits and pituitary and thyroid
responsiveness. Steers were implanted or not implanted with Synovex-S® on d 0; after
which steers initially implanted were re-implanted on d 56. The experimental diet was
formulated using two protein supplements: Protein supplement 1 was formulated to
provide 105% of the metabolizable protein requirement for large-frame steers (350 kg
BW) gaining 1.60 kg/d and was fed until d 56 of the experiment; Protein supplement 2
was formulated to provide 105% of the metabolizable protein requirement for largeframe steers (450 kg BW) gaining 1.60 kg/d and was fed from d 57-112 (NRC, 1996).
The carrier or carrier plus CTC (500 g) was supplied daily at 0900. Steers were returned
to the individual pens from the exercise lot and allowed one hour to consume the
treatments before feeding at 1000. Orts were measured daily immediately after steers
were turned out for exercise. Throughout the study, amount of feed offered was adjusted
to maintain approximately 20% orts.
Releasing-hormone challenges were conducted on d 30, 56, and 106. Jugular
catheters were placed in steers 12 to 18 h prior to hormone challenge and feed was
removed at 1700 on days prior to hormone challenge. On the day of hormone challenge,
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steers were injected via jugular catheter at 0800 with a 10-mL physiological saline bolus
containing TRH (1.0 µg/kg BW) and GHRH (0.1 µg/kg BW). Relative to hormone
challenge, serial, jugular blood samples (10 mL) were collected at -30, -10, 0, 5, 10, 15,
20, 30, 45, 60, 120, 240, and 360 min. Blood samples were centrifuged (1,800 x g @ 4˚C
for 30 min), plasma removed and frozen (-80˚C), and plasma concentrations of GH, TSH,
T 4 , and triiodothyronine (T 3 ) determined by RIA. Upon completion of the hormone
challenge, steers were fed their respective supplements (with or without CTC) and 50%
of their daily allotment of feed.
After 112 d on experimental treatments, steers were slaughtered in groups of four
steers per day over a one-week period in the University of Kentucky abattoir. Each group
contained one steer from each treatment, and selection was from heaviest to lightest
within each treatment. A merit evaluation of each carcass was done according to USDA
standards and performed by a qualified meat scientist. The carcass merit indicators were
hot carcass weight (HCW), dressing percentage, longissimus muscle area, fat over
longissimus muscle, kidney, pelvic, heart fat (KPH), marbling, and bone maturity.
Sample Analyses
Concentrations of GH and TSH were determined by previously validated RIA
(Elsasser et al., 1989, 1992, respectively). The intraassay CV were 7.0% and 8.3%,
whereas the interassay CV were 8.5% and 9.0% for the GH and TSH assays, respectively.
Based on a previous study by Rumsey et al. (1999d) in which full response curves were
obtained, the timepoints chosen for GH and TSH analyses were -10, 0, 10, 15, 30, 60, and
120 min for GH, and 0, 20, 30, 45, 60, 120, 240, and 360 min for TSH. All timepoints
were used for analyses of T 3 and T 4 . Thyroxine and T 3 concentrations were determined
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with a RIA (Coat-A-Count® Total T4 and Total T3, respectively, DPC®, Los Angeles,
CA) with inter- and intra-assay CVs of 7.1 and 5.6% for T 4 and 2.8 and 2.4% for T 3 ,
respectively. Each assay was validated for the upper and lower limits of the
physiological response range for bovine plasma. The recoveries for the upper and lower
limits averaged 107.5% ± 4.4 and 98.3% ± 0.49 for T 4 and T 3 , respectively. The lowest
detectable concentrations across all T 4 and T 3 assays averaged 0.84 and 0.03 ng/mL,
respectively. The GH, TSH, T 4 , and T 3 response curves were evaluated for area-underthe-curve (AUC) using GraphPad Prism software (GraphPad Software, Inc., Aurora,
CO), peak response (visual evaluation of plasma concentrations), and time from
challenge to peak.
Statistical Analyses
Growth performance and carcass data were statistically analyzed by analysis of
variance for a 2 x 2 factorial arrangement of treatments and randomized complete block
design using GLM procedures of SAS (SAS Inst., Inc., Cary, NC, 2003). The model
included group, CTC, implant, and CTC x implant interaction. Hormone data were
analyzed as a repeated, repeated-measure using MIXED procedures of SAS (SAS Inst.,
Inc., Cary, NC, 2003). Main plot effects included CTC, implant, and their interaction,
while the first subplot included day and the interactions, and the second subplot included
time and the interactions. The random statement included group, steer(CTC implant) and
day*steer(CTC implant). The repeated statement included steer(day CTC implant) as the
subject with a compound symmetry covariant structure.
Because of the pulsatile nature of GH release patterns, -10 and 0 timepoint
samples were simply averaged to generate a baseline value for the GH response curve

48

(Figure 3.1); the zero timepoint sample was used as the baseline value for the TSH
response curve (Figure 3.2). Data used to generate T 3 and T 4 response curves (Figures
3.3 & 3.4) were adjusted so that hormone concentrations across time reflected a common
zero-time mean. In order to adjust T 3 and T 4 data to a common baseline value, means for
-30, -10, and 0 timepoint samples were tested for significance using GLM and the
variance associated with those means was tested for significance using a Levene’s test.
Means for -30, -10, and 0 timepoint samples for T 3 and T 4 were not different (P = 0.99
and P = 0.85, respectively). Additionally, variances of the individual steer means for T 3
and T 4 across d 30, 56, and 106 were not different (P = 1.00), therefore, data for both
variables were adjusted to a common baseline value. Main effect means were separated
using the LS MEANS statements in SAS. Due to health reasons unrelated to the
experiment, data from one steer was excluded from analysis; therefore, the control
treatment contained five animals and the SEM for this group was used for data in all
tables and figures. When interactions were significant (P ≤ 0.05), least squares means
were tested using least significant differences for growth performance and carcass merit
data, while the slice option in the LS MEANS statement was used before pair-wise
comparisons were made for all hormone challenge data. Treatment main effects and
interactions were considered significant at P ≤ 0.05 and a tendency to be significant at P
≤ 0.10.
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Results
Growth Performance
Rate of BW gain (calculated as the slope of the line describing change in BW
over time), dry matter intake (DMI), and efficiency of gain (BW gain per unit of DMI)
are summarized in Table 3.2. Regardless of period, there were no treatment effects (P ≥
0.14) on DMI throughout the experiment. During Period 1 (d 0-26), Synovex-S®
increased BW gain (P = 0.01) by 20% and feed efficiency (P = 0.007) by 23%. There
were no treatment effects (P ≥ 0.12) on growth performance during Period 2 (d 27-54).
However, during Period 3 (d 55-82), Synovex-S® increased BW gain (P = 0.02) by 32%
and feed efficiency (P = 0.04) by 34%. During Period 4 (d 83-110), BW gain and
efficiency of gain were similar (P ≥ 0.40) for all treatments. Over the entire experiment
(d 0-110), Synovex-S® increased rate of BW gain (P = 0.009) by 20%, efficiency of gain
(P = 0.001) by 21%, and final BW (P = 0.007) by 6%. It is important to reiterate that the
periods of response to Synovex-S® were observed within the 28-d periods following
implantation (d 0 and 56) and that CTC demonstrated no effects on growth performance
throughout the experiment.
Carcass Merit
Carcass merit data are summarized in Table 3.3. Chlortetracycline and SynovexS® interacted (P ≤ 0.05) to affect slaughter weight and HCW. In the absence of CTC,
steers receiving implant had heavier slaughter weights and HCW (P ≤ 0.002) compared to
steers receiving no implant. However, in the presence of CTC, implant had no effect (P ≥
0.38) on slaughter weight or HCW. Similarly, in the absence of CTC, longissimus dorsi
area was greater (P = 0.008) in steers receiving implant compared with those receiving no
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implant. Conversely, implant had no effect (P = 0.96) on longissimus dorsi area in the
presence of CTC (interaction, P = 0.05). Concurrently, longissimus fat cover and yield
grade were lower (P = 0.03) in implanted steers in the absence of CTC, but implant had
no effect (P ≥ 0.38) when steers were fed CTC (interaction, P ≤ 0.05). There was no
effect (P ≥ 0.19) of treatment on KPH or marbling score. Bone maturity was lower (P =
0.01) for implanted steers.
Growth Hormone
The effects of estrogenic implant and CTC on changes in plasma GH
concentrations following injection of TRH + GHRH are shown in Figure 3.1. The effect
of time was significant (P < 0.0001). The concentration of plasma GH increased
following challenge injection, reached peak concentrations approximately 10 min postinjection, and returned to baseline concentrations by 120 min. There was a tendency (P =
0.10) for higher plasma GH concentrations in implanted steers compared to nonimplanted steers following challenge (Figure 3.1); however, there was no effect (P =
0.80) of CTC on plasma GH concentrations.
A summary of the effects of CTC and Synovex-S® on characteristics of the GH
response curve is shown in Table 3.4. Baseline concentrations of GH (the average of
samples obtained at -10 and 0 min relative to injection time) were not different (P ≥ 0.13)
between treatments. Time to peak was shorter (P = 0.05) for steers receiving implant
compared to steers receiving no implant. However, implant did not alter (P ≥ 0.14) the
magnitude of the GH response or area under the response curve. Overall, oral
administration of CTC had no effect (P ≥ 0.12) on GH response curve characteristics and
there were no CTC x implant interactions (P ≥ 0.39).
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Thyroid-Stimulating Hormone
The effects of Synovex-S® on changes in plasma TSH concentrations after TRH
+ GHRH injection are shown in Figure 3.2. The effect of time was significant (P <
0.0001). Concentration of plasma TSH increased following hormone challenge, reached
peak concentrations approximately 120 min post-injection, and returned to near baseline
6 h after challenge. The implant by time interaction after challenge was significant (P =
0.03), with greater (P ≤ 0.05) TSH concentrations at 45, 60, and 120 min, and a tendency
for greater (P = 0.09) TSH concentrations at 240 min, for implanted compared to nonimplanted steers. Conversely, at all other time-points along the TSH response curve,
there were no differences in the TSH response between implanted and non-implanted
steers. Similarly, there was no effect (P = 0.95) of CTC on the TSH response over the
360-min challenge period (data not shown).
Characteristics of the TSH response curve are shown in Table 3.4. Baseline
concentrations of plasma TSH were greater (P = 0.03) for implanted compared to nonimplanted steers; in contrast, baseline concentrations of TSH were unaffected (P = 0.58)
by CTC. There were no effects (P ≥ 0.19) of treatment on time to peak or magnitude of
the TSH response. Although there were no treatment effects on change in TSH
concentrations, overall peak concentrations showed a slight tendency to be greater (P =
0.11) for implanted compared to non-implanted steers. There were no effects (P ≥ 0.20)
of treatment on TSH area under the response curve.
Thyroid Hormones
The effects of Synovex-S® and CTC on changes in plasma T 3 concentrations
over time relative to injection of TRH + GHRH are shown in Figure 3.3. Because there
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was a significant CTC x implant x time interaction (P = 0.004), the means for implanted
and non-implanted steers are presented in the absence and presence of CTC. In the
absence of CTC, implanted steers had greater (P ≤ 0.02) T 3 responses 120, 240, and 360
min following the releasing hormone challenge relative to the non-implanted steers.
However, in the presence of CTC, implanted steers had only a tendency (P = 0.06) for a
greater response at 240 min compared to non-implanted steers.
There were no effects (P ≥ 0.41) of treatment on the baseline concentrations of T 3
(Table 3.4); however, area under the response curve tended to be greater (P = 0.07) for
implanted compared to non-implanted steers. Additionally, there was a CTC x implant
interaction (P = 0.02) for time to peak for T 3 . In the absence of implant, time to peak
increased (P = 0.03) for steers receiving CTC compared to those not receiving CTC.
Although the magnitude of T 3 response was greater (P = 0.01) for implanted steers
compared to steers receiving no implant, there tended (P = 0.09) to be an interaction
between CTC and implant. In the absence of CTC, the magnitude of the T 3 response was
greater (P = 0.005) for implanted compared to non-implanted steers. Conversely, in the
presence of CTC, the magnitude of the T 3 response was not affected (P = 0.46) by
implant.
The effects of Synovex-S® and CTC on changes in plasma T 4 concentrations
following the injection of TRH + GHRH are shown in Figure 3.4. The response of T 4
plasma concentrations to TRH + GHRH challenge injection in all steers continued to
increase throughout the sampling period, therefore a complete response curve was not
obtained. A review of individual animal data confirmed that the highest concentrations
of T 4 for all steers occurred at 360 min; therefore, peak concentrations must have
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occurred at 360 min or later. Thyroxine concentrations increased (P < 0.0001) after
challenge injection; however, there were no effects (P ≥ 0.34) of treatment on plasma T 4
concentrations. Additionally, there were no treatment effects (P ≥ 0.41) on baseline
concentration, magnitude of response, or area under the response curve (Table 3.4).
Time to maximum response was not analyzed statistically because a complete response
curve was not obtained; therefore a peak value could not be determined.
Effects of Day of Challenge on Pituitary and Thyroid Hormone Responses
Although there were no effects of day of challenge on GH, magnitude of
response, as well as area under the response curve for TSH, T 3 and T 4 were influenced
by day of challenge (data not shown). Day was also significant (P ≤ 0.05) for the peak
TSH concentrations, and baseline concentrations and time to peak for T 3 . Although the
effect of day was significant for these variables, there was not a consistent pattern of an
increased or decreased response throughout the experiment. Moreover, there were no
treatment x day interactions for any hormone variable measured, therefore all treatment
effects were independent of day.

Discussion
Previously, we have shown in beef steers that oral administration of CTC
attenuated pituitary and thyroid hormone responses to a TRH + GHRH challenge on d 56
and increased overall fat deposition during a 91-d experiment (Rumsey et al., 1999d). In
contrast, anabolic implants containing progesterone + estrogen, i.e. Synovex-S®, have
been shown to increase circulating concentrations of GH and thyroid hormones in
response to a GH or TRH + GHRH challenge (Gopinath and Kitts, 1984a; Rumsey et al.,
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1997) and to increase lean body tissue accretion (Rumsey et al., 1999b). However,
research has not evaluated the response of circulating hormone concentrations of GH and
thyroid hormones to a growth implant using a releasing-hormone challenge at multiple
timepoints over the entire course of the feedlot finishing period, nor have the interactive
effects of CTC and growth implant on circulating hormone concentrations been
determined. Furthermore, as CTC has been shown to diminish the pituitary and thyroid
hormone response to a TRH + GHRH challenge at a single timepoint (d 56) in the study
by Rumsey et al. (1999d), it was of interest to determine if this response was acute or
chronic. Therefore, the primary objective of the current study was to test the effects of
oral CTC and Synovex-S® on circulating concentrations of GH and thyroid hormones
induced by an injection of TRH + GHRH in finishing beef steers on d 30, 56, and 106 of
a 112-d finishing study. Additionally, we measured the effects of CTC and Synovex-S®
on growth performance of these steers to determine if changes in circulating hormone
concentrations were reflective of changes in growth and carcass traits. However, the
results of the current experiment showed no effect of CTC alone on the response of
pituitary or thyroid hormones to the releasing hormone challenge on d 30, 56, or 106;
there was also no increase in fat deposition with CTC by d 112. These results disagree
with the previous reports of Rumsey et al. (1999d, 2000), which demonstrated decreased
concentrations of circulating GH and thyroid hormones in response to releasing-hormone
challenge and subsequent increases in fat deposition. However, the lack of an effect of
CTC on circulating hormone concentrations in the current experiment is consistent with
the observed lack of change in fat deposition. Furthermore, a recent study by Kitts et al.
(2006) in which 96 steers were used to evaluate the effects of CTC and Revalor-S® on
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growth and carcass characteristics also showed no effect of CTC on fat deposition of
finishing beef steers. Regardless of the discrepancies in the CTC response between these
studies, this experiment demonstrates the effects of Synovex-S® on growth performance
and hormonal profiles concurrently over the course of the finishing phase, as well as
interactions between CTC and Synovex-S®.
Growth Performance
The DMI, BW gain, and feed efficiency data in this experiment are in agreement
with data concerning use of Synovex-S® implants in growing and finishing cattle
(Rumsey et al., 1992a, 1996, 1999a,c; Mader et al., 1994). The greatest improvements in
BW gain and feed efficiency were observed immediately following the administration of
Synovex-S® (Periods 1 & 3). The 32% increase in BW gain observed for implanted
steers during Period 3 was not unexpected, as steers were reimplanted with Synovex-S®
on d 56. However, there was a diminished response in BW gain to Synovex-S® during
Periods 2 & 4, suggesting a reduction in the effectiveness of this growth implant over a
56-d period. Although BW gain reduced by 32% in the presence, and 14% in the absence
of CTC for implanted compared to non-implanted steers during Period 2, gain reduced by
only 6% and 12% for these same groups during Period 4. While it appears that CTC may
have contributed to the diminished BW gain during Period 2, this was not the case during
Period 4, again suggesting an overall reduction in the effectiveness of Synovex-S®
during a 56-d period. The tremendous response observed during Periods 1 & 3 implies
that the positive effects of estrogenic implants are most apparent in the periods
immediately following implantation. It is important to note that because there was an
increase in BW gain for implanted steers during Periods 1 & 3 and no change in DMI,
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there was an increase in feed efficiency during these periods. As previously stated, there
are rarely changes in DMI when cattle are treated with anabolic implants, therefore an
increase in DMI during this experiment was not expected. Finally, increased BW gain
and feed efficiency during Periods 1 & 3 resulted in an overall increase in these
measurements for the entire experiment (20% and 19%, respectively). These responses
are similar to previous research showing increases of 18% and 12%, respectively
(Hermesmeyer et al., 2000).
Although BW gain and feed efficiency increased with the addition of estrogenic
implants, these measurements were not affected by the addition of CTC. Previously
Rumsey et al. (2000) reported that oral administration of CTC did not alter BW gain in
growing steers, but tended to improve efficiency of BW gain. Similarly, Kitts et al.
(2006) showed that CTC alone did not affect growth performance of finishing cattle over
the course of a 139-d feeding period; however, CTC attenuated the positive effects of
Revalor-S® on efficiency of gain during the latter 54 d of the feeding period. Overall,
the effects of CTC on growth performance have been variable. Research has shown
increased BW gain and efficiency in growing but not finishing steers, whereas other data
suggest improvements in weight gain for feedlot steers (Perry et al., 1954; Brown et al.,
1975). It has been suggested that the effects of CTC on growth performance are more
apparent under stressful conditions that are immunologically challenging to the animal
(Visek, 1978). In the current study and those of Rumsey et al. (2000) and Kitts et al.
(2006), steers were vaccinated and backgrounded for a minimum of 30 d, and adjusted to
the experimental diet prior to initiation of the experiment. In contrast to Kitts et al.
(2006), while ADG was numerically lower for implanted steers in the presence of CTC
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(with the exception of Period 1) in the current experiment, CTC did not attenuate effects
of implant on efficiency of gain. Although the reason for the differences in growth
response between the current study and that of Kitts et al. (2006) is unclear, the
physiological maturity of the steers and type of implant (estrogen vs. trenbolone acetate +
estrogen) differed in each experiment, which could account for the lack of consistency in
responses.
Carcass Merit
The primary objective of the current experiment was to evaluate the effects of oral
CTC and Synovex-S® on the release of GH and thyroid hormones induced by an
injection of TRH + GHRH in finishing beef steers during a 112-d study. However, we
also sought to examine the relationship between time-course of the hormonal responses to
the treatments and final body composition, as changes in GH and thyroid hormone status
should be indicative of changes in overall body composition. Contrary to the previous
study by Rumsey et al. (2000), the current data indicated no changes in intramuscular or
subcutaneous fat for cattle fed CTC alone. Likewise, the study by Kitts et al. (2006)
showed no change in carcass characteristics for cattle fed CTC alone or in the presence of
growth implant.
In general, estrogenic implants have been shown to increase slaughter weight in
finishing cattle (Mader et al., 1994; Rumsey et al., 1999b; Hermesmeyer et al., 2000).
While our data generally agree with these observations, interactions between implant and
CTC occurred for slaughter weight and HCW. These interactions are explained by 9%
and 10% increases in both slaughter weight and HCW for steers receiving growth implant
compared to those receiving no implant in the absence of CTC. However, the positive
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effects of Synovex-S® on slaughter weight and HCW were diminished in the presence of
CTC. Because there was no difference in the dressing percentage for any treatment
group, changes in HCW were directly proportional to changes in slaughter weight.
Although an interaction between steers receiving implant and CTC was largely absent in
the growth performance data, the attenuation of the effects of Synovex-S® by CTC on
slaughter weight and HCW is consistent with the previous observed decrease in growth
efficiency of cattle implanted with Revalor-S® (Kitts et al., 2006).
The observed increase in longissimus muscle area and decrease in fat cover for
implanted compared to non-implanted steers alone is in agreement with previous research
showing increases in protein gain and a reduction in fat gain (Solis et al., 1989; Lemieux
et al., 1990). Additionally, both longissimus fat cover and intramuscular fat have
previously been shown to increase in CTC-fed steers (Bohman and Wade, 1958; Harvey
et al., 1968; Rumsey et al., 2000). Thus, the current observed interaction between CTC
and growth implant for longissimus muscle area and fat cover is consistent with the
aforementioned effects of each of these compounds alone. However, the observation that
CTC failed to increase fat deposition in the current experiment agrees with the report of
Kitts et al. (2006), where no effect of CTC, either alone or in combination with growth
implant, on subcutaneous or intramuscular fat was observed. Control (-CTC, -implant)
steers had 13% smaller longissimus muscle area and 43% greater fat cover compared to
all other treatments. Given the aforementioned and the fact that three of five steers in the
control treatment had subcutaneous fat thicknesses in excess of 0.89 cm, it is equivocal
whether the observed interactions are a function of treatment. Finally, the absence of an
overall effect of CTC on body composition as measured by carcass characteristics agrees
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with the concurrent finding that CTC did not attenuate GH or thyroid hormone status. In
the previous experiment by Rumsey et al. (1999d, 2000), changes in body composition
appear to be associated with changes in GH and thyroid hormones with the
administration of oral CTC; however, it is unclear whether the lack of change in both
carcass composition and hormonal status observed in the current experiment supports this
hypothesis.
Growth Hormone
Previous researchers assessed the pulsatile pattern of GH secretion and
demonstrated that baseline GH concentrations were higher in steers 20 d after implanting
with Synovex-S® compared to steers receiving no implant (Gopinath and Kitts, 1984a).
In the current experiment, we observed only a slight tendency (P = 0.13) for increased
GH baseline concentrations; however, it is important to note that the blood samples used
to measure baseline GH concentrations in the current experiment were those collected 10
and 0 min prior to the TRH + GHRH injection. Due to the pulsatile nature of GH release
from the pituitary, blood samples must be collected for at least several hours to obtain an
accurate profile of baseline concentrations (Davis et al., 1977; McLeod et al., 1995).
Thus, the samples collected in the current experiment would only provide a crude
estimate of the baseline GH concentration.
The experiment by Gopinath and Kitts (1984a) also demonstrated that SynovexS® increases GH secretion from the pituitary rather than clearance from circulation. This
is consistent with the data from the current experiment, which showed a decrease (P =
0.05; Table 3.4) in the time to peak for GH and the overall response curve of GH
concentrations across time induced by a TRH + GHRH challenge tended (P = 0.10;
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Figure 3.1, Panel A) to be greater for the implanted compared to the non-implanted
steers. Taken together, the latter observation suggests that the pituitaries of implanted
steers may have been more sensitive to GHRH, leading to a quicker release of the
available GH pool. Estrogen receptor-α is highly expressed in the anterior pituitary and
has been shown to increase the number of GH-secreting cells (Chowen et al., 2004;
Childs et al., 2005). Additionally, 70% of GHRH neurons contain estrogen receptor-α,
and estradiol replacement in aromatase-knockout, female mice have been shown to
increase levels of GHRH receptor mRNA expression relative to aromatase-knockout
mice alone (Kamegai et al., 2001; Yan et al., 2004). Therefore, increased sensitivity of
the pituitary gland in steers receiving estrogenic implants could be due to either higher
affinity or greater number of GHRH receptors.
Thyroid Hormones
Over the course of the current experiment, estrogenic implant enhanced TRHinduced TSH release, as well as increased the magnitude of the T 3 response. The
increase in baseline TSH concentrations for implanted steers is in agreement with a
previous study by Rumsey et al. (1997). In the current experiment, peak TSH
concentrations after a TRH challenge tended to be higher for implanted compared to nonimplanted steers (Table 3.4). This most likely was a function of higher baseline
concentrations and to a greater extent, larger changes in the magnitude of TSH response
(Table 3.4). Interestingly, there was no difference between implanted and non-implanted
steers in the initial response (20 min, Figure 3.2) of TSH following TRH challenge,
suggesting that the size of the readily-releasable pool was not different. This finding is
supported by research in rats, which failed to demonstrate an effect of estrogen on size of
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releasable pools of TSH in the pituitary (Franklyn et al., 1987). However, in the current
experiment, differences in TSH concentrations occurred at 45, 60, and 120 min following
challenge for implanted vs. non-implanted steers, suggesting that these animals may have
a greater ability to synthesize TSH after depletion of the releasable pool (Figure 3.2).
Rumsey et al. (1997, 1999d) have shown that following a TRH challenge, there is an
initial increase in plasma concentrations of TSH, followed by a small reduction and
another increase, which could be a latent stimulation of TSH synthesis. In addition to
stimulating the releasable pool of TSH from the pituitary, TRH also stimulates the
formation of TSH mRNA (Ross et al., 1983), which may be responsible for subsequent
stimulation of TSH synthesis. Alternatively, the latent release could also be a result of
the secretory pulses of TSH that occur every 1-3 h, regardless of feedback inhibition by
T 3 (Samuels et al., 1991; Larsen 2003). However, the latter appears less plausible
because of 1) the lack of a treatment effect on the readily releasable pool of TSH and 2)
the expectation that the bolus dose of TRH was sufficient to induce the release of the
majority of pre-synthesized TSH. The latter is supported by the fact that higher doses of
TRH than those used in the current experiment do not cause a further increase in
circulating TSH (Rumsey et al., 1997).
Following 120 min post-challenge, plasma TSH concentrations began to decrease
at a time when T 3 had almost reached peak concentrations (Figures 3.2 & 3.3,
respectively). This sequence of events is illustrated by the hormonal response of an
individual steer receiving Synovex-S® (Figure 3.5). As expected, the peak in plasma
TSH concentration occurred prior to the peak in concentration of T 3 and before the
estimated peak of T 4 . A steady, peak TSH concentration occurred by 60 min, while the
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T 3 concentration peaked at 120 min. Because T 3 , the metabolically active form of
thyroid hormone, is synthesized from T 4 in peripheral tissues, an increase in circulating
T 3 several hours after TRH challenge is not surprising (Larsen 2003). Our data is
consistent with this series of events; plasma TSH began to decrease 120 min postchallenge (Figure 3.2) and plasma T 3 was approaching peak concentrations (Figures 3.3
& 3.5). The observation that T 4 concentrations continued to rise at 360 min while T 3
concentrations plateaued and began to decrease suggests that 5’-deiodinase activity was
saturated and/or is reflective of the fact that the half-life of T 3 is approximately 1/16 of
that of T 4 .
It is notable that in the absence of implant, time to peak for T 3 increased for steers
receiving CTC compared to those not receiving CTC, implying that CTC delayed the
initial release of T 3 from the thyroid, and/or the conversion of T 4 to T 3 . This effect of
CTC was not seen in a previous experiment by Rumsey et al. (1999d); however they
reported that CTC decreased 5’-deiodinase activity in the pituitary, which is the enzyme
responsible for converting T 4 to T 3 . Approximately 80% of circulating T 3 is derived
from 5’-deiodinase activity in the pituitary, liver, kidney, and plasma membrane of most
peripheral tissues (e.g., muscle; Larsen 2003). However, 5’-deiodinase activity was not
measured in the current experiment, thus it is unclear if the T 3 time to peak increased due
to decreased activity of this converting enzyme or if direct release of T 3 from the thyroid
was delayed by CTC.
Although CTC may have decreased activity of 5’-deiodinase, Synovex-S® may
have increased the conversion rate of T 4 to T 3 in the peripheral tissues, pituitary, liver, or
kidney. The T 3 response curve demonstrated a CTC x implant x time interaction after the
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releasing hormone challenge (Figure 3.3). In concert with greater TSH concentrations for
implanted compared to non-implanted steers (Figure 3.2), this interaction occurred due to
greater T 3 concentrations 120, 240, and 360 min following challenge injection for
implanted compared to non-implanted steers in the absence of CTC; however, these
differences did not occur in the presence of CTC (Figure 3.3). Although TSH causes an
acute stimulation of T 4 release into the plasma, it stimulates 5’-monodeiodination of only
small amounts of T 4 to T 3 , thus it is unlikely that the increase in circulating T 3 is due to
an increase in T 3 release from the thyroid. The absence of treatment effects on
circulating T 4 does not negate the possibility that, in the absence of CTC, implant
increased T 4 release, which subsequently increased conversion of T 4 to T 3 .
Alternatively, increases in 5’-deiodinase activity could have occurred for implanted
compared to non-implanted steers in the absence of CTC. An increase in this enzyme
would have resulted in increased T 3 concentrations, but would not necessarily have
resulted in decreased T 4 concentrations due to the large circulating pool of T 4 relative to
T 3 (T 4 concentrations 43-fold greater than T 3 ). Conversely, if steers receiving CTC had
decreased concentrations or activity of the 5’-deiodinase enzyme, differences in the T 3
response of these steers would not be expected. This might explain the response curves
in Figure 3.3, Panel B. Although this explanation appears plausible, it does not
completely explain all of the T 3 response data, especially considering the fact that the
magnitude of response for T 3 (Table 3.4) tended (P = 0.09) to show a CTC x implant
interaction. This interaction reflects a marginal decrease (0.06 ng/mL) in the implant
response in the presence of CTC and an increase (0.14 ng/mL) in the response of CTC in
the absence of implant. This observation does not necessarily support the case that CTC
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decreases 5’-deiodinase activity and may, on the surface, support the idea that CTC may
have enhanced the T 3 response in the absence of implant.
When the T 3 and T 4 results in the current experiment are compared with previous
research, some inconsistencies are apparent. First, previous research has shown
Synovex-S® to have either no effect on area under the response curve or to decrease
circulating T 3 (Rumsey et al., 1997; Kahl et al., 1992). These results are in conflict with
the current experiment, in which the response of T 3 was greater for steers receiving an
estrogenic implant. Second, a discrepancy between our data and previous literature is the
failure to demonstrate an effect of CTC or implant on the T 4 response to an injection of
TRH + GHRH. Rumsey et al. (1999d) demonstrated that CTC decreased magnitude of
the T 4 response to a TRH + GHRH challenge, while other research has shown that
Synovex-S® increased circulating concentrations of T 4 in plasma from blood samples
collected 60 d post-implantation or in 2-wk intervals for 56 d, respectively (Kahl et al.,
1978; Gopinath and Kitts, 1984). Rumsey et al. (1997) demonstrated an increased T 4
response to a TRH + GHRH challenge in Synovex-S® implanted compared to nonimplanted steers. The experiments of Rumsey et al. (1997, 1999) allowed development
of more complete T 4 response curves than the current experiment in which T 4
concentrations continued to rise 360 min post-challenge. Two plausible mechanisms
could explain the observed response. First, Larsen (2003) suggests that when a TRH
challenge is given, T 4 concentrations may not change, because the circulating pool of T 4
is large and an increase in release may be too small to detect. Approximately 70% of
circulating T 4 is bound to thyroid-binding globulin and other proteins, while the
remaining 30% circulates in a free form and is considered to be the “metabolically
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active” pool (Larsen 2003). This ratio of bound:free T 4 is tightly regulated and difficult
to alter, therefore the response of T 4 to hormonal treatments such as estrogen implants
may be highly variable between experiments. Secondly, the half-life of T 4 is 6.7 d;
therefore, because the thyroid is a significant reservoir of T 4 , the variability in release
rate after a TRH challenge combined with a long half-life may delay the achievement of a
complete response curve. If blood had been collected past 360 min in the current
experiment, e.g., 480 and 600 min, T 4 plasma concentrations may have begun to decline
within those time periods.
Effects of Estrogenic Implant on Anabolic Hormones and Body Weight Gain
Although previous research has demonstrated that anabolic implants enhance BW
gain through increases in protein accretion, the modes of action have not been clearly
identified. Some research involving estrogenic implants has focused on the roles of
pituitary hormones such as GH and TSH (Gopinath and Kitts, 1984a; Loy et al., 1988a;
Kahl et al., 1992; Aldrich et al., 1996; Rumsey et al., 1996, 1997); however, no research
has examined the response of GH and thyroid hormones to a releasing hormone challenge
at multiple time-points over an entire finishing phase. Clearly, the lack of treatment x
day interactions in the current experiment showed that the response of GH and thyroid
hormones to TRH + GHRH injection was greater for implanted compared to nonimplanted steers throughout the experiment, and the enhanced response of these
hormones appeared to be associated with an overall increase in BW gain for the
implanted compared to non-implanted steers. However, the most significant
enhancement in BW gain was observed for these steers only in the periods immediately
following implantation (d 0-26 and d 55-82). Thus, increased BW gain may not be
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consistently associated with heightened sensitivities of the pituitary and thyroid glands in
steers receiving estrogenic implants, as assessed by the releasing-hormone challenges.
Additionally, our data show that the overall GH response in the implanted steers was
greater compared to the non-implanted steers. Our data also support the notion that the
releasable GH pool may have been greater for the implanted animals, and the pool of
TSH and T 3 was greater for steers receiving Synovex-S®. It is important to note that
estrogenic implants may have a direct effect on skeletal muscle protein synthesis due to
the presence of high-affinity, estrogen receptors, which have been identified in bovine
skeletal muscle (Meyer and Rapp, 1985; Sauerwein and Meyer, 1989). The most likely
mode of action for the increased protein accretion observed with the administration of
estrogenic implants is a combination of increased GH and thyroid hormone secretion
rates, as well as some direct effects of the estrogen on skeletal muscle cells.
In conclusion, Synovex-S® enhanced GH and thyroid hormone status across all
measured time-points and increased overall rate and efficiency of BW gain over the 112d finishing period. However, improvements in growth performance were not consistent
with the increase in pituitary and thyroid hormones throughout individual periods of the
experiment. Although there were no main effects of CTC on pituitary or thyroid
hormones, or tissue accretion, CTC x estrogenic implant interactions were observed for
T 3 , and perhaps carcass protein and fat accretion, suggesting that CTC may mitigate the
effects of implant in beef cattle during the feedlot finishing phase of production.
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Table 3.1 Step-up and experimental diets
Ingredient, % DM
Corn silage
Alfalfa haylage
Cracked corn
Corn gluten meal
Ground corn
Urea
Limestone

Step-Up Step-Up Experimental Experimental
Diet #1 Diet #2 Diet (d -10-56) Diet (d 57-112)
20.00
5.00
--------20.00
20.00
20.00
20.00
50.00
65.00
70.00
70.00
2.97
2.97
2.97
----4.78
4.78
4.78
7.75
0.36
0.36
0.36
0.35
1.07
1.07
1.07
1.07

Trace mineral-salt1

0.51

0.51

0.51

0.51

Vitamins A, D, E2
Choice white grease

0.02
0.31

0.02
0.31

0.02
0.31

0.02
0.30

1

98.5% NaCl, 0.35% Zn, 0.34% Fe, 0.20% Mn, 330 ppm Cu, 70 ppm I,
50 ppm Co, 90 ppm Se
2
8,800 IU/g vitamin A, 1,760 IU/g vitamin D, 1.1 IU/g vitamin E
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Table 3.2 Effects of oral chlortetracyclinea (CTC) and growth implant on
body weight gain, feed intake, and efficiency of gain
-Implant
Item
Period 1, 0-26 d
Initial BW, kg
DMI, kg/d
Body weight gain, kg/d
Gain:DMI, g/kg

-CTC +CTC

+Implant

P<

-CTC +CTC SEMb CTC Implant Xc

363
366
9.60 9.13
1.88 1.89
86.92 91.29

369
363
9.13
9.04
2.21
2.34
106.93 112.41

21.03
0.98
0.33
7.01

0.90
0.50
0.60
0.46

0.85
0.51
0.01
0.005

0.62
0.66
0.70
0.93

Period 2, 27-54 d
Initial BW, kg
DMI, kg/d
Body weight gain, kg/d
Gain:DMI, g/kg

411
415
10.21 9.72
1.49 1.61
69.22 72.06

427
424
10.33
9.32
1.91
1.58
84.29 78.30

18.37
1.24
0.33
6.93

0.94
0.17
0.45
0.81

0.15
0.79
0.19
0.12

0.66
0.62
0.12
0.50

Period 3, 55-82 d
Initial BW, kg
DMI, kg/d
Body weight gain, kg/d
Gain:DMI, g/kg

453
461
9.27 9.66
1.07 1.43
53.64 66.14

480
468
10.15
9.11
1.78
1.59
80.67 80.13

20.04
1.46
0.45
9.65

0.78
0.61
0.66
0.52

0.06
0.79
0.03
0.03

0.26
0.26
0.16
0.48

Period 4, 83-110 d
Initial BW, kg
DMI, kg/d
Body weight gain, kg/d
Gain:DMI, g/kg

483
501
9.83 9.84
1.36 1.40
63.65 65.40

530
512
10.42
9.75
1.55
1.49
68.32 71.06

19.49
1.21
0.36
5.53

0.99
0.52
0.94
0.67

0.002
0.63
0.37
0.33

0.05
0.52
0.72
0.92

0-110 d
Initial BW, kg
Final BW, kg
DMI, kg/d
Body weight gain, kg/d

363
366
522
540
9.73 9.59
1.42 1.57

369
363
574
555
10.02
9.31
1.87
1.74

21.03
26.88
1.05
0.24

0.90
0.99
0.35
0.93

0.85
0.01
0.99
0.01

0.62
0.12
0.53
0.17

67.45 74.17

84.14

Gain:DMI, g/kg
a

84.48 3.76 0.33

Chlortetracycline was fed at 350 mg of CTC per day
per steer
b
Standard error of the mean calculated from analysis of variance using n=5
c
Interaction of CTC x Implant
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0.001 0.37

70

1.80

KPH fat, %

b

1.96

1.27

2.45

1.42

0.57

84.84

d

2.07

1.23

2.87

1.58

0.66

83.17

0.22 0.16

0.04 0.32

0.25 0.18

0.18 0.92

0.04 0.19

0.58 0.19

575
556
24.87 0.88
327
337
15.83 0.48
58.61 58.67 0.51 0.15

Interaction of CTC x Implant
Slaughtered at day 112 or 114
e
Scores: 1.00 = trace00, 2.00 = slight00, 3.00 = small00, 4.00 = modest00
f
Scores: 1.00 = A00

c

1.95

1.33

2.83

1.67

0.55

82.96

P<

0.17

0.01

0.84

0.18

0.29

0.07

0.006
0.007
0.60

0.06

0.87

0.74

0.38

0.03

0.08

0.07
0.03
0.19

-CTC +CTC SEMb CTC Implant Xc

+Implant

Chlortetracycline was fed at 350 mg of CTC per day per steer
Standard error of the mean calculated from analysis of variance using n=5

2.68

Yield grade
a

1.38

Bone maturityf

Marbling

2.58

0.86

Longissimus fat cover slaughter, cmd
e

71.74

Longissimus area, cm2

522
544
301
322
57.70 59.06

Slaughter weight, kg
Hot carcass weight, kg
Dressing percentage

+CTC

-CTC

-Implant
Item

evaluation measures of finishing beef steers

Table 3.3 The effects of oral chlortetracyclinea (CTC) and growth implant on carcass
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b

Standard error of the mean calculated from analysis of variance using n=5
Interaction of CTC x Implant
c
Average across samples taken at –10 and 0 min before the injection of thyrotropin-releasing hormone +
growth hormone-releasing hormone (1.0 + 0.1 µg/kg BW)
d
Average across samples taken at -30, -10, and 0 min before the injection of thyrotropin-releasing hormone +
growth hormone-releasing hormone (1.0 + 0.1 µg/kg BW)
e
Day effect (P ≤ 0.05)

a

Table 3.4 Influence of oral chlortetracycline (CTC) and growth implant on growth hormone (GH),
thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4), hormone responses
to a releasing hormone challenge in finishing beef steers
- Implant
+ Implant
P<
Item
- CTC
+ CTC
- CTC
+ CTC SEMa CTC Implant Xb
GH
Baseline, ng/mLc
2.80
2.59
3.31
4.43
0.91 0.60
0.19
0.46
Time to peak, min
15.67
13.33
12.78
11.14
1.33 0.13
0.06
0.78
Peak-baseline, ng/mL
15.19
18.72
22.41
20.84
3.48 0.77
0.17
0.45
Area, (ng/mL)*min
460.49
498.62
606.92
506.91
97.16 0.74
0.41
0.46
TSH
Baseline, ng/mL
0.15
0.15
0.21
0.18
0.02 0.62
0.04
0.41
Time to Peak 1, min
30.33
33.89
57.78
43.23
9.02 0.52
0.04
0.30
Time to Peak 2, mine
112.00
115.49
108.27
101.90
8.24 0.86
0.29
0.54
Peak 1-baseline, ng/mLe
0.30
0.40
0.48
0.43
0.09 0.74
0.22
0.39
0.43
Peak 2-baseline, ng/mLe
0.36
0.55
0.48
0.10 0.96
0.22
0.49
90.64
100.54
0.20
Area, (ng/mL)*mind
74.08
113.96
19.82 0.93
0.43
T3
Baseline, ng/mLde
1.39
1.37
1.45
1.38
0.05 0.47
0.50
0.67
Time to peak, mine
224.00
286.67
273.33
237.80
18.82 0.48
0.99
0.02
Peak-baseline, ng/mLe
0.62
0.73
0.84
0.78
0.07 0.73
0.06
0.26
Area, (ng/mL)*mine
166.91
193.60
0.20
182.66
208.63
19.42 0.99
0.45
T4
Baseline, ng/mLd
61.18
67.62
65.44
65.44
3.60 0.39
0.78
0.39
e
Peak-baseline, ng/mL
24.34
26.08
26.69
25.35
1.98 0.92
0.69
0.45
Area, (ng/mL)*mine
4818.91 4700.53 4981.87 5204.40 406.42 0.90
0.43
0.68
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b

Standard error of the mean calculated from analysis of variance using n=5
Interaction of CTC x Implant
c
Day effect (P < 0.0001)

a

Table 3.5 Influence of oral chlortetracycline (CTC) and growth implant on biweekly
thyroxine (T4) and triiodothyronine (T3) hormone concentrations in finishing beef steers
- Implant
+ Implant
Item
- CTC
+ CTC
- CTC
+ CTC
SEMa
CTC
T3
ng/mLc
1.64
1.63
1.71
1.69
0.08
0.84
T4
ng/mLc
75.61
89.05
86.49
80.69
4.46
0.37
Xb
0.97
0.03

P<
Implant
0.35
0.77
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Figure 3.1. Plasma growth hormone concentration in beef steers receiving no Synovex S or
Synovex S, fed the same diet top-dressed with either corn meal + molasses carrier or carrier
plus 350 mg of chlortetracycline (CTC) per day, and injected at time zero with 1.0 µg TRH +
0.1 µg GHRH per kg BW. Plasma growth hormone concentration changed with time in
response to the releasing hormone challenge (P < 0.0001).
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Figure 3.2. Plasma thyroid-stimulating hormone (TSH) concentration in beef steers receiving no
Synovex S or Synovex S (200 mg progesterone + 20 mg 17-β estradiol benzoate), fed the same diet
top-dressed with either corn + molasses carrier or carrier plus 350 mg of chlortetracycline (CTC) per
day, and injected at time zero with 1.0 µg TRH + 0.1 µg GHRH per kg BW. Plasma thyroidstimulating hormone concentration changed with time in response to the releasing hormone challenge
(P < 0.0001), and there was an interaction (P = 0.03) between implant and time for the TSH response.
The TSH response at 45, 60, and 120 min after injection was greater (*P ≤ 0.05) for implanted
compared to non-implanted steers.
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Figure 3.3. Plasma triiodothyronine concentration in beef steers receiving no Synovex S or
Synovex S, fed the same diet top-dressed with corn + molasses carrier, and injected at time zero
with 1.0 µg TRH + 0.1 µg GHRH per kg BW. Plasma triiodothyronine concentration changed
with time in response to the releasing hormone challenge (P < 0.0001). In the absence of CTC,
implanted steers had a greater response (*P ≤ 0.02) 120, 240, and 360 min following the releasing
hormone challenge compared to non-implanted steers.
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Figure 3.4. Plasma triiodothyronine concentration in beef steers receiving no Synovex S or
Synovex S, fed the same diet top-dressed with corn + molasses carrier plus 350 mg of
chlortetracycline (CTC) per day, and injected at time zero with 1.0 µg TRH + 0.1 µg GHRH per kg
BW. Plasma triiodothyronine concentration changed with time in response to the releasing
hormone challenge (P < 0.0001). In the presence of CTC, implanted steers tended (**P = 0.06) to
have a greater response at 240 min compared to non-implanted steers.
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Figure 3.5. Plasma thyroxine concentration in beef steers receiving no Synovex S or Synovex S,
fed the same diet top-dressed with either corn + molasses carrier or carrier plus 350 mg of
chlortetracycline (CTC) per day, and injected at time zero with 1.0 µg TRH + 0.1 µg GHRH per kg
BW. Plasma thyroxine concentration changed with time in response to the releasing hormone
challenge (P < 0.0001).
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Figure 3.6. Plasma thyroid- stimulating hormone, thyroxine, and triiodothyronine concentrations in a steer receiving
growth implant, fed a diet top-dressed with a corn + molasses carrier each day, and injected at time zero with 1.0 µg
TRH + 0.1 µg GHRH per kg BW. Standard error of the mean for TSH, T4 and T3 was 0.05, 2.84 and 0.07, respectively.
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Chapter 4
Experiment 2
Effects of chlortetracycline (CTC) and Revalor-S® on growth performance and
carcass quality traits of finishing beef steers

Introduction
Subtherapeutic feeding of chlortetracycline (CTC) has been shown to have
growth-promoting effects for ruminants, swine, and poultry, but the mechanisms
responsible for these effects are not known. Most hypotheses for growth promotion by
antibiotics in ruminants relate to effects on digestive tract microorganisms or gut wall
thinning (Visek, 1978). Based on the effects of CTC on carcass composition of calves, it
has been suggested that CTC may influence growth via an endocrine axis (Landagora et
al., 1957). Previously we have shown that chronic, oral administration of 350 mg CTC
per steer per day elevated circulating IGF-1 (McLeod et al., 2003) concentrations and
reduced plasma concentrations of growth hormone (GH), thyroid-stimulating hormone
(TSH), and thyroxine (T 4 ) following injection of thyrotropin-releasing hormone (TRH)
and growth hormone-releasing hormone (GHRH) in beef steers (Rumsey et al., 1999c).
Corresponding with these shifts in circulating hormone concentrations and sizes of the
releasable pools were increases in both subcutaneous and intramuscular fat deposition
(Rumsey et al., 2000). However, more recently we showed that oral administration of
CTC over a 112-d period did not attenuate the release of GH or TSH in response to TRH
+ GHRH challenges conducted at d 30, 56, and 106 and although CTC had no effect on
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subcutaneous fat deposition, intramuscular fat deposition tended to be greater in CTC-fed
steers (Kitts et al., 2007).
Implants containing estradiol and either progesterone or trenbolone acetate are
used in finishing beef steers to improve feed efficiency and enhance lean tissue growth.
Research has indicated increases in hot carcass weight (HCW), improved average daily
gain (ADG) and feed efficiency, as well as greater longissimus dorsi areas with the use of
anabolic implants in finishing programs for beef cattle (Perry et al., 1991; Herschler et
al., 1995; Johnson et al., 1996; Hermesmeyer et al., 2000; Platter et al., 2003). However,
it has also been demonstrated that marbling scores are lower for cattle receiving growth
implants, resulting in a lower percentage of carcasses grading Choice (Hermesmeyer et
al., 2000; Platter et al., 2003). Current carcass pricing grids provide incentive for the
development of nutritional strategies to improve the carcass grades of finished cattle from
Select to Choice (Select = slight amount of intramuscular fat, Choice = moderate amount
of intramuscular fat; McKenna et al., 2002).
Although research has shown effects of CTC and anabolic implants on growth in
cattle, there is a paucity of information on effects of CTC on growth performance and
carcass characteristics when fed in conjunction with anabolic implants. Therefore, the
objective of the current experiment was to determine if CTC and an anabolic implant
containing estradiol benzoate + trenbolone acetate interact to affect growth performance
and carcass characteristics of finishing beef steers. Specifically, we challenged the
proclivity of CTC to promote marbling using an aggressive implant strategy that would
enhance protein accretion and tend to oppose intramuscular fat deposition.
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Materials and Methods
Animals and Treatments
The protocol for the research discussed in this report was approved by the
University of Kentucky Institutional Animal Care and Use Committee. Ninety-six
English-Continental crossbred steers were purchased from a commercial sale yard in
Central Kentucky. After arriving at the University of Kentucky Animal Research Center,
steers were dewormed using ivermectin (Merial, Duluth, GA), and vaccinated using
Bovi-Shield™4 and Ultrabac®7 (Pfizer Animal Health, Exton, PA). Steers were housed
in group pens (5 steers per pen) for a 56-d backgrounding period during which they had
ad libitum access to a 65:35 concentrate-forage diet. The group pens measured 14.6 x 2.4
m and were located on a concrete pad partially covered with a roof. The steers had
continuous access to automatic waterers.
After the backgrounding period, steers were limit-fed two transition diets for an
additional 30 d at 90% of the previous ad libitum intake. These transition diets consisted
of 75:25 and 85:15 concentrate-forage, respectively, and were fed for adjustment to ad
libitum intake of the experimental diet (Table 4.1). Ad libitum intake of the experimental
diet was established incrementally over a 7-d period during the transition period,
immediately prior to beginning the experiment. Steers were blocked by body weight
(BW; 6 blocks), assigned randomly to pen within their respective block, and pens were
assigned randomly to a 2 x 2 factorial arrangement of treatments within block.
Treatments included feed containing either 0 or 39.6 ppm (DM basis) CTC (Aureomycin,
Alpharma Animal Health, Fort Lee, NJ) and Revalor-S® or no Revalor-S® (120 mg
trenbolone acetate + 24 mg 17-β estradiol benzoate, Intervet Inc., Millsboro, DE). The
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level of CTC used in this study provided approximately 350 mg CTC/steer/d and was the
same as the level used in previous experiments by Rumsey et al. (1999c, 2000) and Kitts
et al. (2005, submitted). Steers assigned to receive Revalor-S® were implanted on d 1
and re-implanted on d 63. The experimental diet was formulated using two protein
supplements: Protein supplement 1 was formulated to provide 105% of the
metabolizable protein (MP) requirement for large-frame steers (345 kg BW) gaining 1.60
kg/d and was fed until d 63 of the experiment; Protein supplement 2 was formulated to
provide 105% of the MP requirement for large-frame steers (450 kg BW) gaining 1.20
kg/d and was fed from d 63-125 or 139 (NRC, 2000). Steers were fed daily at 0900.
Once weekly, orts were measured and the amount of feed offered was adjusted to
maintain approximately 10% orts. Individual diet ingredients were sampled weekly and
analyzed for DM content. Weekly determinations of DM content were used in the
adjustment of the amount of feed offered the following week.
Body weights were measured every 28 d before feeding. Initial and final BW
were determined by weighing steers on two consecutive days. Ultrasound was used on a
subset of steers (approximately 8-10 steers) from the heaviest blocks (Blocks 5 & 6) to
determine the amount of subcutaneous fat over the 12th rib on d 118. Because these
steers met or exceeded 12 mm of backfat, it was determined that they had completed the
finishing phase. On d 125, these steers were transported to a commercial slaughter
facility and killed the following day. Subsequently, the remaining 4 blocks of steers
completed the finishing phase on d 139 and were killed on d 140. A merit evaluation of
each carcass was done according to USDA standards and performed by a qualified meat
scientist the following day. Carcass quality indicators were longissimus muscle area, fat
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over longissimus muscle, kidney, pelvic, and heart fat (KPH), marbling, and bone
maturity.
Statistical analyses
Growth performance and carcass data were statistically analyzed by analysis of
variance for a randomized complete block (weight) design with a 2 x 2 factorial
arrangement of treatments using PROC GLM procedures of SAS (SAS Inst., Inc., Cary,
NC, 2003). Pen was the experimental unit and the model included block, CTC, implant,
and the interaction of CTC and implant. All blocks of animals were used for growth
performance calculations through d 125, while only blocks 1-4 were used for growth
performance calculations from d 126-139 (blocks 5 &6 were killed on d 126). When
interactions were significant (P ≤ 0.10), protected Fisher’s LSD were used to separate
effects of implant within each level of CTC.

Results
Growth Performance
Average daily gain, dry matter intake (DMI), and efficiency of gain (BW gain per
unit of DMI) are summarized in Table 4.2. Over the course of the entire experiment (d 0139), CTC reduced (P = 0.02) DMI by 0.4 kg/d compared to steers receiving no CTC,
while implanted steers gained 0.4 kg/d more (P = 0.0001) BW than non-implanted steers.
Overall, there was an interaction (P = 0.03) between CTC and implant for efficiency of
gain. In the absence of CTC, implanted cattle gained 31% more efficiently than nonimplanted cattle, whereas in the presence of CTC, implant only resulted in a 20%
increase in feed efficiency (P < 0.0001).
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During the early part of the finishing phase (d 0-84), Revalor-S® increased ADG
and efficiency of gain 25% and 26%, respectively, above that of non-implanted steers (P
≤ 0.01). During periods of this same phase, implant and CTC decreased DMI by an
average of 0.5 kg/d (d 0-28 and d 29-56, respectively; P ≤ 0.05). The decrease in DMI
did not affect (P = 0.83) efficiency of gain for the steers fed CTC (d 29-56). There was
an increase (P = 0.01) in ADG for the implanted steers (d 0-28). There were no effects (P
≥ 0.13) of CTC on ADG or efficiency of gain during the rest of this phase.
During the latter part of the finishing phase (d 85-139), interactions occurred
between CTC and implant (P ≤ 0.07) for ADG and efficiency of gain. In the absence of
CTC, implanted steers gained an average of 0.74 kg/d more than non-implanted steers (P
= 0.007), but in the presence of CTC, implant had no effect (P ≥ 0.13). Additionally,
there was a significant (P ≤ 0.07) interaction between CTC and implant for efficiency of
gain. In the absence of CTC, implanted steers gained 60% more efficiently than nonimplanted steers (P ≤ 0.02); however, implant had no effect (P ≥ 0.31) in the presence of
CTC. Additionally, DMI tended to increase (P ≤ 0.06) by 0.84 kg/d for implanted
compared to non-implanted steers. Chlortetracycline had no effect (P ≥ 0.28) on DMI
during this phase of finishing.
Carcass Quality. There were no interactions (P ≥ 0.53) between CTC and implant for
carcass quality measures (Table 4.3). There were no effects (P ≥ 0.22) of treatment on
longissimus dorsi area or fat cover, KPH fat, marbling, or yield grade.
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Discussion
The objective of the current experiment was to determine if CTC and an anabolic
implant containing estradiol benzoate + trenbolone acetate interact to affect growth
performance and carcass characteristics of finishing beef steers. Because it has been
demonstrated that CTC has the ability to increase subcutaneous and intramuscular fat
deposition (Bohman and Wade, 1958; Harvey et al., 1968; Rumsey et al., 2000) and
anabolic implants containing trenbolone acetate + estradiol benzoate have been shown to
reduce marbling score and the percentage of carcasses grading Choice (Hermesmeyer et
al., 2000; Platter et al., 2003), it is of interest to determine if CTC can transcend the
antagonistic effects of an anabolic implant and increase the deposition of intramuscular
fat. Over the course of the entire experiment, implanted steers had greater ADG;
however, an interaction between CTC and implant for feed efficiency revealed that the
presence of CTC slightly attenuated the response to implantation. Furthermore, this
interaction was a result of treatment effects that occurred late in the finishing period,
specifically in the last 27 d. There were no effects of CTC or Revalor-S® on carcass
characteristics, most notably those involving fat deposition. These results are
inconsistent with our hypothesis, considering that previous research has shown CTC and
Revalor-S® to positively and negatively affect fat deposition, respectively.
Growth Performance
It is a common practice to implant cattle in the finishing phase of growth using
different ratios of estradiol benzoate and trenbolone acetate, depending on stage of
finishing (e.g., d 1-70 vs. d 71-140). These combinations of estrogens and androgens
account for an additive growth response in cattle, commonly increasing ADG and
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improving feed efficiency above those of cattle receiving estrogenic implants alone
(Hershler et al., 1995). Although the mechanism for such increases in ADG and feed
efficiency remains somewhat ambiguous, it is known that androgens possibly inhibit
release of hormones that cause muscle degradation, thus increasing protein accretion
above that of estrogenic implants alone (Solis et al., 1989). In the current experiment, it
was expected that implant would positively affect ADG, which increased approximately
28% compared to non-implanted steers. This finding agrees with previous research using
trenbolone acetate + estradiol benzoate implants in which ADG increased 21% in
implanted steers approximately 127 d on feed (Perry et al., 1991; Mader et al., 1994;
Johnson et al., 1996; Hermesmeyer et al., 2000). Additionally, this improvement in ADG
was considerably greater than the 16% increase in ADG of steers implanted with
progesterone + estradiol benzoate (Synovex-S®) in previous studies averaging 108 d
(Rumsey et al., 1992, 1999a; Mader et al., 1994; Hermesmeyer et al., 2000). These data,
in conjunction with previous research, indirectly support the idea that implants containing
trenbolone acetate + estradiol benzoate improve ADG to a greater extent than those
containing progesterone + estradiol benzoate.
In part, the overall increase in ADG for the current experiment was due to an
improvement in ADG of 25% for cattle receiving Revalor-S® during the initial 84 days.
However, in the absence of CTC, there was a greater improvement in ADG (71%) for
implanted compared to non-implanted steers during the final 55 days of the finishing
phase. These results demonstrate that not only did Revalor-S® increase ADG above that
of non-implanted steers during the early phases of finishing, but the improvements were
even more dramatic during the latter phase of finishing, considering that non-implanted
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cattle normally deposit adipose tissue as a greater proportion of empty body gain during
this time (Byers 1982; Owens et al., 1995). Furthermore, other research has shown that
steers receiving a synthetic androgen plus estradiol had increased protein and less fat in
their final empty body gain (Solis et al., 1989), suggesting a greater priority for lean
tissue growth with an anabolic implant. Although protein accretion was not measured
directly in the current experiment, the improvement in ADG for implanted steers
observed throughout this experiment suggest that the combination of androgen and
estrogen may have increased protein accretion, possibly by repartitioning compositional
gain away from fat and towards protein deposition in this group of animals (Herschler et
al., 1995; Solis et al., 1989). Although the mechanism explaining lower ADG for steers
receiving CTC in the presence of implant is unknown, an explanation may be related to
thyroid hormone function. Rumsey et al. (1999c) demonstrated that subtherapeutic
administration of CTC decreased GH and thyroid hormone responses to a TRH + GHRH
challenge in growing steers over a 91-d period. More recently, Kitts et al. (2007) showed
a greater triiodothyronine (T 3 ) response for steers implanted with Synovex-S® (200 mg
progesterone + 20 mg 17-β estradiol benzoate) than those receiving no implant in the
absence of CTC. Triiodothyronine was not affected by implant in the presence of CTC.
Although the implant used contained progesterone + estradiol benzoate, in the current
experiment it is possible that, at least during the final period, the decrease in ADG for
non-implanted and implanted steers in the presence of the CTC may have been associated
with decreased thyroid function through an unknown mechanism which subdued the rate
of BW gain.
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Chlortetracycline and implant interacted to affect efficiency of gain for the entire
experiment (d 0-139). Implanted steers gained more efficiently both in the absence and
presence of CTC; however, the improvement in efficiency of gain for implanted steers in
the presence of CTC was only 20%, compared to a 31% increase in the absence of CTC.
This finding suggests that CTC may have attenuated an improvement in efficiency of
gain for implanted steers. Furthermore, this decrease in efficiency of gain is a function of
the numerically lower ADG for implanted steers in the presence of CTC. Although it is
not altogether surprising that in the absence of implant, CTC had no positive effect on
ADG and efficiency of gain as we have previously shown no effect of CTC these
parameters (Kitts et al., 2007), it is a unique observation that the improved efficiency of
gain for implanted steers was slightly diminished in the presence of CTC. This
interaction between CTC and implant regarding efficiency of gain results from similar
interactions that occurred late in the finishing phase (d 85-139); there was an increase in
efficiency of gain for steers implanted in the absence, but not presence, of CTC. It is
possible that the lower efficiency of gain occurring in the presence of CTC and implant
during the last 27 d was due to both an increase in DMI for implanted steers (P = 0.005)
and no positive effect of implant on ADG in the presence of CTC (P = 0.79).
Although there was no effect of CTC on most parameters of growth during the
finishing phase, DMI decreased an average of 0.4 kg/d for steers fed CTC compared to
steers receiving no CTC. The reason for this decrease in intake is unclear; previous
studies which included oral, subtherapeutic levels of CTC in the diets of finishing steers
and lambs showed no effect of CTC on DMI (Erwin et al., 1956; Bolsen et al., 1968).
Although the steers receiving CTC in the current experiment consumed less during
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Period 2, this decrease in intake did not translate to a significant reduction in ADG or
efficiency of gain. The effects of subtherapeutic, oral administration of CTC on ADG
and efficiency of gain have been shown to be variable. Earlier research has demonstrated
increased BW gain and efficiency in growing but not finishing steers, whereas other data
suggests improvements in weight gain for feedlot steers (Perry et al., 1954; Brown et al.,
1975). The lack of effect of CTC on ADG and efficiency of gain seen in the current
experiment has also been observed in previous experiments by Rumsey et al. (2000) and
Kitts et al. 2007). Although the reason for these discrepancies is unclear, it has been
suggested that the effects of CTC on growth performance are more apparent under
stressful conditions that are immunologically challenging to the animal (Visek, 1978). In
both the current study and those of Rumsey et al. (2000) and Kitts et al. (2007), steers
were vaccinated and backgrounded for a minimum of 30 d, and adjusted to the
experimental diet prior to initiation of the experiment.
Carcass Quality
In previous research involving anabolic implants containing trenbolone acetate +
estradiol benzoate, the effects of this implant on carcass characteristics have been
variable; however, most research has shown that an implant containing estrogen + a
synthetic androgen such as trenbolone acetate negatively affects marbling score and
often, decreases the percentage of carcasses grading Choice (Hermesmeyer et al., 2000;
Roeber et al., 2000; Reiling and Johnson, 2003). Although monetary benefit is realized
through an increase in ADG and feed efficiency with these anabolic implants, a decrease
in marbling and thus, lowering quality grade from Choice to Select reduces the value of a
carcass. Therefore, it is of interest to develop strategies which allow producers to benefit
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from improved ADG and feed efficiencies associated with growth implants, while finding
other compounds capable of improving marbling scores in concert with implants. The
results of the current experiment showed a lack of change in longissimus area or fat cover
and marbling and therefore reflects no effect of implant on compositional gain.
However, these results do not preclude the possibility that compositional gain was altered
during Period 4 (d 85-112), when an interaction between CTC and implant occurred for
ADG. There was no effect of implant or CTC on the remaining carcass characteristics.
These results disagree with most previous research showing lower marbling scores and
percentage of carcasses grading Choice in steers implanted with Revalor-S® (Mader et
al., 1994; Hermesmeyer et al., 2000; Roeber et al., 2000; Reiling and Johnson, 2003).
Conversely, CTC fed to steers has increased longissimus fat cover and numerically
increased marbling scores (Rumsey et al., 2000) and increased the number of carcasses
grading Choice (Perry et al., 1958). Furthermore, longissimus muscle area has been
shown to be greater when Revalor-S® was used in finishing cattle (Johnson et al., 1996;
Hermesmeyer et al., 2000; Roeber et al., 2000). Interestingly, none of these effects were
seen in the current experiment demonstrating that, at least in this group of animals,
Revalor-S® did not negatively, and CTC did not positively, affect carcass quality.
In summary, Revalor-S® increased ADG over the course of the finishing period
as expected; however, the positive effect of implant on feed efficiency was partially
attenuated in the presence of CTC. This attenuation appears to be a function of both DMI
and ADG. Although CTC reduced DMI, the putative mechanism responsible for this
interaction is unclear; it appears to be manifested through changes in both DMI and
ADG, neither of which are mutually exclusive variables. Additionally, inconsistent with
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previous observations, carcass quality traits in the current experiment were not affected
by either Revalor-S® or CTC. Because Revalor-S® did not negatively affect carcass
quality, this shows that growth implants containing estrogen + synthetic androgens
positively affect growth performance, while not discounting carcass value. These data
clearly illustrate the need for further research to identify potential interactions between
anabolic implants and CTC regarding feedlot performance.

Experiment 2 has been previously published in the Journal of Animal and Veterinary
Advances in 2006, Volume 5, pages 70-76.
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92
------

0.03

0.50
0.28

-CTC
53.90
19.57
10.06
5.03
3.52
2.80
3.19
1.12
------

d 0-62

0.02

0.03

0.50
0.28

+CTC
53.90
19.57
10.06
5.03
3.52
2.80
3.16
1.12
------

3

Added to supply 350 mg of CTC per day per steer

92.00% NaCl, 5,500 ppm Zn, 4,790 ppm Mn, 1,835 ppm Cu,
9,275 ppm Fe, 115 ppm I, 65 ppm Co, 18 ppm Se
2
8,800 IU/g vitamin A, 1,760 IU/g vitamin D, 1.1 IU/g vitamin E

1

Aureomycin-90

3

Vitamins A,D,E2

Trace mineralized salt1
Choice white grease

Ingredient, % DM
High moisture corn
Cracked corn
Alfalfa haylage
Corn silage
Feather meal
Corn gluten meal
Ground corn
Limestone
Urea

Table 4.1 Experimental diets

------

0.03

0.50
0.28

0.02

0.03

0.50
0.28

d 63-138
-CTC
+CTC
53.90
53.90
19.57
19.57
10.06
10.06
5.03
5.03
2.12
2.12
1.68
1.68
5.59
5.57
1.12
1.12
0.11
0.11
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+CTC
400
8.41
1.74
208.62
449
9.01
1.36
151.28
487
8.33
1.05
126.12
516
9.05
1.62
179.39

-CTC
401
8.95
1.90
211.40
454
9.61
1.42
149.29
494
9.15
1.37
150.60
533
8.78
1.15
130.69

558
9.26
1.90
214.78

513
8.94
1.61
180.03

461
9.51
1.83
192.84

402
8.15
2.12
261.93

-CTC

553
9.52
1.88
195.92

509
9.07
1.58
173.61

462
9.06
1.67
185.83

401
8.24
2.19
265.55

+CTC

+Implant

b

Chlortetracycline fed at 350 mg of CTC per day per steers
Standard error of the mean calculated from analysis of variance using n=6
c
Interaction of CTC x Implant

a

Item
Period 1, 0-28 d
Initial BW, kg
DMI, kg/d
Body gain, kg/d
Gain:DMI, g/kg
Period 2, 29-56 d
Initial BW, kg
DMI, kg/d
Body gain, kg/d
Gain:DMI, g/kg
Period 3, 57-84 d
Initial BW, kg
DMI, kg/d
Body gain, kg/d
Gain:DMI, g/kg
Period 4, 85-112 d
Initial BW, kg
DMI, kg/d
Body gain, kg/d
Gain:DMI, g/kg

-Implant

9.32
0.23
0.26
11.15

5.07
0.29
0.25
9.64

8.25
0.18
0.22
11.48

1.55
0.23
0.26
11.88

SEMb

Table 4.2 Effects of oral chlortetracyclinea (CTC) and growth implant on
body weight gain, feed intake, and efficiency of gain in finishing beef steers

0.03
0.28
0.08
0.20

0.03
0.25
0.14
0.13

0.53
0.01
0.28
0.83

0.11
0.35
0.72
0.97

CTC

0.0001
0.06
0.0006
0.0004

0.0001
0.38
0.004
0.001

0.02
0.91
0.003
0.004

0.53
0.05
0.01
0.0004

Implant

P<

0.18
0.98
0.06
0.008

0.42
0.12
0.21
0.36

0.41
0.68
0.64
0.70

0.75
0.19
0.37
0.79

Xc
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+CTC
562
9.50
1.14
123.27
400
8.82
1.40
159.08

-CTC
565
9.11
0.93
103.33
401
9.28
1.39
152.53

402
9.34
1.84
200.37

611
10.70
1.65
160.34

-CTC

401
9.02
1.74
190.21

606
10.33
1.21
120.17

+CTC

+Implant

b

Chlortetracycline fed at 350 mg of CTC per day per steers
Standard error of the mean calculated from analysis of variance using n=6
c
Interaction of CTC x Implant

a

Item
Period 5, 113-138 d
Initial BW, kg
DMI, kg/d
Body gain, kg/d
Gain:DMI, g/kg
0-138 d
Initial BW, kg
DMI, kg/d
Body gain, kg/d
Gain:DMI, g/kg

-Implant

1.55
0.15
0.08
3.37

11.90
0.36
0.36
15.36

SEMb

0.11
0.02
0.25
0.60

0.44
0.97
0.51
0.52

CTC

Table 4.2 (continued) Effects of oral chlortetracyclinea (CTC) and growth implant on
body weight gain, feed intake, and efficiency of gain in finishing beef steers

0.53
0.390
0.0001
0.0001

0.0001
0.005
0.03
0.10

0.75
0.65
0.18
0.03

0.88
0.32
0.06
0.07

Implant Xc

P<
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1.54
169.12

4.41
2.99

85.32
1.21
2.06

587
382
65.19

-CTC

1.47
171.01

4.33
3.06

83.60
1.14
2.10

586
378
64.71

+CTC

1.60
166.79

4.07
3.08

84.26
1.12
2.04

647
387
59.89

b

1.63
178.60

4.25
3.03

84.19
1.07
2.04

632
388
61.72

+CTC

+Implant
-CTC

Chlortetracycline fed at 350 mg of CTC per day per steers
Standard error of the mean calculated from analysis of variance using n=6
c
Interaction of CTC x Implant
d
Slaughtered at d 126 or 140
e
Scores: 1.00 = trace00, 2.00 = slight00, 3.00 = small00, 4.00 = modest00
f
Calculated through d 125 or 139

a

Carcass-adjusted measuresf
Body weight gain, kg/d
Gain:DMI, g/kg

Marblinge
Yield grade

Longissimus area, cm2
Longissimus fat cover, cm
KPH fat, %

Slaughter weight, kgd
Carcass weight, kg
Dressing percentage

Carcass measures

-Implant
b

0.21
11.01

0.20
0.12

0.26
0.03
0.03

11.67
17.21
1.32

SEM

Table 4.3 Effects of oral chlortetracyclinea (CTC) and growth implant on carcass evaluation
measures and carcass-adjusted body weight gain and efficiency of gain in finishing beef steers

0.87
0.54

0.80
0.90

0.60
0.81
0.53

0.16
0.85
0.62

CTC

0.27
0.81

0.30
0.80

0.89
0.60
0.22

0.0001
0.34
0.007

Implant

P<

0.65
0.66

0.53
0.64

0.63
0.64
0.53

0.19
0.73
0.40

Xc

Chapter 5
Experiments 3 & 4
Effects of dexamethasone administration and Revalor-S®
on growth, carcass characteristics and visceral organ and fat mass of finishing
beef steers

Introduction
Dexamethasone (DEX) is a synthetic glucocorticoid which acts as an antiinflammatory agent and immunosuppressant. Dexamethasone has been used extensively
in research experiments, particularly to study glucose metabolism in both animals and
humans (Plested et al., 1987; Vernon and Taylor, 1988; Matsumoto et al., 1996; Schneiter
and Tappy, 1998). Many studies also suggest that DEX stimulates fatty acid synthesis in
the liver, subcutaneous and visceral (omental) fat depots in both mice and humans
(Dolinsky et al., 2004; Gounarides et al., 2008; Wang et al., 2004).
Limited research has been conducted in ruminants regarding the use of DEX to
study glucose metabolism or manipulate fat deposition. A study by Brethour (1972) was
performed in response to the observation that foundered cattle treated with DEX tended
to have higher carcass grades. In Brethour’s experiment, cattle were injected
intramuscularly (IM) with 10 mg of DEX 132, 90, 76 or 33 d prior to slaughter. When
cattle were injected with DEX 90, 76 or 33 d prior to slaughter, marbling score, a
measure of intramuscular fat, was improved. These results certainly suggest that single
injections of DEX prior to slaughter have the potential to increase intramuscular fat in
finishing beef cattle, thus increasing carcass value and producer profit.
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Implants containing trenbolone acetate and estradiol are routinely used in
finishing beef cattle to enhance lean tissue deposition and improve feed efficiency.
Research has indicated increases in hot carcass weight, improved average daily gain
(ADG) and feed efficiency, as well as greater longissimus dorsi areas with the use of
anabolic implants in finishing programs for beef cattle (Perry et al., 1991; Herschler et
al., 1995; Johnson et al., 1996; Hermesmeyer et al., 2000; Platter et al., 2003). However,
it has also been demonstrated that marbling scores are lower for cattle receiving growth
implants, resulting in a lower percentage of carcasses grading Choice (Hermesmeyer et
al., 2000; Platter et al., 2003). Because of the negative effects growth implants can have
on marbling scores, there is an incentive to development nutritional strategies to improve
carcass quality grades of finishing cattle from Select to Choice.
Because of the lack of research regarding the use of DEX in finishing beef cattle
to possibly improve marbling when used in conjunction with growth implants, the
objective of the current experiments was to assess the effects of DEX injections in the
presence and absence of growth implant on growth performance, carcass quality, omental
and mesenteric fat depots, and organ weights. We hypothesized that DEX injections
would increase marbling and the amount of omental and mesenteric fat; however, we
hypothesized that the addition of growth implant may mitigate this response.

Materials and methods
The animal procedures for the research discussed in this report were approved by
the University of Kentucky Institutional Animal Care and Use Committee.
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Experiment 3
Animals and Treatments
One hundred forty-four Angus crossbred steers were purchased from a
commercial sale yard in Central Kentucky. After arriving at the University of Kentucky
Animal Research Center, steers were treated for elimination of internal parasites
(Ivermectin, Merial, Duluth, GA) and vaccinated (Bovi-Shield™4 and Ultrabac®7,
Pfizer Animal Health, Exton, PA). Before commencement of the experiment, steers were
housed in group pens and received two transition diets which consisted of 70:30 and
80:20 concentrate:forage ad libitum, respectively. Each diet was fed for 7 d. Ad libitum
intake of the experimental diet (Table 5.1) was established incrementally over a 7-d
period prior to beginning the experiment. Group pens measured 14.6 x 2.4 m and were
located on a concrete pad partially covered with a roof. The steers had continuous access
to automatic waterers.
Steers were blocked by BW (4 blocks; 428 kg ± 4), assigned randomly to pen
within their respective block, and pens were assigned randomly to a 2 x 2 factorial
arrangement of treatments within block. Treatments included either no implant or
Revalor-S® (120 mg trenbolone acetate + 24 mg 17-β estradiol benzoate, Intervet
International, Millsboro, DE) on d 1 and either no or i.m injections of 0.09 mg/kg BW
DEX on d 1, 28, and 56. All cattle were moved to the handling facility for weighing on d
0, 1, 28, 56 and 83 prior to feeding. In order to avoid a singe injection site, DEX was
injected into the right gluteus medius muscle on d 1, the right trapezius muscle on d 28
and the left trapezius muscle on d 56. The level of DEX used in Exp. 3 & 4 was based on
a previous experiment in which a single dose (i.m.) of 0.05 mg/kg BW DEX administered
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90, 76 or 33 d prior to slaughter increased marbling in finished beef cattle (Brethour
1972).
Steers were fed daily at 0900. Once weekly, orts were measured and the amount
of feed offered was adjusted to maintain approximately 10% orts. Individual diet
ingredients were sampled weekly and analyzed for DM content (AOAC, 1984). Weekly
determinations of DM content were used in the adjustment of the amount of feed offered
the following week.
On d 83, all steers were weighed to obtain a final BW. Slaughter weights were
obtained by weighing steers on either d 84 or 86 immediately prior to slaughter. One
hundred twelve steers were transported to a commercial facility and slaughtered on d 84.
A merit evaluation of each carcass was done according to USDA standards and
performed by a qualified meat scientist the following day. Carcass quality indicators
were longissimus muscle area, fat over longissimus muscle, kidney, pelvic and heart fat
(KPH) and marbling.
Blood Glucose Analyses
On d 1, 28, 56 and 83, blood samples were collected from the jugular vein for
determination of whole blood glucose concentration. Samples (10 mL) were collected in
heparinized sample tubes (Vacutainer, Fisher Health Care, Chicago, IL) and immediately
placed on ice. Within 2 h of collection, all samples were analyzed for whole blood
glucose using a membrane-immobilized enzyme system (YSI Model 2700, Yellow
Springs Instrument, Inc., Yellow Springs, OH).
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Visceral Organs and Tissues
Eight steers/block,8 steers/treatment, were selected to be slaughtered on d 84 or
86 in the University of Kentucky abattoir for determination of organ and alimentary fat
mass. This selection was based on representation of the final average BW for each
treatment within each block. On each slaughter day, all treatments were represented and
the order of animal slaughters was randomized to avoid bias of treatment order. Steers
were stunned with a captive bolt gun, exsanguinated, and viscera removed and placed
into a visceral cart for separation. The pyloric valve and ileo-cecal junction were
identified and the proximal and distal ends of the small intestine were ligated prior to
separation to prevent contamination of tissues, particularly adipose, with digesta contents.
Forestomachs (rumen + reticulum and omasum + abomasum) were separated from
connective and omental adipose tissue, digestive contents emptied, rinsed with warm tap
water, blotted, and weighed. Omental adipose tissue was quantitatively collected, rinsed
with warm tap water, blotted, and weighed.
The liver was removed, trimmed of connective tissue, weighed and sampled using
a stainless steel trocar (12 mm internal diameter). In order to obtain a representative
sample, three cross sections (460 mm x 12 mm) were acquired commencing at the right
lobe and concluding at the left lobe of the liver. These samples were pooled, placed in a
foil bag, snap-frozen in liquid nitrogen and stored at -80˚C until analyses. Subsequently,
samples were freeze-dried for 3 d using a Model 18 DX48SA “Keepsake Specialist”
freeze dryer (Botanique Preservation Equipment, Inc., Peoria, AR). Percentage dry
matter of the samples was determined using sample weight before and after freezedrying. Prior to ether extraction (EE), samples were ground using a mortar and pestle.
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Dried samples were weighed (approximately 1 g) in duplicate and extracted for 1 h using
petroleum ether in a Soxtec System HT extraction unit (Foss Tecator AB, Hoeganaes,
Sweden). The extracted fats were dried and weighed to determine liver fat content
(AOAC, 1990) and expressed as a percentage of fresh weight.
The small and large intestines were grossly separated from the mesentery and
mesenteric adipose tissue and weighed. Digestive contents of the small and large
intestines were emptied and the tissues rinsed with warm tap water, blotted and weighed.
Small intestines (SI) and large intestines (LI) with the remaining attached mesenteric
adipose tissue were frozen in separate plastic bags for subsequent freeze-grinding and
analysis of EE. Small and large intestines were freeze-ground three times through a 0.6
cm screen using an Autio Grinder (Model 801GH50T, Autio Company, Astoria, Oregon).
Each sample was ground with approximately 2 kg dry ice. Wet samples were weighed
(approximately 7 g) in duplicate and extracted for 1 h using petroleum ether for
determination of fat content. The following calculation was used to determine total
mesenteric fat (kg):
[(SI EE%) x (SI wt + associated fat)] + [(LI EE%) x (LI wt + associated fat)] +
weighed mesenteric fat at slaughter (kg) = total mesenteric fat (kg)
The following calculation was used to determine SI and LI weight:
(Intestinal segment EE%) x (Intestinal segment wt + associated fat) = measured
intestinal segment-associated mesenteric fat
(Intestinal segment wt + associated fat) – (measured intestinal segmentassociated mesenteric fat) = Intestinal segment weight (kg)
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The day following slaughter, longissimus dorsi samples were removed from the
area between the 12th and 13th ribs for quantitative determination of intramuscular fat.
Samples were trimmed of excess fat and other adjoining muscle, cut to a thickness of
2.54 cm, weighed and frozen at -20˚C. Frozen samples were ground twice at an ambient
temperature of 0˚C using a mixer (KitchenAid® Model KSM150PS, St. Joseph, MI) with
a food grinder attachment. Wet samples were weighed (approximately 7 g) in duplicate
and extracted for 1 h using petroleum ether for determination of fat content.
Experiment 4
Animals and Treatments
Ninety-six Angus crossbred steers were purchased from a commercial sale yard in
Central Kentucky. After arriving at the University of Kentucky Animal Research Center,
steers were treated for elimination of internal parasites (Safe-Guard®, Intervet
International, Millsboro, DE) and vaccinated (Vista®5 VL5 SQ and Vision®7 with
Spur®, Intervet International, Millsboro, DE). Similar to Exp. 3, steers were housed in
group pens and received two transition diets which consisted of 70:30 and 80:20
concentrate:forage ad libitum, respectively. Each diet was fed for 7 d. Ad libitum intake
of the experimental diet (Table 5.1) was established incrementally over a 7-d period prior
to beginning the experiment. The diet used in Exp. 4 consisted of 80% cracked corn vs.
80% high moisture corn in Exp. 3. Because it has been shown that an isoenergetic, postruminal infusion of starch or glucose increases fat deposition in ruminants, it was
hypothesized in the current experiment that feeding a diet high in post-ruminal starch
would increase fat deposition (McLeod et al., 2001; McLeod et al., 2007).
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Group pens measured 14.6 x 2.4 m and were located on a concrete pad partially covered
with a roof. The steers had continuous access to automatic waterers. Steers were
blocked by BW (3 blocks; 385 kg ± 1), assigned randomly to pen within their respective
block, and pens were assigned randomly to a 2 x 2 factorial arrangement of treatments
within block. Treatments were the same as described for Exp. 3 with the following
modification: DEX was injected into the right gluteus medius muscle on d 1, the right
trapezius muscle on d 28, the left trapezius muscle on d 56 and the left gluteus medius
muscle on d 84. Also, the duration of Exp. 4 was 112 d vs. 84 d for Exp. 3.
Steers were fed daily at 0900. Once weekly, orts were measured and the amount
of feed offered was adjusted to maintain approximately 10% orts. Individual diet
ingredients were sampled weekly and analyzed for DM content. Weekly determinations
of DM content were used in the adjustment of the amount of feed offered the following
week. Body weights were measured every 28 d before feeding. Initial and final BW
were determined by weighing steers on two consecutive days.; Slaughter weights were
obtained by weighing steers on d 106, 107, 109, 112, 113, 114, 115, 118 or 119
immediately prior to slaughter.
On d 112, 60 steers were transported to a commercial facility and slaughtered on
d 113. Merit evaluations of each carcass were performed as described for Exp. 3.
Visceral Organs and Tissues
Twelve steers/block (9 steers/trt) were selected to be slaughtered on d 106, 107,
109, 112, 113, 114, 115, 118 or 119 in the University of Kentucky abattoir for
determination of organ and alimentary fat mass. To avoid potential bias of initial BW
that likely occurred in Exp. 3, steers whose average BW was equal across treatments at
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commencement of the experiment were selected. All subsequent procedures related to
visceral organs and tissues, were the same as for Exp. 3 with the following exception: the
spleen, kidneys, heart and lungs were trimmed of adipose and connective tissue and
weighed.
Statistical Analyses for Exp. 3 & 4
All growth performance, organ and fat mass data were statistically analyzed by
analysis of variance for a 2 x 2 factorial arrangement of treatments and randomized
complete block design using MIXED procedures of SAS (v9.1; SAS Inst., Inc., Cary,
NC). The experimental unit was pen for the growth performance data and animal for
carcass, organ and fat mass data. The statistical model included the fixed effect of
treatments and the random effect of block. The following linear model was used:
Y ijk = μ + DEX i + Implant j + (DEX)(Implant) ij + ε ijk
where Y ijk is the observed value for the kth replicate of the ith level of DEX and the jth
level of implant, μ is the grand mean, DEX i is the fixed effect of the ith level of DEX,
Implant j is the fixed effect for the jth level of implant, (DEX)(Implant) ij is the fixed
interaction effect of the ith level of DEX with the jth level of implant and ε ijk is the random
error associated with the Y ijk experimental unit. All carcass data were statistically
analyzed by analysis of variance for a 2 x 2 factorial arrangement of treatments and
randomized complete block split plot design using MIXED procedures of SAS (v9.1;
SAS Inst., Inc., Cary, NC). The statistical model included the fixed effects of treatment
and the random effects of block and location. The following linear model was used:
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Y ijkl = μ + Loc i + DEX j + Implant k + (Block)(Loc) li + (Loc)(DEX) ij + (Loc)(Implant) ik +
(DEX)(Implant) jk + (DEX)(Block)(Loc) jli + (Implant)(Block)(Loc) kli +
(DEX)(Implant)(Block)(Loc) jkli + (Loc)(DEX)(Implant) ijk + ε jkli
where Y ijkl is the observed value for the ith location and the lth block of the jth level of
DEX and the kth level of implant, μ is the grand mean, Loc i is the random effect
associated with the ith location, DEX j is the fixed effect associated with the jth level of
DEX, Implant k is the fixed effect associated with the kth level of Implant, (Block)(Loc) li
is the random interaction effect associated with the lth block of the ith location,
(Loc)(DEX) ij is the random interaction effect associated with the jth level of DEX in the
ith location, (Loc)(Implant) ik is the random interaction effect associated with the kth level
of implant in the ith location, (DEX)(Implant) jk is the fixed interaction effect associated
with the jth level of DEX and kth level of implant, (DEX)(Block)(Loc) jli is the random
interaction effect associated with the jth level of DEX and the lth block of the ith location,
(Implant)(Block)(Loc) kli is the random interaction effect associated with the kth level of
implant and the lth block of the ith location, (DEX)(Implant)(Block)(Loc) jkli is the random
interaction effect associated with the jth level of DEX and the kth level of implant with the
lth block of the ith location, (Loc)(DEX)(Implant) ijk is the random interaction effect
associated with the jth level of DEX and the kth level of implant in the ith location and ε jkli
is the total random error associated with the Y ijkl experimental unit. Whole blood
glucose concentrations were analyzed by analysis of variance for a 2 x 2 factorial
arrangement of treatments and randomized complete block design with day as a repeated
measure. The following linear model was used:
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Y ijkl = μ + Block i + DEX j + Implant k + (DEX)(Implant) jk + ε ijk + Day l + (DEX)(Day) jl +
(Implant)(Day) kl + (DEX)(Implant)(Day) jkl + ε ijkl
where Y ijkl is the observed value for the jth level of DEX and the kth level of implant in
the ith block on the l th day, μ is the grand mean, Block i is random effect of the ith block,
DEX j is the fixed effect of the jth level of DEX, Implant k is the fixed effect for the kth
level of implant, (DEX)(Implant) jk is the fixed interaction effect of the jth level of DEX
with the kth level of implant, ε ijk is the error term for the jth level of DEX and the kth level
of implant in the ith block, Dayl is the fixed effect of the lth day, (DEX)(Day) jl is the fixed
interaction effect of the jth level of DEX on the lth day, (Implant)(Day) kl is the fixed
interaction effect of the kth level of implant on the lth day, (DEX)(Implant)(Day) jkl is the
fixed interaction effect of the jth level of DEX with the kth level of implant on the lth day
and ε ijkl is the total error the jth level of DEX and the kth level of implant in the ith block
on the lth day. When interactions were significant (P ≤ 0.05), the slice option in the LS
MEANS statement was used before pair-wise comparisons were made. Additionally, the
unbalanced number of observations (n=7; Imp + DEX) for pancreatic weight in Exp. 3
reflects unrecorded data. All data are presented as least square means ∀ SE, with the SE
calculated using the least number of observations for each measured variable. Treatment
main effects and interactions were considered significant at P ≤ 0.05 and a tendency to be
significant at P ≤ 0.10.
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RESULTS
Experiment 3
Growth performance
The effects of DEX injections and growth implant on BW gain, feed intake and
efficiency of gain are shown in Table 5.2. Over the course of the entire experiment,
growth implant increased (P = 0.05) DMI by 4% relative to non-implanted steers. This
increase in DMI is representative of an average increase of 4.5% in Periods 1 and 3 for
implanted compared to non-implanted steers. There was an interaction (P = 0.05)
between DEX and growth implant for ADG over 83 d. In the presence of growth
implant, DEX decreased (P = 0.003) ADG by 10% relative to the steers receiving no
DEX. There was no effect (P ≥ 0.10) of DEX in the absence of growth implant.
Additionally, growth implant increased efficiency of BW gain (P = 0.0001) by 16% over
steers with no growth implant. These overall improvements in gain and efficiency are
reflective of increased ADG and efficiency for implanted steers throughout each period
of the experiment. In Period 1, growth implant increased (P = 0.0001) ADG by 31% and
efficiency of gain by 25% relative to steers receiving no implant. In Periods 2 and 3,
these improvements were an average of 16% and 11% for ADG and efficiency of gain,
respectively.
Contrary to the increase in efficiency of gain attributed to growth implant, DEX
injections decreased (P = 0.02) efficiency over the course of the experiment by 5%
compared to animals receiving no DEX. This decrease in efficiency was manifested in
both Periods 1 (P = 0.03) and 2 (P = 0.02) as 6% and 8%, for steers given DEX injections
compared to no injections, respectively. However, no effects (P ≥ 0.10) of DEX
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injections on efficiency of gain were observed during the last 28 d of the feeding period.
Regarding final BW, there was an interaction (P = 0.05) between DEX and growth
implant. As with ADG, in the presence of growth implant, DEX injections decreased (P
= 0.002) final BW by 4% relative to steers receiving no DEX. In the absence of growth
implant, there was no effect (P ≥ 0.10) of DEX.
Carcass measures
The effects of DEX injections and growth implant on carcass evaluation measures
are shown in Table 5.3. There was an interaction (P = 0.01) between treatments for
slaughter weight. In the presence of growth implant, DEX injections decreased (P <
0.0001) slaughter weight by 4% as compared to steers given no DEX. In the absence of
growth implant, there was no effect (P ≥ 0.10). Likewise, there was a tendency for an
interaction (P = 0.06) between treatments for HCW. Again, in the presence of growth
implant, DEX injections decreased (P = 0.009) HCW by 3% relative to steers receiving
no DEX. However, there was no effect (P ≥ 0.10) of DEX in the absence of growth
implant. There was also an interaction (P = 0.04) between DEX injections and growth
implant for dressing percentage. In this case, DEX injections increased (P = 0.02)
dressing percentage by almost 1 percentage point in the presence of implant compared to
steers receiving no DEX. However, in the absence of implant, there was no effect (P ≥
0.10) of DEX. Growth implant increased (P = 0.02) longissimus dorsi area by 3% over
non-implanted steers. There was a tendency for an interaction (P = 0.06) of treatments on
the percentage of ether extract in the longissimus dorsi muscle. In the absence of DEX,
steers receiving growth implant had a lower percentage of fat in the longissimus dorsi
compared to those with no implant. There was no effect (P ≥ 0.10) of growth implant in
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the presence of DEX. However, upon visual appraisal of the longissimus dorsi, there was
no effect (P ≥ 0.10) of treatment on marbling score. Also, there was no effect (P ≥ 0.10)
of treatment on longissimus fat cover, yield grade or quality grade. However, growth
implant decreased (P = 0.02) the percentage of KPH fat relative to non-implanted steers.
Organ and alimentary fat mass
The effects of DEX injections and growth implant on organ and alimentary fat
mass are shown in Table 5.4. A tendency for an interaction between treatments was
observed for total digestive tract (P = 0.08) and forestomach (P = 0.07) weights. For both
the total digestive tract (P = 0.02) and the forestomach complex (P = 0.03), weights were
greater in the absence of DEX for steers receiving growth implant compared to no growth
implant. However, there was no effect (P ≥ 0.10) of growth implant in the presence of
DEX. While there was no effect (P > 0.1) of treatment on the weights of omasum +
abomasum, SI or LI, there was an interaction (P = 0.03) between DEX injections and
growth implant on rumen + reticulum weight. In the presence of growth implant, DEX
injections decreased (P = 0.04) rumen + reticulum weight by 9% compared to no DEX.
In the absence of growth implant, there was no effect (P ≥ 0.10) of DEX. For liver
weight there was an interaction (P = 0.04) between treatments. In the absence of implant,
DEX injections increased (P = 0.005) liver weight by 13% relative to steers receiving no
DEX, but there was no effect (P ≥ 0.10) of DEX injections in the presence of growth
implant. There were no effects (P > 0.09) of treatment on liver DM content. However,
there was a tendency (P = 0.09) for steers receiving DEX to have a lower percentage of
fat in the liver compared to those steers receiving no DEX. There were no effects (P >
0.10) of treatment on pancreas weight. However, there was an interaction (P = 0.03)
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between treatments on the weight of alimentary tract fat. In the absence of growth
implant, there was a tendency (P = 0.08) for steers receiving DEX injections to have
heavier alimentary tract fat weights compared to steers receiving no DEX. In the
presence of growth implant, there was no effect (P ≥ 0.10) of DEX. This interaction for
alimentary tract fat weight is partially explained by an interaction (P = 0.002) between
DEX injections and growth implant on omental fat weight. In the absence of growth
implant, omental fat weights were greater (P = 0.01) for steers receiving DEX injections
relative to steers receiving no DEX. However, in the presence of implant, omental fat
weight decreased (P = 0.04) for steers receiving DEX injections compared to steers
receiving no DEX.
Organ and alimentary fat mass as a percentage of EBW
The effects of DEX injections and growth implant on organ and alimentary fat
mass as a percentage of EBW are shown in Table 5.5. An interaction (P = 0.003)
occurred for final empty body weight (EBW). In the presence of growth implant, DEX
injections decreased (P = 0.001) EBW by 4% compared to steers receiving no DEX. In
the absence of growth implant, there was no effect (P ≥ 0.10) of DEX. There was no
effect (P ≥ 0.1) of treatment on digestive tract, forestomach complex, rumen + reticulum,
omasum + abomasum, small intestine or large intestine weights as a percentage of EBW.
However, DEX injections increased liver (P = 0.01) and pancreatic (P = 0.05) weights as
a percentage of EBW compared to steers receiving no DEX injections. Similar to the
interaction between treatments for alimentary fat mass, there was a tendency (P = 0.09)
for an interaction for alimentary tract fat as a percentage of EBW. Furthermore, there
was an interaction (P = 0.006) between treatments for omental fat as a percentage of
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EBW. In the absence of implant, steers receiving DEX injections had a greater amount
(P = 0.01) of omental fat as a percentage of EBW compared to steers receiving no DEX.
However, there was no effect (P ≥ 0.10) of DEX injections in the presence of implant.
Also, there was no effect of treatment on the amount of mesenteric fat as a percentage of
EBW.
Whole blood glucose concentrations in Exp. 3
The effects of DEX injections and growth implant on the concentrations of
glucose in whole blood over the course of Exp. 3 are shown in Figure 5.1. There was no
effect (P ≥ 0.1) of treatment on whole blood glucose concentrations throughout the
experiment. However, whole blood glucose concentrations in all steers responded
quadratically (P = 0.002) relative to day of the experiment.
Experiment 4
Growth performance
The effects of DEX injections and growth implant on BW gain, DMI and
efficiency of gain for Exp. 4 are shown in Table 5.6. There were no interactions between
treatments for DMI, ADG, efficiency of gain or final BW over 112 d. Also, over the
course of the entire experiment, there was no effect (P ≥ 0.10) of treatment on DMI.
However, in the final period of the study, growth implant tended to increase (P = 0.08)
DMI by 5% relative to non-implanted steers and DEX injections tended (P = 0.06) to
decrease DMI by 5% compared to steers receiving no DEX. Over 112 d, growth implant
increased ADG (P = 0.004) and efficiency of gain (P=0.05)13% over non-implanted
steers. For implanted steers, the overall improvements in body weight gain and
efficiency are reflective of increased ADG and efficiency in Periods 1 and 3 of the
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experiment. In Period 1, growth implant tended to increase (P ≤ 0.07) ADG by 11% and
efficiency of gain by 10% relative to steers receiving no implant. In Period 3, these
improvements (P ≤ 0.02) were 29% and 25% for ADG and efficiency of gain,
respectively.
Unlike the improvement in ADG for implanted steers, DEX decreased (P = 0.007)
ADG by 10% compared to steers receiving no DEX injections over the entire experiment.
This lower ADG was largely due to a 21 % decrease (P = 0.005) in ADG for DEX
relative to non-DEX injected steers during Period 2. There was no effect (P ≥ 0.10) of
DEX injections on efficiency of gain over 112 d. However, in Period 2, efficiency was
decreased (P = 0.001) by 18% for steers receiving DEX compared to no DEX. Regarding
final BW, growth implant increased (P = 0.004) weight by 4% relative to non-implanted
steers and DEX injections decreased (P = 0.01) weight by 3% compared to steers
receiving no DEX.
Carcass measures
There were no interactions (P ≥ 0.10) between treatments for any of the measures
of carcass quality (Table 5.7). Growth implant increased (P = 0.0001) HCW by 5%
compared to steers receiving no growth implant; however, administration of DEX
decreased (P = 0.0007) HCW by 4% relative to steers receiving no DEX. Likewise,
steers receiving growth implant had larger (P 0.02) longissimus dorsi muscle areas
compared to steers with no implant. On the other hand, implanted steers tended (P =
0.11) to have slightly less KPH fat than non-implanted steers. There were no effects (P ≥
0.10) of treatment on dressing percentage, percentage of fat in the longissimus dorsi
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muscle as measured by ether extract, longissimus dorsi fat cover, marbling, yield grade or
quality grade.
Organ and alimentary fat mass
The effects of DEX injections and growth implant on organ and alimentary fat
mass are shown in Table 5.8. The spleen weights of steers given DEX injections were
found to weight 21% less (P = 0.0006) than steers receiving no DEX. Conversely, the
heart weights of implanted steers tended to weigh 6% more (P = 0.09) than nonimplanted steers. There were no effects (P ≥ 0.10) of treatment on kidney or lung
weights. Total digestive tract weights of the steers receiving growth implant were
heavier (P = 0.01) relative to the steers receiving no growth implant. Forestomach
weights tended to be 9.5% heavier (P = 0.10) for implanted compared to non-implanted
steers. The weights of the rumen + reticulum were 13% greater (P = 0.02) for implanted
compared to non-implanted steers. While there was no effect (P > 0.1) of treatment on
the weight of the omasum, there tended to be an interaction (P = 0.09) between DEX
injections and growth implant on the weight of the abomasum. In the absence of DEX,
implanted steers tended (P = 0.09) to have heavier abomasum weights relative to nonimplanted steers. As with the rumen + reticulum weights, implanted steers had 13% and
9% heavier (P ≤ 0.02) SI and LI compared with steers receiving no implant, respectively.
On the other hand, steers receiving DEX injections had SI that weighed 11% less (P =
0.002) and LI that tended (P = 0.10) to weigh 6% less than those receiving no DEX.
Regarding liver weight, implanted steers also had heavier (P = 0.0004) liver compared to
non-implanted steers. Steers receiving DEX had livers that weighed 8% less (P = 0.03)
that steers receiving no DEX. There were no effects of treatment on the percentage of
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DM or EE in the liver. Also, pancreas weight tended (P = 0.06) to be greater for steers
receiving implant relative to no implant. There were no effects (P ≥ 0.10) of treatment on
the weight of alimentary tract fat.
Organ and alimentary fat mass as a percentage of EBW
The effects of DEX injections and growth implant on organ and alimentary fat
mass as a percentage of EBW are shown in Table 5.9. Final EBW was 7% greater (P =
0.001) for implanted compared to non-implanted steers. However, DEX injections
decreased (P = 0.02) final EBW by 5% relative to steers receiving no DEX. Similar to
the results on a wet tissue weight basis, spleen weight was lower (P = 0.005) as a
percentage of EBW for steers treated with DEX compared to no DEX. However, heart
weight was greater (P = 0.03) for steers receiving DEX relative to those given no DEX.
On the other hand, implanted steers tended (P = 0.10) to have lighter kidney weights and
the lungs weighed less (P = 0.02) as a percentage of EBW compared to non-implanted
steers. There was no effect (P ≥ 0.1) of treatment on digestive tract, forestomach
complex, rumen + reticulum, omasum + abomasum, or large intestine weights as a
percentage of EBW. However, both DEX and growth implant had an effect on small
intestine weight as a percentage of EBW. Steers with growth implant had heavier (P =
0.05) SI and steers receiving DEX had SI that weighed less (P = 0.02) on an EBW basis
relative to those animals receiving no growth implant or no DEX, respectively. Also,
implanted steers had heavier (P = 0.006) livers as a percentage of EBW compared to nonimplanted steers. Lastly, steers receiving DEX tended (P = 0.06) to have heavier
pancreas weights relative to steers receiving no DEX. There was no effect of treatment
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on the amount of total alimentary tract fat, omental fat or mesenteric fat as a percentage
of EBW.
DISCUSSION
While a plethora of information exists regarding the effects of DEX on adipose
depots in humans and rats, there is a lack of research regarding these effects in ruminants.
Because DEX has the ability to induce an insulin resistant state in the adipose depots of
humans and rats, glucose begins to be deposited as intramuscular fat in muscle (Asensio
et al., 2004; Hegarty et al., 2003). This phenomenon has been well-documented in
humans, but has not been proven to occur in ruminants (Asensio et al., 2004; Hegarty et
al., 2003). However, a study by Brethour (1972) suggested that steers receiving IM
injections of DEX 90, 76 or 33 d pre-slaughter improved marbling from 8% Choice to
30% Choice, thus improving the USDA quality grade. The additional treatment of
growth implant would determine if the opposing effects of increasing lean tissue
deposition would interact with the effects of increasing fat deposition within muscle and
primary fat depots. Furthermore, few studies have examined the effects of growth
implant on omental and mesenteric fat, as well as organ weights in beef cattle. Based on
the research by Brethour (1972) and the knowledge that DEX causes a shift in fat
deposition from adipose to non-adipose tissue (muscle) in humans and rats, we conducted
the current experiments to assess the effects of DEX injections in the presence and
absence of growth implant on growth performance, carcass quality, omental and
mesenteric fat depots, and organ weights. We hypothesized that DEX injections would
increase marbling and the amount of omental and mesenteric fat; however, we
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hypothesized that the addition of growth implant may mitigate the increase in marbling,
omental and mesenteric fat.

Growth performance
In Exp. 3, overall DMI increased by 4% for steers implanted with Revalor-S®
compared to non-implanted steers, while there was no change in overall DMI for Exp. 4.
The increase in DMI for Exp. 3 was due to increases in DMI for Periods 1 & 3, in which
there was either an increase or tendency for an increase in DMI. The reason as to the
increase in DMI for Exp. 3 is unclear, as most studies have shown no changes in DMI for
steers implanted with Revalor-S® (Samber et al., 1996; Foutz et al., 1997). In an
experiment by Samber et al. (1996), steers were implanted with Revalor-S® on d 30 and
130 of a 150-d study and showed no change in DMI compared to non-implanted steers.
Likewise, a study by Foutz et al. (1997) using steers implanted or not implanted with
Revalor-S® on d 1 showed no differences in DMI over 119 or 126 d. Overall, it was not
expected that DMI would increase in steers implanted with Revalor-S®, as the goal of
anabolic implants is to increase feed efficiency; i.e., increase protein accretion with no
increase in feed intake. Regarding the effects of DEX on DMI, there were no changes in
DMI for steers implanted with DEX in Exp. 3 or 4. A study by Adams and Sanders
(1992) showed an increase in DMI over a 10-d period for sheep injected with DEX.
Another study by Carroll et al. (1963) showed that steers injected three times per week
with one gram of cortisone acetate consumed more feed over the course of a 9 week
experiment. In the current experiment, it is possible that because the animals were
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receiving only one injection of DEX every 28 d, any effects of DEX on DMI were shortterm; i.e., they were only manifested for a few days following injection.
It was expected that implant would increase ADG and while this occurred for
implant alone in Exp. 4, there was an interaction between implant and DEX for Exp. 3.
In the presence of growth implant, DEX decreased ADG by 10% compared to steers
receiving no DEX. This interaction also translated to DEX decreasing slaughter weight
and HCW by 4 and 3%, respectively, in the presence of growth implant. Dexamethasone
also decreased ADG, slaughter weight and HCW in Exp. 4. The reason for these
decreases in ADG is unclear; however, they may be attributed to decreased protein
deposition or increased protein catabolism, or increased heat production. The effect of
DEX decreasing HCW lends support to the theory that protein deposition decreased, or
protein catabolism or heat production increased. Glucocorticoids such as DEX are
known to inhibit protein tissue deposition (Hart 1983). In a study by Carroll et al. (1963),
steers exhibited less protein deposition during a 9-week study in which they were injected
subcutaneously three times per week with one gram of cortisone acetate. Furthermore,
glucocorticoids stimulate muscle breakdown by causing the release of amino acids to fuel
glucose synthesis (McDowell 1983). Another study showed seven-day-old piglets
receiving 0.5 mg/kg BW/d oral DEX for 15 d to exhibit a lower whole body percent lean
mass, which was attributed to protein catabolism (Weiler et al., 1997). A study by
Brillon et al. (1995) evaluated the effect of infusing hydrocortisone overnight into healthy
adults along with labeled amino acids to measure amino acid kinetics. They also used
indirect calorimetry techniques to calculate resting energy expenditure. They found that
hypercortisolemia increased protein catabolism by 5-20% and resting energy expenditure
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increased 9-15%. It is possible that an inhibition of tissue deposition, muscle catabolism
and energy expenditure via increased heat production cooperated to decrease ADG and
ultimately HCW for steers receiving DEX.
An increase in ADG of 13% occurred for implant compared to non-implanted
steers in Exp. 4, which was expected. Efficiency of BW gain also increased by 16% and
13%, respectively for implanted vs. non-implanted steers in Exp. 3 and 4. Studies have
shown trenbolone acetate + estradiol implants to increase both ADG and efficiency of
gain for finishing beef steers. (Foutz et al., 1997; Samber et al., 1996; Scheffler et al.,
2003). Foutz et al. (1997) used 140 crossbred steers (353 kg) receiving either no implant,
Synovex-S®, Revalor-S®, Finaplix-S, or Finaplix-S+ reimplant on d 58. Steers were fed
for either 119 or 126 d and then slaughtered. Average daily gain and feed efficiency
were increased by 6.1 and 7.5%, respectively, for steers receiving the treatments with
trenbolone acetate compared to the steers receiving no trenbolone acetate. In another
experiment by Samber et al. (1996), 560 crossbred steers (286 kg) received no implant,
Ralgro® or Revalor-S® implants on d 0. These steers were reimplanted with either
Synovex-S® or Revalor-S® on d 60 and 130 or d 75 and 150. Two groups of steers
received Revalor-S® or Synovex-S® implants on d 30 and both groups were reimplanted
with Revalor-S® on d 130. All steers were fed for 212 d. Average daily gain and feed
efficiency for steers receiving the Revalor-S® implants on d 30 and 130 increased by 15
and 10%, respectively, compared to the non-implanted steers. The results of the current
experiments agree with these results.
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Carcass quality
Overall, the carcass quality data showed that independent of treatment, the steers
in Exp. 4 ended the experiment with less fat as compared to the steers in Exp. 3. In
comparison, there were decreases of 20% in longissimus fat cover, 1.5% in KPH fat, 14%
in marbling score, 40% in EE% of the LD muscle, 24% in yield grade and 18% in quality
grade. Additionally, there was a 14% decrease in the amount of alimentary tract fat for
steers in Exp. 4 compared to steers in Exp. 3. These results were surprising, considering
that the steers in both experiments finished with similar slaughter weights (558 kg in Exp.
3 and 553 kg in Exp. 4), demonstrating that all steers finished at similar stages of
maturity. Treatments also affected the steers in each experiment differently, with DEX
mitigating the effects of growth implant in Exp. 3 and no interaction of treatments in Exp.
4.
In Exp. 3, steers receiving DEX in the presence of implant had higher dressing
percentages as compared to steers receiving no DEX with implant. This result has
practical implications in that it indicates that while the steers receiving DEX and growth
implant were smaller steers in terms of slaughter weight and HCW, they had a greater
percentage of “usable” carcass compared to steers receiving no DEX with implant. In
Exp. 4 there was no effect of treatment on dressing percentage. In both experiments,
there was an increase in longissimus dorsi (LD) area of 3.7 and 3.8%, respectively, for
implanted compared to non-implanted steers, which was expected. These results are
similar to other studies in which Revalor-S® has been used. In studies by Foutz et al.
(1997; 1990), implanted steers had larger LD areas. It would be expected that implants
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would increase LD area, as they are stimulating an increase in the deposition of lean
tissue.
In Exp. 3, implanted steers had less KPH fat. These results are similar to other
studies in which Revalor-S® has been used. In the studies by Foutz et al. (1997; 1990),
implanted steers had no change in the amount of KPH fat. As mentioned previously,
there was no effect of treatment in either experiment on longissimus fat cover, marbling,
yield grade or quality grade. The lack of effect of Revalor-S® on longissimus fat cover
and marbling agrees with the findings of Foutz et al. (1997) and Samber et al. (1996).
Longissimus fat cover, KPH fat and marbling are some of the most important factors in
determining yield grade; therefore, if these parameters are unaffected by treatment, it is
unlikely that yield grade will be affected. Quality grade is a more subjective evaluation
based mainly on the amount of intramuscular fat, or marbling, within the longissimus
dorsi muscle. In the current experiments, both an objective determination of the ether
extract percentage and a subjective score of marbling were measured in the longissimus
dorsi muscle. There was no effect of implant on marbling scores, leading to no change in
quality grade. However, in Exp. 3, there tended to be an interaction between implant and
DEX for ether extract percentage in the longissimus dorsi muscle, which was explained
as an decrease in the amount of ether extract for implanted steers in the absence of DEX.
The lack of a corresponding interaction for marbling score suggests that this method is
not as sensitive to intramuscular fat differences as an ether extract determination.
Additionally, these results show that DEX increased intramuscular fat despite the
opposing effects of implant, which agrees with the results of Brethour (1972), in which
DEX improved marbling scores.
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Based on previous research, it was anticipated that DEX would increase
longissimus fat cover, KPH fat and marbling, thereby increasing yield grade and
improving quality grade. In experiments with steers and lambs in which cortisone acetate
was injected, administered intraruminally or as an implant, carcass fatness in lambs was
generally increased (Clegg and Spurlock, 1960; Spurlock and Clegg, 1962; Carroll et al.,
1963). Brethour (1972) showed that steers receiving IM injections of DEX 90, 76 or 33 d
pre-slaughter increased marbling from 8% Choice to 30% Choice, thus improving the
USDA quality grade. The steers in the current experiments were injected with DEX
every 28 d throughout both experiments; therefore, it was expected that the increased
frequency of injections would improve quality grade. Dexamethasone has temporal
effects on circulating glucose concentrations, as demonstrated by our preliminary data in
which whole blood glucose concentrations more than doubled for 2 d following IM
injections with either 10 or 20 mg of DEX (data not shown). Along with an increase in
circulating blood glucose, research also shows DEX to stimulate lipolysis in rats, thus
increasing circulating free fatty acids (Krotkiewski et al., 1970). It was hypothesized that
these changes may cause a temporary redistribution of fat from primary to secondary fat
depots, thus increasing intramuscular fat in the LD muscle. It was also hypothesized that
over the course of the experiments, DEX may increase fat deposition in primary fat
depots such as longissimus fat cover and KPH fat. However, these increases were not
observed for steers receiving DEX in either experiment.
Organ and fat mass
The effects of maternal DEX on the weight of the service organs (spleen, kidneys,
heart, lungs) has been evaluated extensively in fetal rats and to a lesser extent, in sheep
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(Frank et al., 1985; Jensen et al., 2002). However, these measurements have not been
reported in finished beef cattle receiving DEX injections prior to slaughter. While
individual spleen, kidney, heart and lung weights were not recorded for Exp. 3, they were
recorded for Exp. 4. Dexamethasone decreased spleen weight by 21% on a wet tissue
mass basis compared to steers receiving no DEX; this difference remained significant
when expressed as a percentage of EBW. This agrees with research in rats treated with 2
mg/kg BW/d DEX during 5 consecutive d (Orzechowski et al., 2000). Spleen wet weight
expressed as a percentage of BW decreased by 65%. The decrease in spleen weight may
be due to a depression in immune function by DEX. A study by Miller et al. (1991) in
which rats were administered varying concentrations of DEX showed decreased spleen
weights along with decreases in immune function. There was no effect of implant on
spleen weight, which disagrees with research by Hutcheson et al. (1997). Twenty-four
genetically identical Brangus steers were either not implanted, implanted with SynovexS®, Finaplix-S or Revalor-S® and slaughtered after 112 d for determination of visceral
organ mass. As a percentage of EBW, the spleens were found to weigh more for the
steers receiving Revalor-S® as compared to steers receiving no implant.
While there were no effects of treatment on kidney, heart or lung wet tissue
weights, there was an effect of DEX on heart weight and an effect of growth implant on
lung weight when expressed as a percentage of EBW in Exp. 4. Dexamethasone
increased heart weight, which agrees with an experiment by Jensen et al. (2002). In this
experiment, pregnant ewes were infused with 80 mg/d hydrocortisone for 10 d beginning
at 119 d gestation. Maternal cortisol infusion increased fetal heart weight by 15%
relative to body weight. It is unknown whether an increase in heart weight may be due to
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hypertrophy or hyperplasia in the current experiment. In the current experiment, lung
weight decreased as a percentage of EBW for steers receiving growth implant compared
to steers receiving no implant. In the study by Hutcheson et al. (1997), heart, lungs and
trachea were weighed together as “pluck,” and there was no effect of treatment on the
weight of the pluck. While there was no effect of DEX on lung weight in the current
experiment, other research in which pregnant rats received 0.2 mg/kg BW of DEX at 48
and 24 h prior to parturition showed the pups to have lower lung weights at birth
compared to pups born to mothers receiving no DEX (Frank et al., 1985).
There were no effects of implant on kidney weight in the current experiment,
which agrees with the study by Hutcheson et al. (1997) in which none of the implant
regimes affected kidney weight as a percentage of EBW. This also agrees with a study
by McClure et al. (2000) in which lambs were implanted with trenbolone acetate +
estradiol benzoate or non-implanted and slaughter at a final BW of 47-50 kg. Organs and
viscera were weighed at slaughter and kidney wet tissue weights were not different
between implanted and non-implanted lambs. Dexamethasone also failed to affect
kidney weight in the current experiment, which agrees with the study by Jensen et al.
(2002), in which maternal hydrocortisone infusions did not affect kidney weights of the
pups.
In Exp. 3, there were interactions between treatments to affect the wet tissue
weights of the digestive tract, forestomach complex and rumen + reticulum. However,
these interactions did not occur when the weights of these tissues were expressed as a
percentage of EBW. In Exp. 4, there was a 7% decrease in digestive tract weight for
steers receiving DEX and an 11% increase in digestive tract weight for steers receiving
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implant. The overall increase in digestive tract weight for implanted steers was due to a
13% increase in rumen + reticulum weight for these animals. However, these changes
did not translate to changes when expressed as a percentage of EBW. These results agree
with research by Gill et al. (1987) in which young calves implanted with estradiol 17-β
had no change in total GIT weights compared to non-implanted calves. However, these
results disagree with the study by Hutcheson et al. (1997) which showed the steers
receiving Revalor-S® to have decreased GIT weights when expressed as a percentage of
EBW.
There was no effect of treatment on SI or LI wet tissue weights alone or expressed
as a percentage of EBW in Exp. 3; however, in Exp. 4, DEX decreased SI wet tissue
weight by 11%, which translated to a decrease as a percentage of EBW. This decrease in
SI tissue weight agrees with research in rats which has shown similar results (Kelly and
Goldspink, 1982). These researchers used male rats injected with saline or 2.5 mg
DEX/kg BW/d for 5 d, after which they were injected with phenylalanine to assess
muscle metabolism and then killed. Dexamethasone caused atrophy of the smooth
muscle of the SI and a 10% decrease in the non-stretched length of the SI. It is possible
that muscle atrophy and decreased length may have contributed to the decreased weight
of the SI of the steers treated with DEX in our experiment.
In Exp. 4, it was determined that growth implant increased SI and LI wet tissue
weights by 13 and 10%, respectively; however, only SI wet tissue increased as a
percentage of EBW due to growth implant. This disagrees with the experiment by
McClure et al. (2000) in which there was no change in SI wet weight between implanted
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and non-implanted lambs; however, there was an increase in LI wet weight of 12% for
implanted compared to non-implanted lambs, which agrees with our experiment.
In Exp. 3, there was an interaction between treatments for liver wet tissue
weights, which was due to an increase in liver weight for steers receiving DEX in the
absence of implant. This interaction did not occur when liver weight was expressed as a
percentage of EBW; however, steers receiving DEX alone had greater liver weights as a
percentage of EBW. These results agree with the study by Jensen et al. (2002) in which
fetal sheep exposed to maternal cortisol infusions had increased liver weights as a
percentage of EBW. In Exp. 4, there was no interaction of treatments to affect liver wet
tissue weight, but DEX alone decreased and implant increased liver wet weight.
However, when expressed as a function of EBW, steers receiving implant had greater
liver weights compared to non-implanted steers. These results agree with the experiment
by Hutcheson et al. (1997), in which steers implanted with Revalor-S® had increased
liver weights as a percentage of EBW compared to non-implanted steers. There was no
effect of treatment on the ether extract percentage of the liver in Exp. 4; however, in Exp.
3, DEX tended to decrease the ether extract percentage of the liver. This tendency for a
decrease in the ether extract percentage for the steers receiving DEX is a function of the
increase in liver weight for the steers given DEX in the absence of implant. The amount
of fat present in the livers of steers receiving no DEX is calculated to be 100.2 g and the
amount of fat present in the livers of steers receiving DEX is 93.4 g; therefore, the
relationship is clear that the decreased ether extract percentage is a function of increased
liver weight and not due to a substantial difference in the amount of fat present in the
liver of DEX-treated steers.
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In Exp. 3, there was no effect of treatment on pancreas wet tissue weight;
however, when expressed as a percentage of EBW, DEX increased pancreas weight. In
Exp. 4, steers receiving implant tended to have increased pancreas wet tissue weights, but
this effect did not occur for implanted steers when expressed as a percentage of EBW.
However, DEX tended to increase pancreas weights in Exp. 4 when expressed as a
percentage of EBW. While the effect of DEX on pancreas was significant only when
weights were expressed as a percentage of EBW. Research in rats has reported the
administration of DEX increases pancreas wet tissue weights. A study by Sugiyama et al.
(2005) used male Wistar rats and examined the effects of DEX on caerulein-induced
acute pancreatitis. Dexamethasone was administered (3 mg/kg BW) prior to induction of
pancreatitis and pancreas weights were increased. While it is unclear why DEX
increased pancreas weight, research performed in vitro has investigated the role of
glucocorticoids in pancreas development using rat and mice embryonic pancreas cells
(Gesina et al., 2004). These cells were treated with or without 100nmol/L DEX. It was
found that DEX decreased the number of differentiated β-cells and increased the
differentiated acinar cell area. In the current experiments, it could be possible that DEX
increases pancreas weight by increasing the number or size of acinar cells in the
pancreas.
While there were no effects of treatment on alimentary tract fat, omental or
mesenteric fat wet tissue weights, and no effects on these weights expressed as a
percentage of EBW in Exp. 4, there were interactions of treatments in Exp. 3 to affect
both alimentary tract fat and omental fat weights. The interaction affecting alimentary
tract fat wet tissue weight was due to an increase in fat for steers receiving DEX in the
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absence of implant; however, there was only a tendency for this interaction to occur when
expressed as a percentage of EBW. Omental fat was a component of total alimentary
tract fat and a similar interaction of treatments occurred to affect this depot. In the
absence of implant, steers receiving DEX had more omental fat on both a wet tissue basis
and as a percentage of EBW. However, the interaction was also caused by a decrease in
omental fat on a wet tissue basis and as a percentage of EBW for steers receiving DEX in
the presence of implant. This response by omental fat decreasing in the presence of
implant was unexpected in this experiment. Research in which omental fat has been
quantified after increased circulating cortisol levels has shown an increase in the amount
of omental fat (Weber-Hamann et al., 2002). It was unknown if ruminants would
respond to a single injection of DEX every 28 d with changes in the omental fat depots,
but it was hypothesized that the injections may increase the amount of fat in the omental
depot if the animals were in an insulin-resistant state. While increased omental adiposity
has been implicated in the metabolic syndrome (glucose intolerance, hyperinsulinemia,
hyperlipidemia) and thus, a feature of Type II diabetes in humans, it is unknown whether
increased omental fat is a result or cause of diabetes (Kissebah et al., 1982; Evans et al.,
1984; Montague and O’Rahilly, 2000). From the current data, it appears that the addition
of implant to the DEX treatment mitigates the increase in omental fat; however, the
mechanism of how this occurs remains to be elucidated.
Whole blood glucose concentrations
Whole blood glucose concentrations were measured on d 0, 28, 56 and 84 in Exp.
3 to ascertain if the steers receiving DEX injections became insulin resistant over the
course of the experiment. There was no effect of treatment on whole blood glucose
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concentrations, but there was a quadratic effect of day. From the preliminary experiment
we conducted of injecting 3 steers with either 10 or 20 mg of DEX and collecting blood
samples for 2 days post-injection, we concluded that whole blood glucose concentrations
more than doubled and remained elevated for approximately 36 h after injection.
Glucose concentrations then slowly returned to baseline concentrations by 48 h postinjection. In the current experiment, we hypothesized that over the course of 84 d, the
DEX injections may cause insulin resistance and thus, possibly increase baseline
concentrations of blood glucose by the conclusion of the experiment. However, this
increase did not occur. Rather, over the course of the experiment, we observed very
minor increases in baseline glucose concentrations for all steers by d 28, followed by
minor decreases until d 84. It is unclear why this effect occurred, but the concentrations
only changed by 1-2 tenths of a milligram; while statistically significant, these changes
cannot be considered biologically significant.
In general, our findings demonstrated in Experiment 3 that DEX mitigated the
effects of growth implant on some of the growth & performance data, while there was
also an interaction between treatments for some of the carcass quality and organ and fat
mass data. This was not the case in Experiment 4, as DEX and growth implant did not
interact to affect any of our measurements. However, DEX clearly decreased growth and
weights of some organs.
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Table 5.1 Experimental diets
Ingredient, % DM
High moisture corn
Cracked corn
Alfalfa haylage
Ground corn
Soybean meal
Urea
Limestone

Exp. 3
80.00
0.00
10.00
6.90
1.23
0.46
0.60

Exp.4
0.00
80.00
10.00
4.39
3.48
0.00
1.30

Trace mineralized salt1
Choice white grease

0.50
0.26

0.51
0.27

Vitamins A,D,E2
Rumensin-80
Tylan-40

0.02
0.02
0.008

0.02
0.02
0.008

1

92.00% NaCl, 5,500 ppm Zn, 4,790 ppm Mn, 1,835 ppm Cu,
9,275 ppm Fe, 115 ppm I, 65 ppm Co, 18 ppm Se
2

8,800 IU/g vitamin A, 1,760 IU/g vitamin D, 1.1 IU/g vitamin E
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130

428
9.51
1.47
154.25
9.92
1.46
147.55
9.88
1.42
144.80
9.77
1.45
148.85
546

9.96
1.56
157.50
9.88
1.37
139.56
9.72
1.47
151.89
550

+Dex

429
9.34
1.48
158.71

-Dex

10.32
1.87
181.85
585

10.60
1.67
158.67

10.50
1.90
181.19

430
9.87
2.02
204.45

-Dex

9.98
1.68
168.05
561

10.06
1.55
153.80

10.09
1.67
164.83

424
9.80
1.83
185.58

+Dex

+Implant

b

Dexamethasone injections administered at 0.09 mg/kg BW on d 1, 28, and 56.
Standard error of the mean calculated from analysis of variance using n=9.
c
Interaction of Dex x Implant.
d
Includes all steers.

a

Period 1, 1-28 d
Initial BW, kg
DMI, kg/d
ADG, kg/d
Gain:DMI, g/kg
Period 2, 29-56 d
DMI, kg/d
ADG, kg/d
Gain:DMI, g/kg
Period 3, 57-83 d
DMI, kg/d
ADG, kg/d
Gain:DMI, g/kg
1-83 d
DMI, kg/d
ADG, kg/d
Gain:DMI, g/kg
Final BW, kgd

Item

-Implant

0.20
0.06
4.61
7.53

0.24
0.07
6.74

0.25
0.09
8.40

5.70
0.20
0.09
7.12

SEM

b

0.46
0.02
0.02
0.01

0.27
0.57
0.98

0.38
0.01
0.02

0.26
0.82
0.16
0.03

Dex

0.05
0.0001
0.0001
0.0001

0.07
0.002
0.05

0.16
0.0002
0.0006

0.43
0.05
0.0001
0.0001

Implant

P<

0.35
0.05
0.12
0.05

0.26
0.17
0.46

0.47
0.29
0.55

0.38
0.55
0.24
0.17

Xc

Table 5.2 Effects of dexamethasone injections and growth implant on body weight (BW) gain, feed intake, and
efficiency of gain in finishing beef steersa for Exp. 3
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1.42
2.17
3.39
3.08
3.64

Longissimus fat, cm
KPH fat, %

Marblingf

Yield grade

Quality gradeg
3.59

3.07

3.43

1.35
2.10

3.42

80.25

338
61.94

544

+Dex

3.83

3.07

3.36

1.40
2.05

2.63

84.43

358
61.29

582

-Dex

3.78

3.06

3.21

1.39
2.06

3.96

82.75

347
62.34

559

+Dex

+Implant

0.44

0.12

0.32

0.17
0.04

0.61

1.46

6.22
0.32

8.83

SEMb

b

Dexamethasone injections administered at 0.09 mg/kg BW on d 1, 28, and 56.
Standard error of the mean calculated from analysis of variance using n=36 except for ether extract (n=8).
c
Interaction of Dex x Implant.
d
Slaughtered at d 84 or 86.
e
Measured on a sample of 2.54 cm-thickness trimmed of adjoining muscle and fat. Wet tissue basis.
f
Scores: 1.00 = trace00, 2.00 = slight00, 3.00 = small00, 4.00 = modest00.
g
Scores: 3.00 = Select+, 4.00 = Choice-, 5.00 = Choice 0, 6.00 = Choice +.

a

4.38

Ether extracte, %

81.64

338
62.19

HCW, kg
Dressing percentage

Longissimus dorsi, cm2

547

-Dex

Slaughter weight, kgd

Carcass measures

-Implant
Dex

0.76

0.89

0.69

0.55
0.42

0.75

0.16

0.07
0.20

0.001

Table 5.3 Effects of dexamethasone injections and growth implant on carcass evaluation measures in
finishing beef steersa for Exp. 3

0.25

0.88

0.35

0.88
0.02

0.31

0.02

0.0001
0.42

0.0001

Implant

P<

0.98

1.00

0.49

0.61
0.26

0.06

0.89

0.06
0.04

0.01

Xc
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10.94

Mesenteric fat

-Dex

11.51

17.68

29.20

0.39

8.01
5.97
5.77
2.48
6.72
1.42
30.62

13.99

10.87

17.39

28.26

0.36

8.93
5.64
6.03
2.50
6.59
1.47
33.69

14.57

Mass, kgd
22.23
23.09

+Dex

b

10.63

14.44

25.07

0.37

8.11
5.65
5.91
2.66
6.57
1.39
33.59

13.76

22.33

+Dex

+Implant

Dexamethasone injections administered at 0.09 mg/kg BW on d 1, 28, and 56.
Standard error of the mean calculated from analysis of variance using n=8.
c
Interaction of Dex x Implant.
d
Wet tissue weight.
e
Slaughtered at d 84 or 86.
f
Measured on liver core samples. Wet tissue basis.
g
n=8 except for Imp + Dex (n=7); SEM calculated using n=7.

a

13.93

24.87

Omental fat

Alimentary tract fat

0.33

7.60
5.44
5.33
2.33
5.95
1.74
33.72

Rumen + reticulum
Omasum + abomasum
Small intestine
Large intestine
Liver
Ether extractf, %
Dry matter, %

Pancreasg

13.04

20.70

-Dex

Forestomach complex

Digestive tract

Item

-Implant

0.81

0.98

1.67

0.03

0.38
0.34
0.27
0.14
0.20
0.13
2.11

0.57

0.73

SEMb

0.84

0.69

0.74

0.12

0.45
0.43
0.54
0.27
0.04
0.09
0.45

0.89

0.55

Dex

Table 5.4 Effects of dexamethasone injections and growth implant on organ and alimentary fat mass in
finishing beef steersa for Exp. 3

0.56

0.91

0.83

0.76

0.01
0.85
0.12
0.22
0.18
0.21
0.49

0.18

0.06

Implant

P<

0.62

0.002

0.03

0.22

0.03
0.44
0.31
0.94
0.04
0.30
0.48

0.07

0.08

Xc
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2.13

Mesenteric fat

-Dex

2.22

3.40

1.99

3.18

4.42
2.66
1.63
1.03
1.10
0.46
1.20
0.07
5.16

548

% EBWd

4.48
2.69
1.54
1.15
1.11
0.48
1.29
0.07
5.62

521

+Dex

2.03

2.76

4.48
2.63
1.55
1.08
1.13
0.51
1.25
0.07
4.79

524

+Dex

+Implant

Dexamethasone injections administered at 0.09 mg/kg BW on d 1, 28, and 56.
b
Standard error of the mean calculated from analysis of variance using n=8.
c
Interaction of Dex x Implant.
d
Wet tissue weight.
e
n=8 except for Imp + Dex (n=7); SEM calculated using n=7.

a

2.71

4.23
2.54
1.48
1.06
1.04
0.45
1.16
0.06
4.84

514

-Dex

Omental fat

Digestive tract
Forestomach complex
Rumen + reticulum
Omasum + abomasum
Small intestine
Large intestine
Liver
Pancrease
Alimentary tract fat

Final empty body weight, kg

Item

-Implant

0.16

0.19

0.14
0.10
0.07
0.06
0.05
0.03
0.03
0.005
0.33

6.02

SEMb

0.67

0.46

0.24
0.53
0.81
0.29
0.33
0.19
0.01
0.05
0.53

0.07

Dex

Table 5.5 Effects of dexamethasone injections and growth implant on organ and alimentary fat mass
as a percentage of EBW in finishing beef steersa for Exp. 3

0.30

0.64

0.47
0.72
0.12
0.47
0.38
0.53
0.91
0.81
0.44

0.0005

Implant

P<

0.89

0.006

0.48
0.32
0.16
0.76
0.69
0.57
0.23
0.45
0.09

0.003

Xc
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8.98
1.03
114.97
8.82
0.98
110.75
9.10
1.32
113.05
532

9.68
1.20
122.53
9.56
1.53
128.54
555

9.44
1.37
144.33

9.85
1.73
174.47
9.63
1.28
133.04

385
9.15
1.89
206.10

+Dex

385
9.07
1.92
210.67

-Dex

9.78
1.67
135.02
573

9.83
1.20
121.48

9.88
1.46
148.12

10.16
1.92
189.77

385
9.24
2.15
233.03

-Dex

9.47
1.55
138.96
559

9.64
1.10
115.30

9.35
1.51
161.55

9.69
1.50
153.99

386
9.21
2.07
225.13

+Dex

+Implant

b

Dexamethasone injections administered at 0.09 mg/kg BW on d 1, 28, 56 and 84.
Standard error of the mean calculated from analysis of variance using n=6.
c
Interaction of Dex x Implant.
d
Includes all steers.

a

Period 1, 1-28 d
Initial BW, kg
DMI, kg/d
ADG, kg/d
Gain:DMI, g/kg
Period 2, 29-56 d
DMI, kg/d
ADG, kg/d
Gain:DMI, g/kg
Period 3, 57-84 d
DMI, kg/d
ADG, kg/d
Gain:DMI, g/kg
Period 4, 85-112 d
DMI, kg/d
ADG, kg/d
Gain:DMI, g/kg
1-112 d
DMI, kg/d
ADG, kg/d
Gain:DMI, g/kg
Final BWd, kg

Item

-Implant

0.41
0.06
10.84
18.55

0.39
0.13
14.76

0.43
0.12
12.44

0.51
0.12
8.90

15.01
0.40
0.15
10.33

SEMb

0.14
0.007
0.46
0.01

0.06
0.15
0.39

0.10
0.37
0.85

0.19
0.005
0.001

0.70
0.87
0.65
0.55

Dex

0.25
0.004
0.05
0.004

0.08
0.54
0.87

0.38
0.01
0.02

0.39
0.18
0.18

0.38
0.49
0.07
0.06

Implant

P<

0.76
0.51
0.22
0.49

0.21
0.55
0.79

0.86
0.22
0.22

0.92
0.79
0.75

0.77
0.73
0.83
0.88

Xc

Table 5.6 Effects of dexamethasone injections and growth implant on body weight (BW) gain, feed intake, and
efficiency of gain in finishing beef steersa for Exp. 4
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+Dex

82.16
2.13
1.14
2.16
2.94
2.41
3.13

83.09
1.97
1.08
2.07
3.00
2.25
3.13

553
528
333
320
60.10 60.40

-Dex

2.41
1.05
1.99
2.68
2.18
2.85

85.96

85.50
2.04
1.18
2.05
2.89
2.46
3.00

556
337
60.47

+Dex

573
349
60.91

-Dex

+Implant

0.40
0.13
0.09
0.22
0.42
0.19

2.35

16.65
9.08
0.93

SEMb

Scores: 1.00 = trace00, 2.00 = slight00, 3.00 = small00, 4.00 = modest00.
Scores: 3.00 = Select+, 4.00 = Choice-, 5.00 = Choice 0, 6.00 = Choice +.

g

f

b

Dexamethasone injections administered at 0.09 mg/kg BW on d 1, 28, 56 and 84.
Standard error of the mean calculated from analysis of variance using n=24 except for ether extract (n=9).
c
Interaction of Dex x Implant.
d
Slaughtered at d 106, 107, 109, 112, 113, 114, 115, 118 or 119.
e
Measured on a sample of 2.54 cm-thickness trimmed of adjoining muscle and fat. Wet tissue basis.

a

Slaughter weight, kgd
HCW, kg
Dressing percentage
Longissimus dorsi (LD)
area, cm2
Ether extracte, %
Longissimus fat cover, cm
KPH fat, %
Marblingf
Yield grade
Quality gradeg

Carcass measures

-Implant

0.50
0.62
0.86
0.50
0.67
0.70

0.86

0.003
0.0007
0.84

Dex

Table 5.7 Effects of dexamethasone injections and growth implant on carcass evaluation measures in
finishing beef steersa for Exp. 4

0.67
0.94
0.11
0.36
0.97
0.29

0.02

0.0006
0.0001
0.21

Implant

P<

0.79
0.20
0.21
0.71
0.16
0.70

0.59

0.56
0.86
0.30

Xc
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Mesenteric fat

9.44

14.16

23.60

0.33

8.43
4.71
1.44
6.07
2.62
6.30
1.89
31.36

14.58

1.11
1.08
2.34
6.91
23.28

-Dex

9.04

12.87

21.92

0.36

8.49
4.58
1.59
5.63
2.51
6.04
1.98
30.99

14.66

9.59

13.85

23.44

0.37

10.17
5.20
1.66
7.13
2.94
7.51
2.02
30.77

17.02

1.13
1.12
2.55
6.80
27.10

-Dex

Mass, kgd
0.91
1.14
2.46
6.60
22.80

+Dex

9.83

13.46

23.28

0.43

8.99
4.51
1.50
6.14
2.70
6.71
1.99
30.85

15.00

0.85
1.04
2.55
6.73
23.84

+Dex

+Implant

b

Dexamethasone injections administered at 0.09 mg/kg BW on d 1, 28, 56 and 84.
Standard error of the mean calculated from analysis of variance using n=9.
c
Interaction of Dex x Implant.
d
Wet tissue weight.
e
Slaughtered at d 106, 107, 109, 112, 113, 114, 115, 118 or 119.
f
Measured on liver core samples. Wet tissue basis.

a

Omental fat

Alimentary tract fat

Pancreasg

Rumen + reticulum
Omasum
Abomasum
Small intestine
Large intestine
Liver
Ether extractf, %
Dry matter, %

Forestomach complex

Spleen
Kidneys
Heart
Lungs
Digestive tract

Item

-Implant

0.74

1.01

1.57

0.03

0.46
0.59
0.09
0.23
0.10
0.26
0.19
0.25

0.85

0.06
0.08
0.13
0.26
1.04

SEM

b

0.91

0.38

0.54

0.16

0.24
0.34
0.94
0.002
0.10
0.03
0.84
0.56

0.24

0.0006
0.84
0.47
0.35
0.05

Dex

Table 5.8 Effects of dexamethasone injections and growth implant on organ and alimentary fat mass in
finishing beef steersa for Exp. 4

0.49

0.89

0.69

0.06

0.02
0.62
0.48
0.0008
0.02
0.0004
0.68
0.15

0.10

0.80
0.70
0.09
0.97
0.01

Implant

P<

0.64

0.64

0.61

0.59

0.19
0.52
0.09
0.21
0.56
0.27
0.72
0.37

0.15

0.54
0.31
0.48
0.55
0.15

Xc
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0.23
0.50
1.47
4.96
3.11
1.80
1.00
0.31
1.30
0.56
1.34
0.07
5.02
3.01
2.01

Kidneys

Heart

Lungs

Digestive tract
Forestomach complex
Rumen + reticulum
Omasum
Abomasum
Small intestine
Large intestine
Liver
Pancreas
Alimentary tract fat

Omental fat

Mesenteric fat

-Dex

1.99

2.83

1.89

2.72

5.33
3.34
2.00
1.02
0.33
1.41
0.58
1.48
0.07
4.61

1.34

0.50

0.22

0.22

507

% EBWd

5.03
3.22
1.87
1.00
0.35
1.25
0.56
1.33
0.08
4.82

1.46

0.54

0.25

0.20

451

+Dex

2.05

2.81

4.99
3.14
1.88
0.95
0.31
1.28
0.57
1.40
0.09
4.86

1.41

0.53

0.22

0.18

479

+Dex

+Implant

Dexamethasone injections administered at 0.09 mg/kg BW on d 1, 28, 56 and 84.
b
Standard error of the mean calculated from analysis of variance using n=9.
c
Interaction of Dex x Implant.
d
Wet tissue weight as a percentage of EBW.
e
Slaughtered at d 106, 107, 109, 112, 113, 114, 115, 118, or 119.

a

0.24

469

-Dex

Spleen

Final empty body weight, kg

Item

-Implant

0.14

0.19

0.17
0.15
0.08
0.12
0.02
0.04
0.02
0.04
0.005
0.29

0.04

0.03

0.01

0.01

9.05

SEMb

0.60

0.81

0.36
0.77
0.77
0.69
0.37
0.02
0.71
0.25
0.06
0.93

0.50

0.03

0.48

0.005

0.02

Dex

0.79

0.39

0.27
0.59
0.18
0.81
0.61
0.05
0.51
0.006
0.31
0.50

0.02

0.87

0.10

0.19

0.001

Implant

P<

0.48

0.46

0.17
0.27
0.22
0.69
0.12
0.29
0.77
0.34
0.53
0.43

0.32

0.64

0.31

0.66

0.56

Xc

Table 5.9 Effects of dexamethasone injections and growth implant on organ and alimentary fat mass as a percentage of EBW in
finishing beef steersa
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Whole blood glucose concentration, (mM)

3

3.1

3.2

3.3

3.4

3.5

3.6

3.7

28
Experimental Day

56

83

Dex + Imp

Dex

Implant

Control

Figure 5.1. Whole blood glucose concentrations in beef steers receiving no implant or Revalor-S (120 mg
trenbolone acetate + 24 mg 17-β estradiol benzoate) and no dexamethasone injection or dexamethasone injection
administered intramuscularly at 0.09 mg/kg BW on d 1, 28 and 56. Over the course of the finishing period, whole
blood glucose concentrations responded quadratically relative to day of experiment (P = 0.002).

1

Day, P = 0.02
Quadratic Day, P = 0.002

Chapter 6
General Discussion

In finishing beef cattle, a goal of producers is to maximize lean tissue growth as
efficiently as possible. This goal is generally accomplished through use of anabolic
growth implants containing various combinations of estrogen, progesterone and
trenbolone acetate. Historically, the drawback of using these growth implants has been a
negative impact on marbling, or intramuscular fat content within the longissimus dorsi
muscle. The amount of marbling at slaughter determines the USDA quality grade
assigned to the carcass, leading to a significant profit if the carcass grades “Choice.”
Research has shown that growth implants have the potential to decrease the amount of
marbling in finishing cattle, thus decreasing profit for producers. Therefore, the addition
of a compound to the finishing program of beef cattle to counteract the negative impact
of growth implants on marbling may increase profit.
The results of the current experiments provide greater understanding of the
physiological effects of the adipogenic compounds, chlortetracycline and dexamethasone,
on fat deposition in ruminants. Furthermore, insight was gained regarding the interaction
of these compounds with anabolic growth implants, which are routinely used in finishing
beef cattle. Chlortetracycline (CTC) has been shown in previous research with swine,
lambs and cattle to improve carcass quality; however, in our experiments, we did not see
a significant improvement in marbling or overall fatness of the finished steers. While the
reason for this lack of effect in these experiments is unclear, we discovered that CTC
attenuated the positive effects of growth implant on lean tissue gain and efficiency of
gain. Furthermore, by evaluating the growth hormone (GH) and thyroid hormone status
139

of these cattle, we found that CTC may be causing the mitigation in lean tissue gain and
efficiency of gain via attenuation of triiodothyronine response. This suggests that CTC
may be initiating effects on fat deposition by moderating the effects of thyroid hormones.
We also gained new information in describing the time course response of GH and
thyroid hormones over a typical finishing period for beef cattle implanted with growth
implants. In general, we found that finishing cattle have elevated circulating thyroid
hormone concentrations and greater thyroid hormone responses to a releasing-hormone
challenge. As the use of subtherapeutic antibiotics becomes more unfavorable in
production animals, the importance of discovering the mechanism of action of CTC
regarding fat deposition becomes more imperative. If this mechanism can be determined,
it may be possible to manufacture only the part of the compound responsible for
increasing fat deposition and administer this compound to finishing beef cattle to improve
marbling.
In the latter two experiments, we used dexamethasone (DEX) in conjunction with
growth implants to study another possible mechanism for improving marbling in
finishing cattle. In humans and rodents, it has been shown in numerous experiments that
DEX induces both short-term and long-term insulin resistance, which in turn has been
shown to cause fat deposition to shift from adipose to non-adipose tissue (muscle).
Previous research had shown DEX injections up to 90 d prior to slaughter in finishing
beef cattle improved carcass quality grade via increases in marbling. We hypothesized
that these increases may be due to insulin resistance caused by DEX; thus the hypothesis
in the current experiments was that injections of DEX every 28 d prior to slaughter would
increase marbling, increase fat in omental and alimentary fat depots and decrease weight
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of service organs. These injections were also administered in conjunction with growth
implants to evaluate the effects on lean tissue gain and fat deposition both in
intramuscular fat and other fat depots such as omental and alimentary fat. In general, we
found that while DEX did not improve marbling, as measured by either subjective scores
or objective total crude fat determination in the longissimus dorsi muscle, DEX
attenuated both the increased ADG and final BW for steers also receiving growth
implant. Interestingly, we also saw increases in omental fat weights without implant, but
decreases in omental fat with implant. New information gained from these experiments
included characterization of the effects of both DEX and growth implant on weights of
the parts of the GIT, fat depots and service organs. To date there has been little published
research regarding the effects of growth implants, and no published research regarding
the effects of DEX, on the weights of these tissues in finishing cattle. Finally, while
preliminary research in 3 steers administered DEX injections demonstrated a two-fold
increase in circulating blood glucose concentrations for 2 d, long-term effects on
circulating blood glucose concentrations were not observed. To sustain an increase in
blood glucose concentrations, it is likely necessary to give more frequent DEX injections,
such as every 2-3 days. While we did not see this increase in blood glucose, we
hypothesized that DEX injections every 28 d may have long-term effects on the
expression of genes involved in lipogenesis, lipolysis and glucose metabolism, i.e., fat
deposition may still be shifted from primary to secondary fat depots within muscle.
While we did not observe these changes in the current experiments, it is worthwhile to
modify the research methods and continue to study the possibility of inducing insulin
resistance in ruminants and observing possible effects on marbling. Furthermore,
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determination of the mechanisms and metabolic pathways involved in the control of fat
deposition in ruminants also remain unclear; therefore, more research is necessary to
elucidate these pathways as well.
Because the producer is paid based on the quality grade of the carcass and quality
grade is determined by the amount of marbling, it is necessary to continue research
regarding ways to improve marbling in cattle administered growth implants. We have
studied two compounds in these experiments aimed at improving marbling and have only
begun to understand how these compounds manipulate fat deposition and also how they
interact with growth implants.

Copyright © Susanna E. Kitts 2011
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